10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

x (Do not check if a smaller reporting company)

Smaller reporting company

0001193125-16-764353.txt : 20161109 0001193125-16-764353.hdr.sgml : 20161109 20161109161259 ACCESSION NUMBER: 0001193125-16-764353 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161109 DATE AS OF CHANGE: 20161109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 161984374 BUSINESS ADDRESS: STREET 1: 400 EAST JAMIE COURT, SUITE 101 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 400 EAST JAMIE COURT, SUITE 101 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 10-Q 1 d446427d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-37539

Global Blood Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

27-4825712

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

400 East Jamie Court, Suite 101, South San Francisco

South San Francisco, CA 94080

(Address of principal executive offices)

(650) 741-7700

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of November 1, 2016, there were 37,316,451 shares of the registrant’s Common Stock, par value $0.001 per share, outstanding.

TABLE OF CONTENTS


		Page
PART I. – FINANCIAL INFORMATION			3

Item 1.	Financial Statements (Unaudited)		3

	Condensed Consolidated Balance Sheets as of September 30, 2016 (Unaudited) and December 31, 2015		3

	Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2016 and 2015 (Unaudited)		4

	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2016 and 2015 (Unaudited)		5

	Notes to Unaudited Interim Condensed Consolidated Financial Statements		6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		15

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		22

Item 4.	Controls and Procedures		22

PART II. – OTHER INFORMATION			23

Item 1.	Legal Proceedings		23

Item 1A.	Risk Factors		23

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		55

Item 3.	Defaults Upon Senior Securities		55

Item 4.	Mine Safety Disclosures		55

Item 5.	Other Information		55

Item 6.	Exhibits		55

SIGNATURES			56

PART I. – FINANCIAL INFORMATION

Item 1. Financial Statements

GLOBAL BLOOD THERAPEUTICS, INC.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)


	September 30, 2016			December 31, 2015
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	217,837		$	148,502
Prepaid expenses		1,706			1,222
Other assets, current		1,723			1,096

Total current assets		221,266			150,820
Property and equipment, net		2,626			2,114
Restricted cash		140			140

Total assets	$	224,032		$	153,074

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	3,038		$	3,361
Accrued liabilities		5,863			4,400
Accrued compensation		3,351			2,242
Other liabilities, current		905			720

Total current liabilities		13,157			10,723
Other liabilities, noncurrent		775			1,556

Total liabilities		13,932			12,279

Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized as of September 30, 2016 (unaudited) and December 31, 2015		—			—
Common stock, $0.001 par value, 150,000,000 shares authorized as of September 30, 2016 (unaudited) and December 31, 2015, respectively; 36,516,130 and 29,359,800 shares issued and outstanding as of September 30, 2016 (unaudited) and December 31, 2015, respectively		37			29
Additional paid-in capital		363,789			239,231
Accumulated deficit		(153,726	)		(98,465	)

Total stockholders’ equity		210,100			140,795

Total liabilities and stockholders’ equity	$	224,032		$	153,074

See accompanying notes to unaudited interim condensed consolidated financial statements.

GLOBAL BLOOD THERAPEUTICS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share amounts)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Operating expenses:
Research and development	$	15,145		$	12,106		$	40,847		$	25,257
General and administrative		5,999			2,669			14,821			5,473
Related party expenses		—			—			—			65

Total operating expenses		21,144			14,775			55,668			30,795

Loss from operations		(21,144	)		(14,775	)		(55,668	)		(30,795	)
Interest and other (expense) income, net		159			11			407			20

Net loss and comprehensive loss	$	(20,985	)	$	(14,764	)	$	(55,261	)	$	(30,775	)

Net loss attributable to common stockholders	$	(20,985	)	$	(15,551	)	$	(55,261	)	$	(34,955	)

Net loss per share attributable to common stockholders, basic and diluted	$	(0.58	)	$	(0.90	)	$	(1.72	)	$	(4.83	)

Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted		36,353,958			17,288,610			32,074,779			7,242,559

See accompanying notes to unaudited interim condensed consolidated financial statements.

GLOBAL BLOOD THERAPEUTICS, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)


	Nine Months Ended September 30,
	2016			2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(55,261	)	$	(30,775	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		841			606
Loss on disposal of fixed assets		—			29
Stock-based compensation		5,884			1,731
Fair value of stock issued for license		—			4,492
Changes in operating assets and liabilities:
Prepaid expenses		(484	)		(489	)
Other assets, current		(3	)		(210	)
Accounts payable		(1,478	)		851
Accrued liabilities		1,746			1,928
Accrued compensation		1,109			601
Other liabilities		(25	)		(7	)

Net cash used in operating activities		(47,671	)		(21,243	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(1,106	)		(775	)

Net cash used in investing activities		(1,106	)		(775	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of issuance costs		116,995			126,360
Proceeds from issuance of restricted stock awards		—			2,108
Repurchase of unvested restricted stock awards		—			(66	)
Proceeds from issuance of common stock in settlement of employee stock purchase plan and exercise of stock options		1,117			44

Net cash provided by financing activities		118,112			128,446

Net increase in cash and cash equivalents		69,335			106,428
Cash and cash equivalents at beginning of period		148,502			52,069

Cash and cash equivalents at end of period	$	217,837		$	158,497

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Accretion of Series A and Series B redeemable convertible preferred stock	$	—		$	4,180

Conversion of redeemable convertible preferred stock to common stock at closing of initial public offering	$	—		$	106,342

Accrued purchase of property and equipment	$	247		$	—

Accrued offering costs	$	—		$	130

See accompanying notes to unaudited interim condensed consolidated financial statements.

GLOBAL BLOOD THERAPEUTICS, INC.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

1. Organization and Basis of Presentation

Global Blood Therapeutics Inc. (the “Company”, “we”, “us”, and “our”) was incorporated in Delaware in February 2011 and commenced operations in May 2012. We are a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. Our primary activities have been establishing our facilities, recruiting personnel, conducting development of our product candidates, including clinical trials, and raising capital. Our principal operations are based in South San Francisco, California, and we operate in one segment.

Follow-on Offering

On June 24, 2016, we completed a follow-on offering and issued 6,400,000 shares of common stock at a price of $18.75 per share. In July 2016, we sold an additional 267,228 shares of our common stock directly to the underwriters when they exercised their over-allotment option at the price of $18.75 per share. We received total proceeds of $117.0 million from the offering, net of underwriting costs and commissions, and offering expenses.

Need for Additional Capital

In the course of our development activities, we have sustained operating losses and we expect such losses to continue over the next several years. Our ultimate success depends on the outcome of our research and development activities. Since inception through September 30, 2016, we have incurred cumulative net losses of $153.7 million. We expect to incur additional losses in the future to conduct product research and development and we recognize the need to raise additional capital to fully implement our business plan. We intend to raise such capital through the issuance of additional equity, and potentially through borrowings, and strategic alliances with partner companies. However, if such financing is not available at adequate levels, we will need to reevaluate our operating plans. We believe that our existing cash and cash equivalents will be sufficient to fund our cash requirements for at least the next twelve months.

2. Summary of Significant Accounting Policies

Basis of Preparation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2015 has been derived from audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as our annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair presentation of our financial information. The results of operations for the three and nine months ended September 30, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016 or for any other interim period or for any other future year.

The accompanying interim unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2015 included in our Annual Report on Form 10-K, filed with the SEC on March 29, 2016.

GLOBAL BLOOD THERAPEUTICS, INC.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

Use of Estimates

The preparation of the accompanying unaudited interim condensed consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of costs and expenses during the reporting period. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results could differ from these estimates under different assumptions or conditions.

Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation.

Cash and Cash Equivalents

We consider all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. Cash equivalents, which consist primarily of amounts invested in money market accounts, are stated at fair value.

Accruals of Research and Development Costs

We record accruals for estimated costs of research, preclinical, nonclinical and clinical studies and manufacturing development. These costs are a significant component of our research and development expenses. A substantial portion of our ongoing research and development activities are conducted by third-party service providers, including contract research organizations. We accrue the costs incurred under our agreements with these third parties based on actual work completed in accordance with agreements established with these third parties. We determine the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrual balance in each reporting period. As actual costs become known, we adjust our accruals. We have not experienced any material deviations between accrued clinical trial expenses and actual clinical trial expenses. However, actual services performed, number of subjects enrolled, and the rate of subject enrollment may vary from our estimates, resulting in adjustments to clinical trial expense in future periods. Changes in these estimates that result in material changes to our accruals could materially affect our results of operations.

Concentration of Credit Risk

Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Our cash and cash equivalents are held primarily in one large financial institution in the United States as of September 30, 2016. We believe that this financial institution is financially sound, and accordingly, minimal credit risk exists with respect to this financial institution.

Fair Value Measurement

The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.

Research and Development Costs

Research and development costs are expensed as incurred and consist of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to other nonemployees and entities that conduct certain research and development activities and manufacturing of clinical materials on our behalf. Amounts incurred in connection with license agreements are also included in research and development expense. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and then expensed as the related goods are delivered or the services are performed.

GLOBAL BLOOD THERAPEUTICS, INC.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

Stock-based Compensation

We measure and recognize stock-based compensation expense, including employee and non-employee equity awards, based on fair value at the grant date. We use the Black-Scholes option-pricing model to calculate fair value. Stock-based compensation expense recognized in the statements of operations is based on options ultimately expected to vest, taking into consideration estimated forfeitures. Stock-based compensation expense is revised in subsequent periods, if necessary, if actual forfeitures differ from these estimates. When estimating forfeitures, we consider historic voluntary termination behaviors as well as trends of actual option forfeitures. For options granted to non-employees, we revalue the unearned portion of the stock-based compensation and the resulting change in fair value is recognized in the statements of operations over the period the related services are rendered.

Net Loss per Share Attributable to Common Stockholders

Net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. The net loss attributable to common stockholders is calculated by adjusting our net loss for the accretion and dividends on redeemable convertible preferred stock prior to the conversion of the redeemable convertible preferred stock upon our initial public offering, or IPO, in August 2015. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since the effects of potentially dilutive securities are antidilutive given our net loss.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial statements upon adoption.

In February 2016, the FASB issued Accounting Standards Update, or ASU No. 2016-02, Leases. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. We are currently in the process of evaluating the impact the adoption of this new standard will have on our financial position or results of operations.

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting. The new standard simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are currently in the process of evaluating the impact the adoption of this new standard will have on our financial position or results of operations and have not elected to early adopt the amendment.

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. The new standard provides guidance on eight specific cash flow classification issues. The standard is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. We believe that the adoption of this new standard will have no impact on our financial position or results of operations and have not elected to early adopt the amendment.

GLOBAL BLOOD THERAPEUTICS, INC.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

3. Fair Value Measurements

Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, restricted cash, accounts payable and accrued liabilities that approximate fair value due to their relatively short maturities.

Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;

Level 2 – Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

Level 3 – Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.

Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements are as follows (in thousands):


	September 30, 2016
	Level 1		Level 2		Level 3		Total
Financial Assets:
Money market funds	$	208,616	$	—	$	—	$	208,616

Total financial assets	$	208,616	$	—	$	—	$	208,616


	December 31, 2015
	Level 1		Level 2		Level 3		Total
Financial Assets:
Money market funds	$	148,642	$	—	$	—	$	148,642

Total financial assets	$	148,642	$	—	$	—	$	148,642

Our financial instruments consist of Level 1 assets. Where quoted prices for identical assets are available in an active market, securities are classified as Level 1. Level 1 assets consist of highly liquid money market funds, which as of September 30, 2016 and December 31, 2015 includes $140,000 of funds that are collateral for our facility lease that are included within restricted cash. There were no unrealized gains and losses in our investments in these money market funds.

GLOBAL BLOOD THERAPEUTICS, INC.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

4. Balance Sheet Components

Property and Equipment

Property and equipment consists of the following (in thousands):


	September 30, 2016			December 31, 2015
Laboratory equipment	$	3,715		$	3,151
Computer equipment		970			596
Leasehold improvements		678			340
Construction-in-progress		206			129

Total property and equipment		5,569			4,216
Less: accumulated depreciation and amortization		(2,943	)		(2,102	)

Property and equipment, net	$	2,626		$	2,114

Accrued liabilities

Accrued liabilities consist of the following (in thousands):


	September 30, 2016		December 31, 2015
Accrued clinical and manufacturing expenses	$	4,823	$	4,025
Accrued professional and consulting services		921		287
Other		119		88

Total accrued liabilities	$	5,863	$	4,400

Other liabilities, current and noncurrent

Other liabilities consist of the following (in thousands):


	September 30, 2016		December 31, 2015
Restricted shares subject to repurchase, current	$	850	$	677
Deferred rent, current		53		38
Other taxes payable		2		5

Total other liabilities, current	$	905	$	720

Restricted shares subject to repurchase, noncurrent	$	728	$	1,470
Deferred rent, noncurrent		47		86

Total other liabilities, noncurrent	$	775	$	1,556

5. Stockholders’ Equity

Common Stock

We have reserved the following shares of common stock for issuance:


	September 30, 2016
Restricted shares subject to future vesting		752,220
Options issued and outstanding		2,703,252
Options available for future grants		1,484,701
Employee stock purchase plan		76,118

Total common stock reserved for issuance		5,016,291

Restricted Stock

We have issued restricted stock awards to employees under our 2012 Stock Option and Grant Plan (the “2012 Plan”). Under the related stock purchase agreements, we have the right to repurchase the common stock at the lower of fair market value and the stockholders’ original purchase price which right lapses according to individual vesting schedules.

GLOBAL BLOOD THERAPEUTICS, INC.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

In order to vest, the holders are required to provide continued service to us. Upon vesting, the appropriate amounts are transferred from liabilities to additional paid-in capital. If the employment or other service relationship of the holder of any unvested restricted common stock is terminated for any reason, we have the right to repurchase the unvested shares at the lower of fair market value or the stockholder’s original purchase price. As such, the shares subject to future vesting are not deemed outstanding for accounting purposes until the shares vest.

Restricted shares subject to repurchase and related liability were as follows (in thousands, except share data):


	September 30, 2016		December 31, 2015
Restricted shares subject to repurchase:
Shares issued to founders		—		6,250
Shares issued pursuant to the 2012 Stock Option and Grant Plan		777,041		1,091,038

Total restricted shares subject to repurchase		777,041		1,097,288

Liability pertaining to restricted shares subject to repurchase
Other liabilities, current	$	850	$	677
Other liabilities, noncurrent		728		1,470

Total liabilities pertaining to shares subject to repurchase	$	1,578	$	2,147

6. Stock-based Awards

Equity Incentive Plans

In July 2015, we adopted the 2015 Stock Option and Incentive Plan (the “2015 Plan”). Under the 2015 Plan, 1,430,000 shares of our common stock were initially reserved for the issuance of stock options, restricted stock, and other equity-based awards to employees, non-employee directors, and consultants under terms and provisions established by the Board of Directors and approved by our stockholders. The 2015 Plan also provides for automatic annual increases in the number of shares reserved for future issuance. As of September 30, 2016, there were 1,484,701 shares available for future grants under the 2015 Plan.

In 2012, we adopted the 2012 Plan under which the Board of Directors was authorized to grant incentive stock options to employees, including officers and members of the Board of Directors who are also employees of ours, and non-statutory stock options (options that do not qualify as incentive options) and/or our restricted stock and other equity-based awards to employees, officers, directors, or consultants of ours. Upon adoption of the 2015 Plan, no new awards or grants are permitted under the 2012 Plan.

GLOBAL BLOOD THERAPEUTICS, INC.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

Employee Stock Purchase Plan

In July 2015, we adopted the 2015 Employee Stock Purchase Plan (the “2015 ESPP”). Under the 2015 ESPP, 50,000 shares of our common stock were initially reserved for employee purchases of our common stock under terms and provisions established by the Board of Directors and approved by our stockholders. The 2015 ESPP also provides for automatic annual increases in the number of shares reserved for future issuance.

Stock Option Awards

The following summarizes option activity under the 2015 Plan and the 2012 Plan:


	Number of Options			Weighted- Average Exercise Price		Weighted- Average remaining contractual term (years)		Aggregate Intrinsic Value
								(in thousands)
Balance Outstanding, December 31, 2015		2,058,787		$	8.71		9.0
Options granted		1,034,575		$	16.74
Options exercised		(103,602	)	$	0.95
Options canceled		(286,508	)	$	18.96

Balance Outstanding, September 30, 2016		2,703,252		$	10.99		8.7	$	35,600

Exercisable, September 30, 2016		823,118		$	6.59		7.9	$	14,082

Vested and expected to vest, September 30, 2016		2,508,295		$	10.78		8.6	$	33,533

Stock Options Granted to Employees with Service-Based Vesting Conditions Valuation Assumptions

The fair values of stock options granted to employees were calculated using the following assumptions:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Expected term (in years)		6.0-6.1		5.3-6.3		5.3-6.1		5.3-6.3
Volatility		70.6%-70.9%		73.8%-75.3%		70.6%-82.3%		73.8%-77.0%
Risk-free interest rate		1.3%-1.5%		1.6%-1.8%		1.1%-1.9%		1.5%-1.8%
Dividend yield		—		—		—		—

Performance-Contingent Awards

On April 9, 2015, our Board of Directors granted a total of 326,424 performance-contingent awards to members of our senior management team. Of the total performance-contingent awards granted, 227,139 were performance-contingent options and 99,285 were performance-contingent shares of restricted common stock. The exercise price of each performance-contingent option and the purchase price for the performance-contingent restricted shares is $3.40 per share, which the Board of Directors determined was the fair market value on the grant date.

These awards have dual triggers of vesting based upon the successful achievement of four corporate operating milestones within specified timelines, as well as a requirement for continued employment. When a performance goal is deemed to be probable of achievement, time-based vesting and recognition of stock-based compensation expense commences. In the event any of the corporate operating milestones are not achieved by the specified timelines, such vesting tranche will terminate and no longer be exercisable with respect to that portion of the shares. During the nine months ended September 30, 2016, the Compensation Committee of our Board of Directors modified one of the corporate operating milestones, which resulted in two of the corporate operating milestones being achieved; accordingly, an aggregate of 94,502 shares underlying options and 49,643 shares of restricted stock associated with these two milestones vested and, as a result, $1.5 million of compensation cost was recognized for the performance-contingent awards, including $1.4 million of compensation cost related to the modified corporate operating milestone. One of the remaining two corporate operating milestones was not met within the timeframe required for achievement during the nine months ended September 30, 2016; accordingly, 47,500 shares underlying options and 24,821 shares of restricted stock associated with the milestone were forfeited. As of September 30, 2016, unvested performance-contingent awards included 47,495 shares underlying options and 24,821 shares of restricted stock associated with the remaining operating milestone.

GLOBAL BLOOD THERAPEUTICS, INC.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

Market-Condition Award

On April 9, 2015, our Board of Directors granted a market-condition award to our Chief Executive Officer of 99,285 shares of restricted common stock. The market-condition award does not vest until our market capitalization (determined based on the number of shares of common stock outstanding multiplied by the closing market price for our common stock as reported on NASDAQ) exceeds at least $2.0 billion for 20 consecutive trading days on or before the date twenty-four (24) months after the closing of our initial public offering, or IPO.

The fair value of the market-condition award of $0.70 was determined on the grant date utilizing a lattice model that was prepared by a third party valuation firm with an expected term of 2.4 years. In August 2015, we began to recognize compensation costs for this award concurrent with the closing of our IPO.

Stock-Based Compensation Expense

Total stock-based compensation recognized by function was as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Research and development	$	1,019	$	527	$	2,065	$	1,232
General and administrative		2,133		347		3,819		499

Total stock-based compensation expense	$	3,152	$	874	$	5,884	$	1,731

Total stock-based compensation recognized for employees and non-employees was as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Employee options and restricted stock awards	$	3,044	$	534	$	5,651	$	1,366
Non-employee options		108		340		233		365

Total stock-based compensation expense	$	3,152	$	874	$	5,884	$	1,731

Unrecognized Stock-Based Compensation Expense and Weighted-Average Remaining Amortization Period

As of September 30, 2016 the unrecognized stock-based compensation cost, net of expected forfeitures, and the estimated weighted-average amortization period, using the straight-line attribution method, was as follows (in thousands, except amortization period):


	Unrecognized Compensation Cost		Weighted-average remaining amortization period (years)
Options	$	12,864		2.5
Restricted stock awards		607		1.8
2015 ESPP		193		0.2

Total unrecognized stock-based compensation expense	$	13,664

GLOBAL BLOOD THERAPEUTICS, INC.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

7. Net Loss per Share Attributable to Common Stockholders

The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders during the three and nine months ended September 30, 2016 and 2015, respectively (in thousands, except share and per share data):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Numerator:
Net loss	$	(20,985	)	$	(14,764	)	$	(55,261	)	$	(30,775	)
Accretion and dividends on redeemable convertible preferred stock		—			(787	)		—			(4,180	)

Net loss attributable to common stockholders	$	(20,985	)	$	(15,551	)	$	(55,261	)	$	(34,955	)

Denominator:
Weighted average common shares outstanding		36,353,958			17,288,610			32,074,779			7,242,559

Net loss per share attributable to common stockholders, basic and diluted	$	(0.58	)	$	(0.90	)	$	(1.72	)	$	(4.83	)

Since we were in a loss position for all periods presented, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Share issuances under equity incentive plan		2,703,252		1,990,473		2,703,252		1,990,473
Restricted stock subject to future vesting		752,220		1,171,506		752,220		1,171,506

Total		3,455,472		3,161,979		3,455,472		3,161,979

8. Related Party Transactions

Our largest investors include investment funds controlled by Third Rock Ventures, LLC (“TRV”) and two members of our Board of Directors are affiliated with TRV. Management and advisory fee expenses incurred with TRV were zero for both the three and nine months ended September 30, 2016 and zero and $65,000 for the three and nine months ended September 30, 2015, respectively.

9. License Agreement

In September 2015, we executed an agreement with the Regents of the University of California, or the Regents, for an exclusive license to those rights the Regents may own in certain patents and patent applications relating to GBT440 and GBT440 analogs, and in exchange have committed to pay a royalty of less than 1% on future net sales. In connection with this agreement we issued 85,714 shares of our common stock with an estimated fair value of $4.5 million, which was recorded in research and development expense in our statement of operations.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited financial statements and related notes thereto for the year ended December 31, 2015, included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2016, or our Annual Report.

This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. In some cases you can identify forward-looking statements by terms such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “predict,” “potential,” “believe,” “should” and similar expressions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this Quarterly Report on Form 10-Q titled “Risk Factors.” We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. Except as may be required by law, we assume no obligation to update these forward-looking statements or the reasons that results could differ from these forward-looking statements.

Overview

We are a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. We are developing our initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease, or SCD. We are currently evaluating GBT440 in SCD patients in an ongoing Phase 1/2 clinical trial, and are preparing to initiate a Phase 3 clinical trial of GBT440 in adult and adolescent patients with SCD. In addition, we are evaluating the safety and pharmacokinetics of single and multiple doses of GBT440 in adolescent patients with SCD.

SCD is a genetic disease marked by red blood cell, or RBC, destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In our clinical trials of GBT440 in SCD patients to date, we observed reduced markers of red blood cell destruction, improvements in anemia, improvements in markers of tissue oxygenation, and reduced numbers of sickled RBCs.

In addition, we are conducting a Phase 2a clinical trial of GBT440 for the treatment of idiopathic pulmonary fibrosis, or IPF, which is a hypoxemic pulmonary disorder. We are also engaged in other pre-clinical research and development activities. We own or jointly own and have exclusively licensed rights to our portfolio of product candidates in the United States, Europe and other major markets. We own two issued U.S. patents that cover the composition of matter of GBT440, which are due to expire in 2032 and 2035, respectively (absent any applicable patent term extensions), and we own or co-own additional pending patent applications in the United States and selected foreign countries.

Since our inception in 2011, we have devoted substantially all of our resources to identifying and developing our product candidates, including conducting clinical trials and preclinical studies and providing general and administrative support for these operations.

Prior to our initial public offering, or IPO, we had funded our operations primarily from the issuance and sale of redeemable convertible preferred stock. In August 2015, we completed our IPO pursuant to which we issued 6,900,000 shares of our common stock at a price of $20.00 per share. We received $126.2 million from the IPO, net of underwriting discounts and commissions, and offering expenses. In July 2016, we completed a follow-on offering pursuant to which we issued an aggregate of 6,667,228 shares of our common stock at a price of $18.75 per share, including 6,400,000 shares sold at the initial closing in June 2016 and 267,228 shares sold pursuant to the exercise of the underwriters’ over-allotment option to purchase additional shares in July 2016. We received aggregate proceeds of $117.0 million from the offering, net of underwriting discounts and commissions, and offering expenses. In October 2016, we filed our shelf registration statement on Form S-3 for the potential offering, issuance and sale by us of up to a maximum aggregate offering price of $250 million of our common stock, preferred stock, debt securities, warrants, and/or units. However, future financing may not be available in amounts or on terms acceptable to us, if at all.

We have never been profitable and have incurred net losses in each year since inception. Our net losses were $21.0 million and $14.8 million for the three months ended September 30, 2016 and 2015, respectively. As of September 30, 2016 we had an accumulated deficit of $153.7 million. To date, we have not generated any revenue. We do not expect to receive any revenue from any product candidates that we develop unless we obtain regulatory approval and commercialize our products or enter into collaborative agreements with third parties. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. As of September 30, 2016, we had $217.8 million of cash and cash equivalents.

Critical Accounting Polices and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes to our critical accounting policies from those described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report filed with the SEC on March 29, 2016.

Results of Operations

Comparison of the Three Months Ended September 30, 2016 and 2015


	Three Months Ended September 30,						$ Change			% Change
	2016			2015			$ Change			% Change
	(in thousands, except percentages)
Operating expenses:
Research and development	$	15,145		$	12,106		$	3,039			25	%
General and administrative		5,999			2,669			3,330			125	%

Total operating expenses		21,144			14,775			6,369			43	%

Loss from operations		(21,144	)		(14,775	)		(6,369	)		43	%
Interest and other (expense) income, net		159			11			148			*	%

Net loss	$	(20,985	)	$	(14,764	)	$	(6,221	)		42	%

*	Change is not meaningful

The largest component of our total operating expenses is our investment in research and development activities, including the pre-clinical and clinical development of GBT440. We allocate research and development salaries, benefits, stock-based compensation and indirect costs to GBT440 and other product candidates that we may pursue on a program-specific basis, and we include these costs in the program-specific expenses.

We expect our research and development expenses will increase in future periods as we continue to invest in research and development activities related to developing our product candidates, especially GBT440, and as programs advance into later stages of development that involve additional and larger clinical trials. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.

The following table summarizes our research and development expenses incurred during the respective periods:


	Three Months Ended September 30,				$ Change		% Change
	2016		2015		$ Change		% Change
	(in thousands, except percentages)
Research and development expenses:
GBT440 for the treatment of SCD	$	10,108	$	9,844	$	264		3	%
GBT440 for the treatment of hypoxemic pulmonary disorders		1,991		409		1,582		387	%
Other preclinical programs		3,046		1,853		1,193		64	%

Total research and development expenses	$	15,145	$	12,106	$	3,039		25	%

Research and development expenses increased by $3.0 million or 25%, to $15.1 million for the three months ended September 30, 2016 from $12.1 million for the three months ended September 30, 2015. The increase was primarily due to $4.8 million in increased external costs related to our SCD program for GBT440 as we continued our Phase 1/2 clinical trial and incurred start-up costs related to our Phase 3 study, which was partially offset by a decrease in expenses of $4.5 million for licensed intellectual property rights for GBT440 incurred in 2015, $1.6 million in increased internal and external costs associated with initiation of our Phase 2a clinical trial of GBT440 in idiopathic pulmonary fibrosis (IPF), and $2.0 million in increased expenses related to preclinical efforts for our other research-stage programs. These overall increases were further offset by $0.8 million in decreased expenditures on our HAE program as a result of the discontinuation of the program in the quarter ended September 30, 2016. Stock compensation expense was $1.0 million for the three months ended September 30, 2016 and $0.5 million for the three months ended September 30, 2015. The increase was primarily due to hiring additional personnel and recognition of the stock-based compensation expenses related to the modification and achievement of the performance-contingent awards.

General and administrative

General and administrative expenses increased by $3.3 million or 125%, to $6.0 million for the three months ended September 30, 2016 from $2.7 million for the three months ended September 30, 2015. The increase was primarily due to an increase of $3.0 million in salaries and benefits as a result of our hiring additional personnel and recognition of $0.9 million in stock-based compensation expenses related to the modification and achievement of the performance-contingent awards.

We expect to incur additional expenses in the future as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission, The NASDAQ Global Select Market, additional insurance expenses, investor relations activities and other administrative and professional services.

Comparison of the Nine Months Ended September 30, 2016 and 2015


	Nine Months Ended September 30,						$ Change			% Change
	2016			2015			$ Change			% Change
	(in thousands, except percentages)
Operating expenses:
Research and development	$	40,847		$	25,257		$	15,590			62	%
General and administrative		14,821			5,473			9,348			171	%
Related party expenses		—			65			(65	)		(100	)%

Total operating expenses		55,668			30,795			24,873			81	%

Loss from operations		(55,668	)		(30,795	)		(24,873	)		81	%
Interest and other (expense) income, net		407			20			387			*	%

Net loss	$	(55,261	)	$	(30,775	)	$	(24,486	)		80	%

*	Change is not meaningful

Research and development

The following table summarizes our research and development expenses incurred during the respective periods:


	Nine Months Ended September 30,				$ Change		% Change
	2016		2015		$ Change		% Change
	(in thousands, except percentages)
Research and development expenses:
GBT440 for the treatment of SCD	$	24,810	$	19,144	$	5,666		30	%
GBT440 for the treatment of hypoxemic pulmonary disorders		4,482		888		3,594		405	%
Other preclinical programs		11,555		5,225		6,330		121	%

Total research and development expenses	$	40,847	$	25,257	$	15,590		62	%

Research and development expenses increased by $15.6 million or 62% to $40.8 million for the nine months ended September 30, 2016 from $25.3 million for the nine months ended September 30, 2015. The increase was primarily due to increased external expense of $10.2 million related to our SCD program for GBT440 as we continued our Phase 1/2 clinical trial and incurred start-up costs related to our Phase 3 study, which was partially offset by a decrease in expenses of $4.5 million for licensed intellectual property rights for GBT440 incurred in 2015, $3.6 million in increased internal and external costs associated with initiation of our Phase 2a clinical trial of GBT440 in IPF, and $6.3 million in increased expenses related to preclinical efforts for our other research-stage programs, including our HAE program which was discontinued in the current quarter. Stock-based compensation expense was $2.1 million for the nine months ended September 30, 2016 and $1.2 million for the nine months ended September 30, 2015. The increase was primarily due to hiring additional personnel and recognition of the stock-based compensation expenses related to the modification and achievement of the performance-contingent awards.

General and administrative

General and administrative expenses increased by $9.3 million or 171%, to $14.8 million for the nine months ended September 30, 2016 from $5.5 million for the nine months ended September 30, 2015. The increase was primarily due to an increase of $6.7 million in salaries and benefits as a result of our hiring additional personnel and recognition of $0.9 million in stock-based compensation expenses related to the modification and achievement of the performance-contingent awards and an increase of $2.1 million in professional and consulting services primarily as we transitioned to a public company from a private company.

Related party expenses

Related party expenses were zero for the nine months ended September 30, 2016 compared to $65,000 for the nine months ended September 30, 2015. The decrease was due to a reduction in management services which we requested from TRV as we expanded our internal business management team.

Liquidity, Capital Resources and Plan of Operations

We are not profitable and have incurred losses and negative cash flows from operations each year since our inception. Prior to our IPO, our operations were financed primarily by net proceeds from the sale and issuance of convertible preferred stock. In August 2015, we completed our IPO pursuant to which we issued 6,900,000 shares of our common stock at a price to the public of $20.00 per share and received proceeds of $126.2 million, net of underwriting discounts and commissions, and offering expenses. In July 2016, we completed a follow-on offering pursuant to which we issued an aggregate of 6,667,228 shares of our common stock at a price of $18.75 per share, including 6,400,000 shares sold at the initial closing in June 2016 and 267,228 shares sold pursuant to the exercise of the underwriters’ over-allotment option to purchase additional shares in July 2016. We received aggregate proceeds of $117.0 million from the offering, net of underwriting discounts and commissions, and offering expenses. As of September 30, 2016, we had $217.8 million in cash and cash equivalents. In October 2016, we filed our shelf registration statement on Form S-3 for the potential offering, issuance and sale by us of up to a maximum aggregate offering price of $250 million of our common stock, preferred stock, debt securities, warrants, and/or units. However, future financing may not be available in amounts or on terms acceptable to us, if at all.

Our primary use of cash is to fund operations, which consist primarily of research and development expenditures. Cash used to fund operations is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.

We believe that our existing capital resources will be sufficient to fund our planned operations for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance GBT440 through any completion of clinical development, to develop other potential product candidates from our research programs and to fund operations for the foreseeable future. We will continue to seek funds through equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. Our future funding requirements will depend on many factors, including:

•

the time and cost necessary to conduct and complete any additional clinical trials required to pursue regulatory approvals for GBT440 for SCD or any other indications, and the costs of post-marketing studies that could be required by regulatory authorities or other post-marketing studies that we deem necessary for product lifecycle management;

•

the progress and results of the HOPE study, as well as our ongoing Phase 1/2 clinical trial of GBT440 for the treatment of SCD, and our other clinical trials of GBT440;

•

the progress, timing, scope and costs of our nonclinical studies, clinical trials and other related activities, including the ability to enroll subjects in a timely manner for our ongoing SCD, IPF and potential future clinical trials;

•

the costs of obtaining clinical and commercial supplies of GBT440 and any other product candidates we may identify and develop;

•

our ability to advance our other programs through preclinical and clinical development, and the timing and scope of these development activities;

•

our ability to successfully commercialize GBT440 and any other product candidates we may identify and develop;

•

the manufacturing, selling and marketing costs associated with the potential commercialization of GBT440 and any other product candidates we may identify and develop, including the cost and timing of establishing our sales and marketing capabilities;

•

the amount and timing of sales and other revenues from GBT440 and any other product candidates we may identify and develop, including the sales price and the availability of adequate third-party reimbursement;

•

the cash requirements of any future acquisitions or discovery of product candidates;

•

the time and cost necessary to respond to technological and market developments;

•

the extent to which we may acquire or in-license other product candidates and technologies;

•

our ability to attract, hire and retain qualified personnel; and

•

the costs of maintaining, expanding and protecting our intellectual property portfolio.

Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development expenditures. We currently have no credit facility or committed sources of capital. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidate, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical studies and research and development activities.

The following table summarizes our cash flows for the periods indicated:


	Nine Months Ended September 30,
	2016			2015
	(unaudited, in thousands)
Cash used in operating activities	$	(47,671	)	$	(21,243	)
Cash used in investing activities		(1,106	)		(775	)
Cash provided by financing activities		118,l12			128,446

Net increase in cash and cash equivalents	$	69,335		$	106,428

Cash flows from operating activities

Cash used in operating activities for the nine months ended September 30, 2016 was $47.7 million, consisting of a net loss of $55.3 million, which was partially offset by non-cash charges of $5.9 million for stock-based compensation and $0.8 million for depreciation and amortization expense. The change in our net operating assets and liabilities was primarily due to an increase of $1.7 million in our accrued expenses related to our ongoing preclinical and clinical trials for SCD, an increase of $1.1 million in accrued compensation primarily related to additional headcount, which was partially offset by an increase of $0.5 million in our prepaid expenses related to corporate insurance and a decrease of $1.5 million in our accounts payable.

Cash used in operating activities for the nine months ended September 30, 2015 was $21.2 million, consisting of a net loss of $30.8 million, which was offset by non-cash charges of $4.5 million for the fair value of stock issued for the Regents of the University of California license, $1.7 million for stock-based compensation and $0.6 million for depreciation and amortization expense. The change in our net operating assets and liabilities was due primarily to an increase of $1.9 million in our accrued expenses related to our ongoing Phase 1/2 clinical trial of GBT440 for SCD, an increase of $0.9 million in accounts payable due to an increase in our research and development activities, and an increase of $0.6 million in accrued compensation primarily related to additional headcount, which was partially offset by an increase of $0.5 million in our prepaid expenses related to corporate insurance.

Cash flows from investing activities

Cash used in investing activities for the nine months ended September 30, 2016 and 2015 was related to our purchase of property and equipment for our office and laboratory facility.

Cash flows from financing activities

Cash provided by financing activities for the nine months ended September 30, 2016 was $118.1 million, primarily from net proceeds of $117.0 million from the issuance of common stock in connection with our follow-on offering which was completed in July 2016 and to a lesser extent, proceeds of $1.1 million from the issuance of common stock to participants in the employee stock purchase plan and exercise of stock options.

Cash provided by financing activities for the nine months ended September 30, 2015 was $128.4 million, primarily from net proceeds of $126.4 million from the issuance of common stock in connection with our IPO in August 2015 and to a lesser extent, proceeds of $2.1 million from the issuance of restricted stock awards.

Off-Balance Sheet Arrangements

As of September 30, 2016, we had no off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K as promulgated by the SEC.

Contractual Obligations and Other Commitments

In September 2016, we entered into a sublease (the “Sublease”) with NexSteppe Inc., as sublandlord (“NexSteppe”) for approximately 4,700 square feet of space in a building located at 400 East Jamie Court in South San Francisco, California (the “Sublease Premises”). Subject to certain conditions, we intend to expand the Sublease Premises to include an additional 1,000 square feet of space, which would comprise all of the Premises, on or around December 31, 2016 (the “Expansion Date”). The term of the Sublease commenced on October 1, 2016 and will expire on December 31, 2017 or such earlier date as the Master Lease may be terminated pursuant to the terms thereof. The monthly commitment related to the Sublease Premises is approximately $23,000 from October 1, 2016 to December 31, 2017. The copy of the Sublease is filed herewith and is included as Exhibit 10.1.

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. We are currently in the process of evaluating the impact the adoption of this new standard will have on our financial position or results of operations.

In March 2016, the FASB issued ASU No. 2016-09, Stock Compensation. The new standard simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are currently in the process of evaluating the impact the adoption of this new standard will have on our financial position or results of operations and have elected not to early adopt the amendment.

GLOBAL BLOOD THERAPEUTICS, INC.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Sensitivity

We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. We had cash and cash equivalents of $217.8 million as of September 30, 2016 and $148.5 million as of December 31, 2015, which consist of bank deposits and money market funds. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant. We had no outstanding debt as of September 30, 2016 and December 31, 2015.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2016. Based on the evaluation of our disclosure controls and procedures as of September 30, 2016, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2016, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We are not currently a party to any material litigation or other material legal proceedings.

Item 1A. Risk Factors.

This Quarterly Report on Form 10-Q contains forward-looking information based on our current expectations. Because our business is subject to many risks and our actual results may differ materially from any forward-looking statements made by or on behalf of us, this section includes a discussion of important factors that could affect our business, operating results, financial condition and the trading price of our common stock. You should consider all of the risk factors described in this section, as well as in our other public filings, when evaluating our business. This discussion should be read in conjunction with our financial statements as of September 30, 2016 and December 31, 2015 and the notes accompanying those financial statements.

Risks Related to Our Business and the Clinical Development, Regulatory Review and Approval of Our Product Candidates

If we are unable to obtain regulatory approval in one or more jurisdictions for GBT440 or any other product candidates that we may identify and develop, our business will be substantially harmed.

We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Approval by the FDA and comparable foreign regulatory authorities is lengthy and unpredictable, and depends upon numerous factors. Approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. We have not obtained regulatory approval for any product candidate, including GBT440, and it is possible that neither GBT440 nor any other product candidates we may seek to develop in the future will ever receive regulatory approval.

Applications for GBT440 or any other product candidates we may develop could fail to receive regulatory approval for many reasons, including but not limited to:

•

we may not be able to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that GBT440 or any other product candidates we may develop are safe and effective for any of their intended indications;

•

the FDA or comparable foreign regulatory authorities may disagree with our plans regarding the pathways and endpoints for approval or the design or implementation of our clinical trials;

•

the population studied in our clinical programs may not be sufficiently broad or representative to assure safety or demonstrate efficacy in the full population for which we seek approval;

•

the FDA or comparable foreign regulatory authorities may require additional preclinical studies or clinical trials beyond those we anticipate;

•

the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical studies or clinical trials;

•

the data and results collected from clinical trials of GBT440 and any other product candidates that we may identify and pursue may not be sufficient to support the submission of a new drug application, or NDA, or other submission for regulatory approval in the United States or elsewhere;

•

we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that any product candidate’s risk-benefit ratio for its proposed indication is acceptable;

•

the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and

•

the approval policies or regulations of the FDA or comparable foreign regulatory authorities may change in a manner that renders our development and manufacturing efforts insufficient for approval.

The lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market GBT440 and any other product candidates that we may pursue in the United States or elsewhere, which would significantly harm our business, prospects, financial condition and results of operations.

We are heavily dependent on the success of our lead product candidate, GBT440, and all of our other programs are still in the preclinical development stage. If we are unable to successfully complete clinical development, obtain regulatory approval for, or commercialize GBT440, or experience delays in doing so, our business will be materially harmed.

To date, we have invested a majority of our efforts and financial resources in the preclinical and clinical development of GBT440, including conducting preclinical studies and clinical trials and providing general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and commercialize GBT440. Before we can generate any revenues from sales of GBT440, we will be required to conduct additional clinical development, including, among other things, completion of ongoing studies, including toxicology studies, and one or more larger registrational clinical trials to demonstrate safety and efficacy of GBT440 for any potential indication. In addition, we will need to seek and obtain regulatory approval, secure adequate manufacturing supply to support larger clinical trials and commercial sales and build a commercial organization. Further, the success of GBT440 will depend on patent and trade secret protection, acceptance of GBT440 by patients, the medical community and third-party payors, its ability to compete with other therapies, healthcare coverage and reimbursement, and maintenance of an acceptable safety profile following approval, among other factors. If we do not achieve these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize GBT440, which would materially harm our business.

Our initial product candidate, GBT440, is currently our only product candidate to have advanced into clinical trials. We are developing GBT440 as an oral, once-daily therapy for sickle cell disease, or SCD. We are currently evaluating GBT440 in SCD patients in an ongoing Phase 1/2 clinical trial, and are preparing to initiate a Phase 3 clinical trial of GBT440 in adult and adolescent patients with SCD. In addition, we are evaluating the safety and pharmacokinetics of single and multiple doses of GBT440 in adolescent patients with SCD, and we are also conducting a Phase 2a clinical trial of GBT440 for the treatment of idiopathic pulmonary fibrosis, or IPF, which is a hypoxemic pulmonary disorder.

All of our other programs are in an early stage of research and development, and we have no other product candidates in clinical trials. We have recently discontinued development of our former kallikrein inhibitor product candidate for the prevention of angioedema attacks associated with HAE, and we have not yet selected any other product candidates that would enable the filing of an Investigational New Drug application, or IND.

We are preparing to initiate a randomized, double-blind, placebo-controlled, multi-national Phase 3 study designed to enroll up to 400 SCD patients, age 12 years and older, who have had at least one episode of vaso-occlusive crisis in the previous year, which we are calling the HOPE study. The primary endpoint of the HOPE study relates to the proportion of patients who achieve an increase in hemoglobin levels (compared to baseline) as pre-specified in the study protocol. We have not previously conducted a clinical study of GBT440 in SCD patients using this primary endpoint, and we do not believe this measure has been used as a primary endpoint for any registration studies for any other SCD therapies. In addition, the HOPE study will also use a new patient reported outcomes (PRO) instrument that we have recently developed, and that has not been utilized before in any clinical studies, to generate data for a secondary endpoint in the HOPE study. However, before being able to seek or to obtain full or even conditional approval of GBT440 for the treatment of SCD, we may be required to conduct additional clinical trials of GBT440, including one or more additional Phase 3 clinical trials or other studies. We do not have a special protocol assessment agreement in place with the FDA.

We cannot be certain that GBT440 or any other product candidates will be successful in preclinical or clinical trials or receive regulatory approval. If we do not receive regulatory approval for, or otherwise fail to successfully commercialize, GBT440 or any other product candidates, we may need to spend significant additional time and resources to identify other product candidates, advance them through preclinical and clinical development and apply for regulatory approvals, which would adversely affect our business, prospects, financial condition and results of operations.

We may encounter substantial delays in completing our clinical trials, which in turn will result in additional costs and may ultimately prevent successful or timely completion of the clinical development and commercialization of our product candidates.

Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, time-consuming and uncertain as to the outcome. We expect to conduct the HOPE study, which will enroll up to 400 SCD patients, at multiple clinical sites located in the United States, Europe, Africa and the Middle East. We cannot guarantee that the HOPE study or any other clinical trials for our product candidates will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:

•

delays in reaching, or any failure to reach, a consensus with regulatory agencies on study design, including clinical endpoints sufficient to support an approved decision;

•

delays in reaching, or any failure to reach, agreement on acceptable terms with a sufficient number of prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

•

delays in obtaining required Institutional Review Board, or IRB, approval at each clinical trial site;

•

delays in recruiting a sufficient number of suitable patients to participate in our clinical trials;

•

imposition of a clinical hold by regulatory agencies due to safety concerns after an inspection of our clinical trial operations or study sites;

•

failure by our CROs, other third parties or us to adhere to clinical trial, regulatory or legal requirements;

•

failure to perform in accordance with the FDA’s good clinical practices, or GCP, or applicable regulatory guidelines in other countries;

•

delays in the testing, validation, manufacturing and delivery of sufficient quantities of our product candidates to the clinical sites;

•

delays in having patients enroll or complete participation in a study in accordance with applicable protocols

•

or return for post-treatment follow-up;

•

clinical trial sites or patients dropping out of a trial;

•

failure to address in an adequate or timely manner any patient safety concerns that arise during the course of a trial;

•

unanticipated costs or increases in costs of clinical trials of our product candidates;

•

occurrence of serious adverse events or other safety concerns associated with the product candidate that are viewed to outweigh its potential benefits; or

•

changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.

We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by an independent Safety Review Board for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, and failure to demonstrate a benefit from using a drug. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions.

Clinical trial delays could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to obtain regulatory approvals, commence product sales and generate revenues. Any of these occurrences may significantly harm our business, prospects, financial condition and results of operations.

Difficulty in enrolling patients or maintaining patient compliance with dosing requirements in our clinical trials could delay or prevent clinical trials of our product candidates, which in turn could delay or prevent our ability to obtain the regulatory approvals necessary to commercialize our product candidates.

Identifying and qualifying patients to participate in our ongoing and planned clinical trials of GBT440, especially for the HOPE study of GBT440 for SCD, and any other product candidates that we may develop are critical to our success. Our clinical development efforts are initially focused on rare chronic blood diseases. For example, according to CDC estimates, the prevalence of SCD, for which GBT440 is being studied, is 90,000 to 100,000 individuals in the United States. For IPF, it is estimated that less than 150,000 people in the United States are affected. Accordingly, there are limited patient pools from which to draw for clinical trials in our target indications. The HOPE study is designed to enroll up to 400 SCD patients in multiple study centers in the United States, Europe, Africa and the Middle East. We may not be able to identify, recruit, and enroll a sufficient number of subjects to complete our clinical trials of GBT440 because of the perceived risks and benefits of GBT440, the availability of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective subjects and the subject referral practices of physicians. Further, if subjects in our clinical trials fail to comply with our dosing regimens we may not be able to generate clinical data acceptable to the FDA in our trials. For the HOPE study, enrolled participants must use a patient reported outcomes (PRO) instrument to complete very frequent patient surveys generating data relevant to a secondary endpoint. If HOPE study participants fail to comply consistently with these PRO-related steps and procedures, the quality of these study data and our ability to interpret these data and results could be impaired, and these data and results may not be acceptable to the FDA. If patients are unwilling or unable to participate in, complete or comply with the protocols for our studies for any reason, the timeline for recruiting subjects, conducting studies and obtaining regulatory approval of potential products may be delayed.

If we experience difficulties or delays in enrollment or are otherwise unable to successfully complete any clinical trial of GBT440, especially the HOPE study, or our other product candidates, our costs may increase, and our ability to obtain regulatory approval and generate product revenue from any of these product candidates will be impaired. Any of these occurrences would harm our business, prospects, financial condition and results of operations.

The development of GBT440 as a potential disease-modifying anti-sickling agent in SCD and as a treatment for low oxygen levels in IPF represent novel therapeutic approaches to SCD and hypoxemic pulmonary disorders and there is a risk that the outcomes of our clinical trials will not be favorable or otherwise support a decision to seek regulatory approval or a decision to grant regulatory approval.

We have concentrated our therapeutic product research and development efforts on developing novel, mechanism-based therapeutics for the treatment of grievous blood-based disorders with significant unmet need, including SCD and IPF, and our future success depends on the successful development of this therapeutic approach. The clinical trial requirements of the FDA and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential product. At the moment, there is only one approved therapy for SCD, hydroxyurea, and there are no approved therapeutics directed toward preventing the polymerization of hemoglobin molecules as a mechanism to reduce RBC sickling in SCD patients. As a result, the design and conduct of clinical trials for a therapeutic that targets this mechanism in SCD are subject to unknown risks, and we may experience setbacks with our ongoing or planned clinical trials of GBT440 in SCD because of the limited clinical experience with its mechanism of action in SCD patients. In particular, regulatory authorities in the United States have not issued definitive guidance as to how to measure and achieve efficacy in SCD. In our Phase1/ 2 clinical trial of GBT440 for SCD, we are evaluating exploratory endpoints, including anti-sickling and anti-hemolytic effects, changes in hemoglobin levels, and reticulocyte counts. Based on our discussion with the FDA regarding the design for our Phase 3 clinical trial of GBT440 for SCD, we have determined to measure change in hemoglobin levels as the primary endpoint in the HOPE study. This primary endpoint has not been used previously in a registration study for an SCD treatment. As a result, regulators have not determined that such data signifies a clinically meaningful result in SCD patients or can support seeking or obtaining regulatory approval.

With the exception of oxygen supplementation, there is currently no approved therapy to relieve low oxygenation in patients with hypoxemic pulmonary disorders. Similar to our development program in SCD, the design and conduct of clinical trials for a therapeutic agent that targets this mechanism in IPF are subject to unknown risks, and we may experience setbacks with our ongoing or planned clinical trials of GBT440 because of the lack of clinical experience with its mechanism of action in IPF patients.

We may not achieve our pre-specified endpoints in the HOPE study, or in other clinical trials where there is limited or no regulatory guidance regarding appropriate clinical endpoints, which would decrease the probability of obtaining marketing approval for GBT440 or any other product candidate we may develop. Any inability to design clinical trials with protocols and endpoints acceptable to applicable regulatory authorities, and to obtain regulatory approvals for GBT440 and other product candidates that we may pursue, would have an adverse impact on our business, prospects, financial condition and results of operations.

Results of earlier studies may not be predictive of future clinical trial results, and initial studies may not establish an adequate safety or efficacy profile for GBT440 and other product candidates that we may pursue to justify proceeding to advanced clinical trials or an application for regulatory approval.

The results of nonclinical and preclinical studies and clinical trials of GBT440 and other product candidates that we may pursue may not be predictive of the results of later-stage clinical trials, and interim results of a clinical trial do not necessarily predict final results. For example, our preclinical studies and clinical trials of GBT440 in SCD to date have involved mostly one genotype of SCD, HbSS, and the results of these studies may not be replicated in other genotypes of SCD or in subsequent clinical trials. Additionally, any positive results generated in our Phase 1/2 clinical trial of GBT440 in SCD in adults do not ensure that we will achieve similar results in our Phase 3 study of GBT440 in SCD called the HOPE study, or in any other larger, registrational clinical trials or in clinical trials of GBT440 in SCD in pediatric populations, including our Phase 2a clinical trial of GBT440 in adolescents with SCD, or in other potential indications for GBT440, such as IPF and other hypoxemic pulmonary disorders. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval. Product candidates in later stages of clinical trials may fail to demonstrate the desired safety and efficacy despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies, and we cannot be certain that we will not face similar setbacks. Even if early stage clinical trials are successful, we will need to conduct additional clinical trials for product candidates in additional patient populations or under different treatment conditions before we are able to seek approvals from the FDA and regulatory authorities outside the United States to market and sell these product candidates. Our failure to demonstrate the required characteristics to support marketing approval for GBT440 or any other product candidate we may choose to develop in any ongoing or future clinical trials would substantially harm our business, prospects, financial condition and results of operations.

Before we are able to submit GBT440 for marketing approval, the FDA and comparable foreign regulatory authorities require that we conduct additional clinical trials and may impose additional requirements, the scope of which are not fully known at this time.

Before we can submit an NDA to the FDA for GBT440, we must successfully complete our ongoing clinical trials and one or more additional larger clinical trials. The FDA typically requires at least two pivotal, well-controlled clinical trials as a condition to the submission of an NDA and does not consider a single clinical trial to be adequate to support product approval. The FDA will typically only consider relying on one pivotal trial if, in addition, other well-controlled studies of the drug exist (for example, for other dosage forms or in other populations) or if the pivotal trial is a multi-center trial that provides highly reliable and statistically strong evidence of an important clinical benefit, such as effect on survival, organ function or patient reported outcomes and a confirmatory study would have been difficult to conduct on ethical grounds. Based on our discussions with the FDA regarding the design of the Phase 3 HOPE study of GBT440 in SCD patients, we believe that if the HOPE study meets the primary endpoint and at least one key secondary endpoint, the data and results from this Phase 3 clinical trial could form the basis for regulatory approval of GBT440 for SCD treatment. Before being able to seek or to obtain full or even conditional approval of GBT440 for the treatment of SCD, we may be required to conduct additional clinical trials of GBT440, including one or more additional Phase 3 clinical trials or other studies. We do not have a special protocol assessment agreement in place with the FDA. The FDA may also require a longer follow-up period for subjects treated with GBT440 prior to accepting an NDA submission.

The FDA or the comparable foreign authorities may not consider the design or results of our ongoing and planned clinical trials, including the HOPE study in SCD patients, to be sufficient for approval of GBT440 for SCD or IPF. If the FDA or comparable foreign regulatory authorities require additional clinical trials or data beyond that which we currently anticipate, we would incur increased costs and delays in the clinical development and marketing approval process, which may require us to expend more resources than are available to us. In addition, it is possible that the FDA and the comparable foreign authorities may have divergent opinions on the elements necessary for a successful NDA and Marketing Authorization Application, or MAA, respectively, which may cause us to alter our development, regulatory and/or commercialization strategies.

If serious adverse events or unacceptable side effects are identified during the development of our product candidates, we may need to delay, limit or terminate our clinical development activities.

Clinical trials by their nature utilize a sample of the potential patient population. Our Phase 1/2 clinical trial of GBT440 in SCD is designed to enroll between 96 and 128 subjects, and our Phase 2a clinical trial in IPF up to 30 subjects. Our Phase 3 HOPE study of GBT440 in SCD is designed to enroll up to 400 subjects. Any rare and severe side effects of GBT440 may be uncovered only in later stages of our ongoing clinical trials or only in trials involving different patient populations, such as pediatric patients, or any larger trials that we may conduct (including the HOPE study). Many product candidates that initially showed promise in early stage testing have later been found to cause side effects that prevented their further development. Moreover, a preclinical toxicology study with GBT440 in non-humans and clinical trials involving other hemoglobin modifiers have shown a decrease in oxygen delivery to tissue when the percentage of modified hemoglobin is significant. Hemoglobin modifiers, by increasing sickle hemoglobin’s, or HbS’s, affinity for oxygen, can cause a shift in oxygen levels, potentially resulting in tissue hypoxia. If GBT440 or any product candidates that we may develop are associated with tissue hypoxia or other undesirable side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which could adversely affect our business, prospects, financial condition and results of operations.

Although we intend to pursue expedited regulatory approval pathways for GBT440, it may not qualify for expedited development or, if it does qualify for expedited development, it may not actually lead to a faster development or regulatory review or approval process.

Although we believe there may be an opportunity to accelerate the development of GBT440 through one or more of the FDA’s expedited programs, such as fast track, breakthrough therapy, accelerated approval or priority review, and we intend to pursue one or more of these expedited programs, we cannot be assured that GBT440 or any other product candidates that we may develop will qualify for such programs.

In October 2015, the FDA designated our investigation of GBT440 for the treatment of SCD as a Fast Track development program. Fast Track is a process designated to facilitate the development and expedite the review of drugs to treat serious conditions and that demonstrate the potential to address an unmet medical need. While Fast Track designation may provide more frequent access and communication with the FDA, it does not ensure that regulatory approval for GBT440 will occur on an expedited basis.

In addition, a drug may be eligible for designation as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Although breakthrough designation or access to any other expedited program may expedite the development or approval process, it does not change the standards for approval. If we apply for breakthrough therapy designation or any other expedited program for GBT440, the FDA may determine that GBT440, our proposed target indication or other aspects of our clinical development plans do not qualify for such expedited program. Even if we are successful in obtaining a breakthrough therapy designation or access to any other expedited program, we may not experience faster development timelines or achieve faster review or approval compared to conventional FDA procedures.

Furthermore, access to an expedited program may also be withdrawn by the FDA if it believes that the designation is no longer supported by data from our clinical development program. Additionally, qualification for Fast Track or any other expedited review procedure does not ensure that we will ultimately obtain regulatory approval for GBT440 or any other product candidate that we may develop in a timely manner, or at all.

Although the FDA has granted orphan drug designation to GBT440 for the treatment of SCD, we may not receive orphan drug designation for GBT440 in other jurisdictions or for other indications that we may pursue, or for any other product candidates for which we may submit new applications for orphan drug designation, and any orphan drug designations that we have received or may receive may not confer marketing exclusivity or other expected commercial benefits.

Our business strategy focuses on the development of product candidates for the treatment of rare, chronic blood disorders that may be eligible for FDA or European Union, or EU, orphan drug designation. Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. In the EU, the Committee for Orphan Medicinal Products of the European Medicines Agency, or EMA, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU (or where it is unlikely that the development of the medicine would generate sufficient return to justify the investment) and for which no satisfactory method of diagnosis, prevention, or treatment is authorized or, if a method exists, the product would be of significant benefit to those affected by the condition. In December 2015, the FDA granted orphan drug designation for GBT440 for the treatment of patients with SCD.

Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same drug for that time period. The applicable period is seven years in the United States and 10 years in the EU. The EU exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.

Although the FDA has granted orphan drug designation to GBT440 for the treatment of SCD, we may apply for orphan drug designation for GBT440 in other jurisdictions or for other indications, or for other product candidates we may develop, and applicable regulatory authorities may not grant us these additional designations. In addition, the exclusivity granted under any orphan drug designations that we have received or may receive may not effectively protect the product candidate from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve another drug for the same condition if the FDA concludes that the later drug is clinically superior, in that it is shown to be safer, more effective or makes a major contribution to patient care. Any inability to secure or maintain orphan drug designation or the exclusivity benefits of this designation would have an adverse impact on our ability to develop and commercialize our product candidates.

Even if we receive regulatory approval for GBT440 or any other product candidate that we may develop, we will be subject to ongoing regulatory obligations and scrutiny and may be subject to product labeling and other post-marketing restrictions.

Even if a product candidate is approved, regulatory authorities may still impose significant restrictions on its indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing studies. Furthermore, any new legislation addressing drug safety issues could result in delays or increased costs to assure compliance. If GBT440 or any other product candidates that we may develop are approved, they will each be subject to ongoing regulatory requirements for labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information, including both federal and state requirements in the United States. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. For example, the development of GBT440 for the treatment of SCD in pediatric patients is an important part of our current business strategy, and if we are unable to obtain regulatory approval for the desired age ranges, our business may suffer.

In addition, manufacturers and manufacturers’ facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices, or cGMP. As such, we and our contract manufacturers are subject to continual review and periodic inspections to assess compliance with cGMP and must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. We will also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for our products. The timing of our obligation to report adverse events would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved label. As such, we may not promote our products for indications or uses for which they do not have FDA approval.

If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing, or labeling of a product, a regulatory agency may impose restrictions or sanctions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may:

•

issue untitled or warning letters;

•

impose civil or criminal penalties;

•

impose injunctions;

•

suspend regulatory approval;

•

suspend any of our ongoing clinical trials;

•

impose product recalls and publicity requirements;

•

refuse to approve pending applications or supplements to approved applications submitted by us;

•

impose restrictions on our operations, including closing our contract manufacturers’ facilities; or

•

seize or detain products.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues from GBT440 or any future product candidates. If we are subject to regulatory sanctions or if regulatory approval for our product candidates is withdrawn or limited, our business, prospects, financial condition and results of operations would be harmed.

Risks Related to Our Financial Position and Need for Additional Capital

We are a clinical development-stage biopharmaceutical company with a limited operating history. We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We have only one product candidate in clinical development and have not generated any revenue since our inception, which, together with our limited operating history, may make it difficult for you to assess our future viability.

We are a clinical development-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have focused principally on developing our lead product candidate, GBT440, which is our only product candidate in clinical development.

We are not profitable and have incurred losses in each year since our inception in February 2011 and the commencement of our principal operations in May 2012. Our net losses for the years ended December 31, 2015, 2014 and 2013 were $46.4 million, $20.8 million and $18.1 million, respectively. Our net losses for the nine months ended September 30, 2016 and 2015 were $55.3 million and $30.8 million, respectively. As of September 30, 2016, we had an accumulated deficit of $153.7 million. We have not generated any revenue since our inception, and have financed our operations primarily through the sale of equity securities. We continue to incur significant research and development and other expenses related to our ongoing operations and expect to incur losses for the foreseeable future. We anticipate these losses will increase as we:

•

continue to advance GBT440 in clinical development for SCD, including as we prepare to initiate our Phase 3 HOPE study of GBT440 for SCD;

•

establish and maintain manufacturing and supply relationships with third parties that can provide adequate supplies (in amount and quality) of GBT440 to support further clinical development and, if approved, commercialization;

•

seek and obtain regulatory and marketing approvals for GBT440;

•

build a sales and marketing organization or enter into selected collaborations to commercialize GBT440, if approved;

•

advance our other programs, including our programs for the clinical investigation of GBT440 in IPF patients with hypoxemia and our other preclinical programs through preclinical and clinical development and commence development activities for any additional product candidates we may identify; and

•

expand our organization to support our research, development and commercialization activities and our operations as a public company.

We have never generated any revenues from product sales and may never be able to develop or commercialize a marketable drug or achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to achieve sustained profitability would depress the value of our company and could impair our ability to raise capital, expand our business, diversify our research and development pipeline, market GBT440 or any other product candidates we may identify and pursue, if approved, or continue our operations. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ equity and working capital.

We will require substantial additional funding to achieve our business goals. If we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our product development efforts or other operations. Raising additional capital may subject us to unfavorable terms, cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates and technologies.

We are currently advancing GBT440 through clinical development, including by initiating a multi-national Phase 3 study that will enroll up to 400 patients with SCD, and we are conducting preclinical research activities in our other programs. Developing biopharmaceutical products is expensive and time-consuming, and we expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance GBT440 and other product candidates that we may identify and pursue in clinical trials. As of September 30, 2016 and December 31, 2015, we had working capital of $208.1 million and $140.1 million, respectively, and capital resources consisting of cash and cash equivalents of $217.8 million and $148.5 million, respectively. Because the outcome of any clinical development and regulatory approval process is highly uncertain, we cannot reasonably estimate the actual capital amounts necessary to successfully complete the development, regulatory approval process and commercialization of GBT440 and any future product candidates.

In August 2015 we sold 6,900,000 shares of common stock in our IPO, the net proceeds of which totaled $126.2 million, after deducting underwriting discounts and commissions and offering expenses. In July 2016 we completed the sale of 6,667,228 shares of common stock in a follow-on offering, the net proceeds of which totaled $117.0 million, after deducting underwriting discounts and commissions and offering expenses. We expect that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next twelve months. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations or license and development agreements. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize GBT440 and other product candidates that we may identify and pursue. Moreover, such financing may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.

Our future funding requirements will depend on many factors, including, but not limited to:

•

the time and cost necessary to initiate and complete our Phase 3 study of GBT440 for SCD, called the HOPE study, as well as to complete our ongoing Phase 1/ 2 clinical trial of GBT440 for the treatment of SCD and our Phase 2a clinical trial of GBT440 in IPF, to conduct and complete any additional clinical studies required to pursue regulatory approvals for GBT440 for SCD or any other indication, and the costs of post-marketing studies that could be required by regulatory authorities;

•

the progress and results of our Phase 3 HOPE study, as well as of our Phase 1/2 clinical trial of GBT440 for the treatment of SCD and our other clinical trials of GBT440;

•

the costs of obtaining clinical and commercial supplies of GBT440 and any other product candidates we may identify and develop;

•

our ability to advance our other programs, including our programs for the clinical investigation of GBT440 in IPF patients with hypoxemic disorders through preclinical and clinical development, and the timing and scope of these development activities;

•

our ability to successfully commercialize GBT440 and any other product candidates we may identify and develop;

•

the cash requirements of any future acquisitions or discovery of product candidates;

•

the time and cost necessary to respond to technological and market developments;

•

the extent to which we may acquire or in-license other product candidates and technologies;

•

our ability to attract, hire and retain qualified personnel; and

•

the costs of maintaining, expanding and protecting our intellectual property portfolio.

Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit or terminate the clinical development of GBT440 in one or more indications or one or more of our other research or development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially and adversely affect our business, prospects, financial condition and results of operations.

Risks Related to Our Reliance on Third Parties

We rely, and will continue to rely, on third parties to conduct some of our nonclinical studies and all of our clinical trials and also to perform other tasks for us. If these third parties perform in an unsatisfactory manner, it may harm our business.

We have relied upon and plan to continue to rely upon third-party CROs, including our CRO who monitors our clinical trials of GBT440, to monitor and manage data for some of our ongoing nonclinical and all of our clinical programs. We rely on these parties for execution of our nonclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials are conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with cGMP or GCP, and Good Laboratory Practices, or GLP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities. Regulatory authorities enforce these regulations through periodic inspections of study sponsors, principal investigators, study sites, and other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations, the data generated in our nonclinical studies and clinical trials may be deemed unreliable and the applicable regulatory authorities may require us to repeat or to perform additional nonclinical and clinical studies before approving our marketing applications, which would delay the regulatory approval process.

In addition, the execution of preclinical studies and clinical trials, and the subsequent compilation and analysis of the data produced, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. These third parties may terminate their agreements with us upon as little as 30 days prior written notice of a material breach by us that is not cured within 30 days. Many of these agreements may also be terminated by such third parties under certain other circumstances, including for convenience or upon our failure to comply with applicable laws. If any of our relationships with our third-party CROs terminates, we may not be able to enter into arrangements with alternative CROs on a timely basis or at all, or do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether they devote sufficient time and resources to our programs. Furthermore, these third party CROs may also have relationships with other entities, some of which may be our competitors. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements, or for other reasons, our development activities may be extended, delayed, or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. Switching or adding CROs involves additional cost, time and management resources and focus. CROs may also generate higher costs than anticipated.

Accordingly, our dependence on third-party CROs and other vendors may subject us to challenges, delays and costs that have a material adverse impact on our business, prospects, financial condition and results of operations.

We rely entirely on third parties for the manufacturing of our product candidates for preclinical studies and clinical trials and expect to continue to do so for any product commercialization. Our business could be harmed if any of those third parties fail to provide us with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices.

We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture drug supplies for our ongoing and planned clinical trials of GBT440 or any additional clinical trials that we may conduct, and we lack the resources to manufacture any of our product candidates on a commercial scale. We rely, and expect to continue to rely, on third-party manufacturers to produce our product candidates for our clinical trials, including our planned HOPE study, as well as for commercial manufacture if any of our product candidates receives marketing approval. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the trial, any significant delay or discontinuity in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay the clinical development and potential regulatory approval of our product candidates, which could harm our business and results of operations. We also expect to rely on multiple third parties for the manufacture of commercial supplies of GBT440 or any other product candidates, if approved.

We may be unable to establish or maintain agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish or maintain agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

•

reliance on the third party for regulatory compliance and quality assurance;

•

the possible breach of the manufacturing agreement by the third party;

•

the possible misappropriation of our proprietary information, including our trade secrets and know-how; and

•

the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for us.

Furthermore, all of our contract manufacturers are engaged with other companies to supply and/or manufacture materials or products for such companies, which exposes our manufacturers to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may affect the regulatory clearance of our contract manufacturers’ facilities generally. If the FDA or a comparable foreign regulatory agency does not approve these facilities for the manufacture of our product candidates or if any agency withdraws its approval in the future, we may need to find alternative manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.

GBT440 and any future product candidates that we may develop may compete with other product candidates and marketed drugs for access to manufacturing facilities. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We are currently manufacturing GBT440 through third parties. Although we currently have adequate supplies to conduct our ongoing clinical trials, if we are unable to enter into relationships with additional contract manufacturers, or our current or future contract manufacturers cannot perform as agreed, we may experience delays and incur additional costs in our clinical development and commercialization activities. Our current and anticipated future dependence upon others for the manufacturing of our product candidates or marketed drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.

If the contract manufacturing facilities on which we rely do not continue to meet regulatory requirements or are unable to meet our supply demands, our business will be harmed.

All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP, or similar regulatory requirements outside the United States. These regulations govern manufacturing processes and procedures, including recordkeeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, suspension of production, seizures or recalls of product candidates or marketed drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect clinical or commercial supplies of our product candidates.

We or our contract manufacturers must supply all necessary documentation in support of an NDA or MAA on a timely basis and must adhere to GLP and cGMP regulations enforced by the FDA and other regulatory agencies through their facilities inspection program. Some of our contract manufacturers have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals to do so. The facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the contract manufacturers, we cannot control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever.

The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.

Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA supplement or MAA variation, or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.

These factors could cause us to incur higher costs and could cause the delay or termination of clinical trials, regulatory submissions, required approvals, or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.

Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Because we rely on third parties to manufacture GBT440 and conduct other aspects of our clinical development activities, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with any collaborators, CROs, manufacturers and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.

In addition, these agreements typically restrict the ability of certain collaborators, CROs, manufacturers and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. A competitor’s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.

Risks Related to Our Intellectual Property

If we or our licensors are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize product candidates similar or identical to ours, and our ability to successfully commercialize GBT440 and other product candidates that we may pursue may be impaired. Changes in patent policy and rules could impair our ability to protect our products and increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.

As is the case with other biopharmaceutical companies, our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may exclusively license or own solely and jointly with others, particularly patents, in the United States and other countries with respect to our product candidates and technology. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates.

Obtaining and enforcing biopharmaceutical patents is costly, time consuming and complex, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal, technological and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive product candidates. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative product candidates in a non-infringing manner.

Moreover, we may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or the USPTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.

In addition, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical product candidates, or limit the duration of the patent protection of our product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.

The United States has enacted and is currently implementing wide-ranging patent reform legislation. The United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would diminish the value of our patents and patent applications or narrow the scope of our patent protection, or weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

Assuming the other requirements for patentability are met, in the United States prior to March 15, 2013, the first to make the claimed invention is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act, or the Leahy-Smith Act, enacted on September 16, 2011, the United States has moved to a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. The effects of these changes are currently unclear as the USPTO must still implement various regulations, the courts have yet to address certain of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of patents that may issue from such patent applications, all of which could have a material adverse effect on our business and financial condition. Any further changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents and patent applications or narrow the scope of our potential patent protection.

We may become subject to claims alleging infringement of third parties’ patents or proprietary rights and/or claims seeking to invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, delay or prevent the development and commercialization of GBT440 or any future product candidates that we may develop.

We cannot assure that GBT440 or any future product candidates that we may develop will not infringe existing or future third-party patents. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be applications now pending of which we are unaware and which may later result in issued patents that we may infringe by commercializing GBT440 or any future product candidates that we may develop. We may additionally be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of GBT440 or any of our other product candidates.

We may in the future become party to, or be threatened with, adversarial proceedings or litigation against us regarding intellectual property rights with respect to our product candidates, that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages, including treble damages and attorneys’ fees if we are found to be willfully infringing a third party’s patents. We may also be required to indemnify parties with whom we have contractual relationships against such claims. If a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we may choose to seek, or be required to seek, a license from the third party to continue developing, manufacturing and marketing our product candidates and would most likely be required to pay license fees or royalties or both, that could be significant. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property licensed to us. Ultimately, we could be prevented from commercializing a product, or forced to redesign it, or to cease some aspect of our business operations if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. Even if we are successful in defending against such claims, such litigation can be expensive and time consuming to litigate and would divert management’s attention from our core business. Any of these events could harm our business significantly.

In addition to infringement claims against us, if third parties prepare and file patent applications in the United States that also claim technology similar or identical to ours, we may have to participate in interference or derivation proceedings in the USPTO, to determine which party is entitled to a patent on the disputed invention. We may also become involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology.

We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.

Competitors may infringe our patents or other intellectual property. Although we are not currently involved in any litigation, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.

Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.

We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, inventorship disputes may arise from conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership or we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

We jointly own patents and patent applications with third parties. Our ability to exploit or enforce these patent rights, or to prevent the third party from granting licenses to others with respect to these patent rights, may be limited in some circumstances.

We jointly own certain patents and patent applications with third parties. In the absence of an agreement with each co-owner of jointly owned patent rights, we will be subject to default rules pertaining to joint ownership. Some countries require the consent of all joint owners to exploit, license or assign jointly owned patents, and if we are unable to obtain that consent from the joint owners, we may be unable to exploit the invention or to license or assign our rights under these patents and patent applications in those countries. For example, in September 2015 we secured exclusive rights from the Regents of the University of California for certain patents and patent applications that they jointly own related to GBT440 and GBT440 analogs. Additionally, in the United States, each co-owner may be required to be joined as a party to any claim or action we may wish to bring to enforce these patent rights, which may limit our ability to pursue third party infringement claims.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employees’ former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed.

We seek to protect our confidential proprietary information, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Risks Related to Commercialization

Even if GBT440 or any other product candidate that we may develop receives marketing approval, their commercial success will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the medical community.

If GBT440 or other product candidates that we may pursue receives marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenue from drug sales and we may not become profitable. Before granting reimbursement approval, healthcare payors may require us to demonstrate that our product candidates, in addition to treating these target indications, also provide incremental health benefits to patients. Our efforts to educate the medical community and third-party payors about the benefits of our product candidates may require significant resources and may never be successful. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:

•

the efficacy and potential advantages compared to alternative treatments, such as, in the case of GBT440 for SCD, hydroxyurea;

•

our ability to offer our drugs for sale at competitive prices;

•

the convenience and ease of administration compared to alternative treatments, including future alternative treatments;

•

the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;

•

the availability of products and their ability to meet market demand, including a reliable supply for long-term daily treatment;

•

the strength of marketing and distribution support;

•

the availability of third-party coverage and adequate reimbursement;

•

the clinical indications for which the product is approved;

•

the prevalence and severity of any side effects and overall safety profile; and

•

any restrictions on the use of our drugs together with other medications.

If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unsuccessful in commercializing our product candidates when approved by health authorities.

Although some of our employees have experience with commercializing products while employed at other companies, we as a company have no experience selling and marketing our product candidates and we currently have no marketing or sales organization. To successfully commercialize any products that may result from our development programs, we will need to develop these capabilities, either on our own or with others. If our product candidates receive regulatory approval, we intend to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in major markets, which will be expensive, difficult and time consuming. Any failure or delay in the development of our internal sales, marketing, and distribution capabilities would adversely impact the commercialization of our products.

Further, given our lack of prior experience in marketing and selling biopharmaceutical products, our initial estimate of the size of the required sales force may be materially more or less than the size of the sales force actually required to effectively commercialize our product candidates. As such, we may be required to hire substantially more sales representatives to adequately support the commercialization of our product candidates or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect to certain geographical markets, we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If our future collaborators do not commit sufficient resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We may be competing with companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.

The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.

Our target patient populations are small, and accordingly the pricing, coverage and reimbursement of our product candidates, if approved, must be adequate to support our commercial infrastructure. Our per-patient prices must be sufficient to recover our development and manufacturing costs and potentially achieve profitability. Accordingly, the availability of government funded or private insurance coverage for our product candidates for any approved indications, and the extent of reimbursement by governmental and private payors, will be essential for most patients to be able to afford expensive treatments, such as ours, assuming approval. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.

There is significant uncertainty related to the insurance coverage and reimbursement of newly approved drug products. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare & Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicaid or Medicare However, the practices and requirements relating to the payment of rebates by drug manufacturers for Medicaid purchases are determined by each state, and in some cases, if a company does not enter into a rebate agreement, its Medicaid sales will be subjected to a “prior authorization” procedure that requires state agency approval to qualify a doctor’s prescription for reimbursement.

Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.

Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and levels of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative and political changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, drug prices are under significant scrutiny in the markets in which our products may be sold, and drug pricing and other healthcare costs continue to be subject to intense political and social pressures which we anticipate will continue and escalate on a global basis. As a result, our business and reputation may be harmed, our stock price may be adversely impacted and experience periods of volatility, we may have difficulty raising funds and our results of operations may be adversely impacted.

In light of the large population of patients with SCD who reside in foreign countries, our ability to generate meaningful revenues in those jurisdictions may be limited due to the strict price controls and reimbursement limitations imposed by governments outside of the United States.

In some countries, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our product candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially, based on the large population of patients with SCD who reside in foreign countries.

Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.

In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the Health Care Reform Law, was passed, which substantially changes the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The Health Care Reform Law, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and promoted a new Medicare Part D coverage gap discount program.

In addition, other legislative changes have been proposed and adopted in the United States since the Health Care Reform Law was enacted. On August 2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year. On January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, delayed for another two months the budget cuts mandated by these sequestration provisions of the Budget Control Act of 2011. On March 1, 2013, the President signed an executive order implementing sequestration, and on April 1, 2013, the 2% Medicare payment reductions went into effect. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.

We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We are currently aware of various existing therapies and development candidates that may compete with our product candidates. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies. Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development, marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization and market penetration than we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.

If the market opportunities for our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. Our ability to successfully identify patients and acquire a significant market share will be necessary for us to achieve profitability and growth.

Our initial research and product development efforts are focused on treatments for SCD and IPF. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat is in early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability despite obtaining such significant market share.

Risks Related to Our Business and Industry

Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.

We are highly dependent on the management, research and development, clinical, financial and business development expertise of our executive officers, as well as the other members of our scientific and clinical teams. Although we have employment offer letters with each of our executive officers, each of them may terminate their employment with us at any time. We do not maintain “key person” insurance for any of our executives or employees.

Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of our drug pipeline toward scaling up for commercialization, sales and marketing personnel, will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval for and commercialize our product candidates. Competition to hire qualified personnel in our industry and geographic market is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. Furthermore, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.

We expect to expand our product development capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of research, drug development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.

If we are not successful in discovering, developing, acquiring or commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.

Although a substantial amount of our effort will focus on the continued clinical testing, potential approval and commercialization of GBT440, a key element of our strategy is to pursue, develop and commercialize a portfolio of products utilizing proprietary discovery and development technology. We are seeking to do so through our internal research programs and may also selectively pursue commercially synergistic in-licensing or acquisition of additional assets. With the exception of GBT440, all of our other potential product candidates remain in the preclinical development stage. Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following:

•

the research methodology used may not be successful in identifying potential product candidates;

•

competitors may develop alternatives that render our product candidates obsolete or less attractive;

•

product candidates we develop may nevertheless be covered by third parties’ patents or other exclusive rights;

•

the market for a product candidate may change during our program so that such a product may become unreasonable to continue to develop;

•

a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;

•

a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and

•

a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable.

If we fail to develop and successfully commercialize other product candidates, our business and future prospects may be harmed and our business will be more vulnerable to any problems that we encounter in developing and commercializing GBT440.

If successful product liability claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients, or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.

The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:

•

impairment of our business reputation;

•

withdrawal of clinical trial participants;

•

costs due to related litigation;

•

distraction of management’s attention from our primary business;

•

substantial monetary awards to patients or other claimants;

•

increased FDA warnings on product labels;

•

the inability to commercialize our product candidates; and

•

decreased demand for our product candidates, if approved for commercial sale.

We carry product liability insurance in amounts that we believe are sufficient in light of our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.

During the course of treatment, patients may suffer adverse events, including death, for reasons that may or may not be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our product candidates, if approved, or require us to suspend or abandon our commercialization efforts of any approved product candidates. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

We may choose to use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on other programs or product candidates that may ultimately be more profitable or for which there is a greater likelihood of success.

Because we have limited resources, we may forego or delay the pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for product candidates, including GBT440, may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other partnering arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.

Any collaboration arrangements that we might enter into in the future may not be successful, which could adversely affect our operations and financial condition.

We may seek collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization of GBT440 and potential future product candidates. We may enter into these arrangements on a selective basis depending on the merits of retaining commercialization rights for ourselves as compared to entering into selective collaboration arrangements with leading pharmaceutical or biotechnology companies for our product candidates, both in the United States and internationally. We will face, to the extent that we decide to enter into collaboration agreements, significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for a product candidate, the costs and complexities of manufacturing and delivering a product candidate to patients, the potential of competing products, any uncertainty with respect to our ownership of technology, which can occur if there is a challenge to our ownership without regard to the merits of the challenge and industry and market conditions generally. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and implement, and we have not previously established our ability to do so successfully. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements should we so chose to enter into such arrangements. The terms of any collaborations or other arrangements that we may establish may not be favorable to us.

Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority under the collaboration agreement. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation.

Our anticipated international operations may expose us to business, regulatory, political, operational, financial, pricing and reimbursement and economic risks associated with doing business outside of the United States.

Our business strategy incorporates potential international expansion as we prepare to initiate our multi-national HOPE study and seek to obtain regulatory approval for, and commercialize, GBT440 in patient populations outside the United States. If GBT440 is approved, we may hire sales representatives and conduct physician and patient association outreach activities outside of the United States. Doing business internationally involves a number of risks, including but not limited to:

•

multiple, conflicting, and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and any requirements to obtain other governmental approvals, permits, and licenses;

•

failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;

•

additional potentially relevant third-party patent rights;

•

complexities and difficulties in obtaining protection for and enforcing our intellectual property;

•

difficulties in staffing and managing foreign operations;

•

complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;

•

limits in our ability to penetrate international markets;

•

financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations;

•

natural disasters, political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions;

•

certain expenses including, among others, expenses for travel, translation, and insurance; and

•

regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions.

Any of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.

The Referendum on the United Kingdom’s Membership of the European Union may adversely affect our business operations and our ability to raise capital.

On June 23, 2016, the United Kingdom (or the U.K.) held a referendum in which voters supported the exit of the U. K. from the EU (commonly referred to as “Brexit”), which could cause disruptions to and create uncertainty surrounding our business, including affecting our existing relationships with third parties that conduct some of our nonclinical studies and clinical trials and our ability to enter into new relationships with vendors and other third-party contractors, which could have an adverse effect on our business, financial results and operations. The referendum is non-binding; however if passed into law, negotiations would commence to determine the future terms of the U.K.’s relationship with the EU, including the terms of trade between the U.K. and the EU. Brexit has already and could continue to adversely affect European and/or worldwide economic and market conditions and could continue to contribute to instability in the global financial markets. The long-term effects of Brexit will depend in part on any agreements the U.K. makes to retain access to EU markets either during a transitional period or more permanently.

The measures could also adversely affect our ability to raise additional capital, potentially disrupt the markets in which we currently conduct and plan to conduct operations and the tax jurisdictions in which we operate and adversely change tax benefits or liabilities in these or other jurisdictions. In addition, Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the U.K. determines which EU laws to replace or replicate, which may present difficulties for our clinical and regulatory strategy.

Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.

Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets which biotechnology companies such as ourselves rely upon for sources of capital. In the past, global financial crises caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including reduced ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.

We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.

Our internal computer systems, or those of our CROs, CMOs, or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our drug development programs.

Despite the implementation of security measures, our internal computer systems and those of our CROs, CMOs, and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of data from completed or ongoing clinical trials or preclinical studies for any of our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed.

Risks Related to Our Equity Securities

If we fail to maintain proper and effective systems of disclosure controls and internal controls over financial reporting to the extent required under applicable regulations, the accuracy and timeliness of our financial reporting may be adversely affected, and we could be subject to sanctions or other penalties that would harm our business.

As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, Section 404, or Section 404, of the Sarbanes-Oxley Act of 2002, or Sarbanes Oxley, and the rules and regulations of The NASDAQ Stock Market. Section 404 generally requires our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Company responsibilities required by Sarbanes Oxley include establishing and maintaining corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.

Beginning with the annual report on Form 10-K for the fiscal year ending December 31, 2016, Section 404 requires an annual management assessment of the effectiveness of our internal control over financial reporting. Once we are no longer an emerging growth company under the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. We expect to incur additional professional fees and internal costs to expand our accounting and finance functions and to expend significant management efforts in order to comply with these requirements. Previously we have never been required to test our internal controls within a specified period and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner.

To date, we have never conducted a review of our internal control over financial reporting for the purpose of providing the reports required by Section 404. However, during the course of our subsequent review and testing, we may identify material weaknesses or significant deficiencies and be unable to remediate them before we must provide the required reports. If material weaknesses or significant deficiencies in our internal control over financial reporting are identified in the future, we may not detect or remediate errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from The NASDAQ Global Select Market or other adverse consequences that would materially harm our business.

We are an “emerging growth company,” and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our common stock less attractive to investors.

We are an “emerging growth company” as defined in the JOBS Act, and we have elected to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earliest of (1) December 31, 2020, (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.0 billion, (3) the last day of the fiscal year in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th and (4) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. We cannot predict if investors will find our common stock less attractive because we may rely on certain reporting exemptions available to emerging growth companies. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

The market price of our common stock has been and may continue to be highly volatile.

The market price of our common stock has experienced volatility since our IPO in August 2015 and is likely to continue to be volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:

•

adverse results or delays in our preclinical studies or clinical trials;

•

reports of adverse events in other treatments for SCD, IPF or other indications that we may pursue, or clinical trials of such products;

•

any delay in filing an IND or NDA for any of our product candidates that we may develop and any adverse development or perceived adverse development with respect to the FDA’s review of that IND or NDA;

•

failure to develop successfully and commercialize GBT440 or any other product candidates that we may develop;

•

adverse regulatory decisions affecting our product candidates or development programs;

•

inability to obtain additional funding;

•

our failure to prosecute, maintain or enforce our intellectual property rights;

•

changes in laws or regulations applicable to future products;

•

inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices;

•

introduction of new products, services or technologies by our competitors;

•

failure to enter into strategic collaborations;

•

failure to meet or exceed any financial projections that we or the investment community may provide;

•

the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;

•

announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;

•

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

•

additions or departures of key scientific or management personnel;

•

significant lawsuits, including patent or stockholder litigation;

•

changes in the market valuations of similar companies;

•

sales of our common stock by us or our stockholders in the future;

•

trading volume of our common stock; and

•

the other risks described in this “Risk Factors” section.

In addition, companies trading in the stock market in general, and The NASDAQ Global Select Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively impacted, and may continue to negatively impact, the markets for biotechnology and pharmaceutical stocks. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management’s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects.

Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.

Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. Our operating results may fluctuate due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:

•

the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may change from time to time;

•

the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;

•

our ability to obtain regulatory approval for our product candidates, and the timing and scope of any such approvals we may receive;

•

the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;

•

our ability to attract, hire and retain qualified personnel;

•

expenditures that we will or may incur to acquire or develop additional product candidates and technologies;

•

the level of demand for our product candidates, should they receive approval, which may vary significantly;

•

future accounting pronouncements or changes in our accounting policies;

•

the risk/benefit profile, cost and reimbursement policies with respect to our products candidates, if approved, and existing and potential future drugs that compete with our product candidates; and

•

the changing and volatile U.S., European and global economic environments.

The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue and/or earnings guidance we may provide.

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, would result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

We will need additional capital in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.

Pursuant to our 2015 Stock Option and Incentive Plan, or the 2015 Plan, we are authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under the 2015 Plan will automatically increase each year by up to 4% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our board of directors or compensation committee to take action to reduce the size of the increase in any given year. In addition, we have reserved shares of common stock for issuance pursuant to our 2015 Employee Stock Purchase Plan, or 2015 ESPP, which number of shares will automatically increase each year on January 1, from January 1, 2016 to January 1, 2025, by the lesser of (i) 3,000,000 shares of common stock, (ii) 1% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, or (iii) such lesser number of shares as determined by the administrator of our 2015 ESPP. Currently, we plan to register the increased number of shares available for issuance under the 2015 Plan and the 2015 ESPP each year. If our board of directors elects to increase the number of shares available for future grant by the maximum amount each year, our stockholders may experience additional dilution, and our stock price may fall.

A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly.

Sales of a substantial number of shares of our common stock in the public market could occur at any time. A significant portion of our outstanding shares of common stock are held by a small number of stockholders, including our directors, officers and affiliates. Sales by our stockholders of a substantial number of shares, or the expectation that such sales may occur, could significantly reduce the market price of our common stock.

We have also registered all shares of our common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. As a result, these shares will be available for sale in the public market subject to vesting arrangements and exercise of options, and restrictions under applicable securities laws. In addition, our directors, executive officers and certain affiliates have established or may in the future establish programmed selling plans under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, for the purpose of effecting sales of our common stock. If any of these events cause a large number of our shares to be sold in the public market, the sales could reduce the trading price of our common stock and impede our ability to raise future capital.

Additionally, certain holders of our common stock, or their transferees, have rights to require us to file one or more registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. If we were to register the resale of these shares, they could be freely sold in the public market. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Our executive officers, directors, five percent stockholders and their affiliates beneficially owned approximately 56.6% of our outstanding voting stock as of November 1, 2016 based on the latest publicly available information.

These stockholders have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.

We have broad discretion in the use of our cash and cash equivalents, and may invest or spend our cash resources in ways with which you do not agree or in ways that ultimately may not increase the value of your investment.

We have broad discretion over the use of our cash and cash equivalents. You may not agree with our decisions, and our use of our cash resources may not yield any returns to our stockholders. We expect to use our existing cash resources to continue the clinical development of GBT440, to fund the research and development of our other programs, and for working capital and general corporate purposes. Our failure to apply our cash resources effectively could compromise our ability to pursue our growth strategy and we might not be able to yield a significant return, if any, on our investment of these resources. Our stockholders will not have the opportunity to influence our decisions on how to use our cash resources.

Provisions in our restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.

Our restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our restated certificate of incorporation and amended and restated bylaws include provisions that:

•

authorize “blank check” preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;

•

create a classified board of directors whose members serve staggered three-year terms;

•

specify that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors, our chief executive officer or our president;

•

prohibit stockholder action by written consent;

•

establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;

•

provide that our directors may be removed only for cause;

•

provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;

•

specify that no stockholder is permitted to cumulate votes at any election of directors;

•

expressly authorize our board of directors to modify, alter or repeal our amended and restated bylaws; and

•

require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated bylaws.

These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management.

In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.

Any provision of our restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.

Our future ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.

We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change,” generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation’s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We experienced an ownership change as a result of our IPO, however we do not believe that this ownership change will significantly limit our ability to use these pre-change NOL carryforwards. We may experience subsequent shifts in our stock ownership, including as a result of our follow-on offering in June 2016, some of which are outside of our control. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.

We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders’ ability to achieve a return on their investment will depend on appreciation in the price of our common stock.

We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.

We will continue to incur significant costs as a result of operating as a public company, and our management will devote substantial time to compliance initiatives.

As a public company, we incur significant legal, accounting, and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and The NASDAQ Global Select Market have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as “say on pay” and pay parity. Recent legislation permits smaller “emerging growth companies” to implement many of these requirements over a longer period and up to five years from the pricing of our IPO. We have elected to take advantage of this legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of such coverage.

New laws and regulations as well as changes to existing laws and regulations affecting public companies, including the provisions of the Sarbanes-Oxley Act and rules adopted by the SEC and by NASDAQ, would likely result in increased costs to us as we respond to their requirements.

If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.

The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts may not publish an adequate amount of research on our company, which may negatively impact the trading price for our stock. In addition, if one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. Further, if our operating results fail to meet the forecasts of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

a) None.

b) None.

c) None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

See the Exhibit Index on the page immediately following the signature page to this Quarterly Report on Form 10-Q for a list of the exhibits filed as part of this Quarterly Report, which Exhibit Index is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Global Blood Therapeutics, Inc.

Date: November 9, 2016	By:	/s/ Ted W. Love, M.D.
		Ted W. Love, M.D.
		President and Chief Executive Officer
		(Principal Executive Officer)

Date: November 9, 2016	By:	/s/ Jeffrey Farrow
		Jeffrey Farrow
		Chief Financial Officer
		(Principal Financial Officer)

EXHIBIT INDEX


		Incorporated by Reference
Exhibit Number	Exhibit Description	Form	Date	Number	Filed Herewith

3.1	Restated Certificate of Incorporation	S-1/A	7/31/2015	3.2

3.2	Amended and Restated Bylaws	S-1/A	7/31/2015	3.4

4.1	Specimen Common Stock Certificate	S-1/A	7/31/2015	4.1

10.1	Sublease by and between the registrant and NexSteppe Inc., dated September 15, 2016				X

31.1	Certification of Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002				X

31.2	Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002				X

32.1*	Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002				X

101.INS	XBRL Instance Document				X

101.SCH	XBRL Taxonomy Extension Schema Document				X

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document				X

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.				X

101.LAB	XBRL Taxonomy Extension Label Linkbase Document.				X

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.				X

The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Global Blood Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.

EX-10.1 2 d446427dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

SUBLEASE

THIS SUBLEASE, dated September 15, 2016, is entered into by and between NEXSTEPPE INC., a Delaware corporation (“Sublandlord”), and GLOBAL BLOOD THERAPEUTICS, INC., a Delaware corporation (“Subtenant”).

RECITALS

A. ARE-EAST JAMIE COURT, LLC, a Delaware limited liability company (“Master Landlord”) and Sublandlord entered into that certain Lease Agreement dated February 22, 2012 (as amended by that certain First Amendment to Lease dated April 4, 2013, and by that certain Second Amendment to Lease dated July 2, 2015, the “Master Lease”), pursuant to which Sublandlord leases certain premises (the “Premises”) consisting of approximately 5,700 rentable square feet of space located in that certain building located at 400 East Jamie Court, South San Francisco, California (the “Building”). A copy of the Master Lease is attached hereto as Exhibit A. Except as otherwise expressly provided herein, any capitalized terms herein without definition shall have the same meaning as they have in the Master Lease.

B. Sublandlord desires to sublease to Subtenant, and Subtenant desires to Sublease from Sublandlord, approximately 4,700 square feet of the Premises, as more particularly described in Exhibit B hereto and made a part hereof (the “Sublease Premises”), during the Term (as defined below), pursuant to the terms and provisions hereof.

C. Provided that certain conditions are met, as specified herein, Subtenant desires to expand the Sublease Premises to include all of the Premises, upon the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the covenants and conditions contained herein, Sublandlord and Subtenant agree as follows:

Agreement

1. Term. The term of this Sublease (the “Term”) shall commence on the later of (i) October I, 2016, (ii) the date Sublandlord has delivered possession of the Sublease Premises to Subtenant, or (iii) the date Master Landlord consents to this Sublease (the “Commencement Date”) and shall expire, unless sooner terminated pursuant to the further provisions hereof, on December 31, 2017 or such earlier date as the Master Lease may be terminated pursuant to the terms thereof. If the Commencement Date does not occur on or before November 1, 2016, then Subtenant shall have the right to terminate this Sublease upon ten (10) days’ prior written notice to Sublandlord, and in such event Sublandlord shall immediately return to Subtenant all monies previously paid by Subtenant to Sublandlord.

2. Sublease.

(a) Sublease of Sublease Premises. Sublandlord hereby subleases the Sublease Premises to Subtenant, and Subtenant hereby subleases the Sublease Premises from Sublandlord, for the Term, on the terms and conditions set forth herein.

(b) Common Areas. Subtenant shall have the non-exclusive right to the use the Common Areas, including the break room, storage room and conference room on the second story of the Building.

(c) Lab Space. Subtenant does not hereby sublease, and Sublandlord continues to lease directly from Master Landlord, approximately 1,000 square feet of the Premises, as more particularly described in Exhibit B hereto and made a part hereof (the “Lab Space”). The door between the Sublease Premises and the Lab Space shall remain closed at all times, so that the Lab Space is separate from the Sublease Premises, with its own entrance. Until the Expansion Date (as defined below), Sublandlord shall retain the non-exclusive right to use the Common Areas on the second floor of the Building.

(d) Measurement. The square footage of the Sublease Premises set forth in Recital B, and the square footage of the Lab Space set forth in Section 2(c), are agreed by the parties to be an accurate measurement of the Sublease Premises and the Lab Space, respectively, and shall not be subject to revision.

3. Expansion of Sublease Premises.

(a) Expansion on Expansion Date. Effective upon the Expansion Date (as defined below), the Lab Space shall automatically be incorporated into the Sublease Premises, such that on and after that date, Sublandlord shall sublease the Lab Space to Subtenant, Tenant shall sublease the Lab Space from Sublandlord, and the “Sublease Premises” shall include all of the Premises.

(b) Conditions Precedent to Expansion. The following shall be conditions precedent to the incorporation of the Lab Space into the Sublease Premises: (i) Sublandlord shall comply with all of the requirements of Section 28 of the Master Lease insofar as they relate to the Lab Space, including without limitation the preparation of a Surrender Plan, the reimbursement of Master Landlord’s out of pocket expenses and the cost of any Master Landlord actions required to ensure compliance with said Section 28; and (ii) Sublandlord shall remove all of Sublandlord’s personal property, including without limitation all of the personal property listed on Exhibit F to the Master Lease, from the Lab Space.

(c) Expansion Date. The “Expansion Date” shall be the date on which Sublandlord provides to Subtenant confirmation reasonably acceptable to Subtenant that: (i) Master Landlord has accepted Sublandlord’s Surrender Plan and Sublandlord has surrendered the Lab Space free of Tenant HazMat Operations; and (ii) Sublandlord has removed its personal property from the Lab Space. Sublandlord and Subtenant anticipate that the Expansion Date will occur on or around December 31, 2016.

4. Rent.

(a) Base Rent. Commencing as of the Commencement Date and continuing thereafter on the first (1st) day of each and every month during the Term, Subtenant shall pay to Sublandlord, as Base Rent for the Sublease Premises, $4.00 per rentable square foot of the Sublease Premises (“Base Rent”). Prior to the Expansion Date, Base Rent for the Sublease Premises shall be $18,800.00 per month. On and after the Expansion Date, Base Rent for the Sublease Premises shall be $22,800.00 per month.

(b) Additional Rent. All monetary obligations of Subtenant to Sublandlord under this Sublease (other than Base Rent) shall be deemed additional rent (“Additional Rent”). Commencing as of the Commencement Date and continuing thereafter on the first (1st day of each and every month during the Term, Subtenant shall pay to Sublandlord, Tenant’s Share of all Operating Expenses and Taxes allocable to the Premises under the Master Lease, notwithstanding that, until the Lab Space is incorporated into the Sublease Premises, Subtenant will be subleasing less than all of the Premises. Sublandlord shall promptly forward the appropriate invoices and backup documentation received from Master Landlord regarding Operating Expenses and Taxes. In addition, Subtenant shall pay to Sublandlord on demand any other expenses under the Master Lease that are applicable to the Sublease Premises and required to be paid by Sublandlord to Master Landlord, or otherwise required to be paid by Sublandlord under the Master Lease, and allocable to the Sublease Premises.

(c) Payment of Rent. Base Rent and Additional Rent (collectively, “Rent”), except as otherwise set forth herein, shall be paid to Sublandlord on or before the first (1st) day of each month during the Term. Rent for any period during the Term which is for less than one month of the Term shall be a pro-rata portion of the monthly installment based on a calendar month. Rent shall be payable without notice or demand and without any deduction, offset, or abatement, in lawful money of the United States of America. Rent shall be paid directly to Sublandlord at the address set forth in Section 21 or such other address as may be designated in writing by Sublandlord.

5. Security Deposit. Upon execution of this Sublease, Subtenant shall deposit with Sublandlord the sum of$ 14,535.00, by means of an irrevocable letter of credit, as security for Subtenant’s obligation under this Sublease (“Security Deposit”). The Security Deposit shall be governed by the provisions of Section 6 of the Master Lease, as incorporated herein, except that any reference to the “Security Deposit” or “the amount set forth on page 1 of this Lease” shall be deemed to refer to the Security Deposit described in this Section 5.

6. Condition of the Sublease Premises.

(a) Generally. Sublandlord shall provide the Sublease Premises in “broom clean” condition, with all operating systems in good condition and repair, and with all cubicles and personal property removed. Except as set forth in the preceding sentence, Subtenant agrees that Sublandlord has made no representations or warranties of any kind or nature whatsoever respecting the Sublease Premises, or its suitability for Subtenant’s use, and Subtenant agrees to accept the Sublease Premises “as is, where is,” condition. Sublandlord shall have no obligation to make or pay the cost of any alterations or improvements to the Sublease Premises, or to perform any of the repairs (or capital improvements) required to be performed by Master Landlord under the terms of the Master Lease.

(b) Alterations By Subtenant. Subtenant shall have the right to make alterations, modifications or improvements to the Sublease Premises with Sublandlord’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed, and the consent of Master Landlord, to the extent required under the Master Lease.

7. Use. Subtenant may use the Sublease Premises only for the Permitted Use as set forth in the Master Lease, and for no other purpose without the approval of the Master Landlord and Sublandlord.

8. Master Lease. This Sublease shall be subject and subordinate to all of the terms and provisions of the Master Lease. Subtenant shall not commit or permit any of its employees or agents to commit on the Sublease Premises any act or omission which shall violate any term or condition of the Master Lease. Except for (a) payments of Rent (which payments shall be made by Sublandlord), (b) Sublandlord’s obligations with respect to the surrender of the Lab Space pursuant to Section 3(b) hereof, and (c) those provisions of the Master Lease excluded by Section 9 below, Subtenant hereby assumes and agrees to perform, during the Term, all of Sublandlord’s obligations under the Master Lease to the extent such obligations are applicable to the Sublease Premises and accrue after the date hereof pursuant to this Sublease.

9. Sublease Terms.

(a) Incorporation by Reference. Except as otherwise provided herein, all of the terms and provisions of the Master Lease are incorporated into and made a part of this Sublease and the rights and obligations of the parties under the Master Lease are hereby granted to or imposed upon the parties hereto with respect to the Sublease Premises, except that (i) each reference to “Lease” shall be deemed a reference to “Sublease,” (ii) each reference to the Premises shall be deemed a reference to the Sublease Premises as defined herein, (iii) each reference to “Landlord” and “Tenant” shall be deemed a reference to “Sublandlord” and “Subtenant,” respectively.

(b) Provisions Not Incorporated By Reference. Notwithstanding the incorporation by reference set forth in Section 9(a),

(i) the following provisions of the Master Lease are expressly not incorporated by reference herein:

•

Summary of Basic Lease Information (except Tenant’s Share of Operating Expenses for the Building, Tenant’s Share of Operating Expenses for the Project and Permitted Use, which are incorporated herein);

•

the 1^st sentence of Section I ;

•

Section 2;

•

Section 3(a);

•

Section 4;

•

Section 39;

•

Section 40;

•

Section 41 – Shared Lab Area;

•

Section 42(c);

•

Exhibit C;

•

Exhibit D;

•

Exhibit F – Tenant’s Personal Property;

•

Exhibit G-1;

•

Exhibit G-2;

•

Exhibit H;

•

Exhibit I – Shared Lab Area;

•

Exhibit J;

•

The First Amendment to Lease;

•

The Second Amendment to Lease (except for Sections 1 and 3); and

(ii) the following provisions of the Master Lease, as incorporated herein, the term Landlord shall refer to Master Landlord only:

•

the third sentence of Section 1;

•

the first sentence of the second paragraph in Section 7;

•

the first and the final three sentences of Section 9;

•

the penultimate sentence of the first paragraph of Section 10;

•

the first three sentences of Section 11;

•

Section 13;

•

Section 14;

•

Section 18;

•

Section 19;

•

Section 26;

•

Section 31;

•

Section 32;

•

Section 35;

•

Section 36; and

•

Section 41 – Shared Lab Area.

(c) Sublandlord’s Obligations. With respect to work, services, repairs, restoration, insurance, capital improvements, or the performance of any other obligation of Master Landlord under the Master Lease, Sublandlord shall request the same in writing from Master Landlord as and when requested to do so by Subtenant, and shall use Sublandlord’s reasonable efforts (provided Subtenant pays all reasonable costs incurred by Sublandlord in connection therewith) to obtain Master Landlord’s performance. If, following such request, Master Landlord shall fail or refuse to comply with any of the terms of the Master Lease, Subtenant shall have the right, upon notice to Sublandlord, to exercise, in its own name, and that of Sublandlord, all the rights available to Sublandlord under the Master Lease to enforce performance on the part of Master Landlord. Subtenant shall reimburse all reasonable costs and expenses Sublandlord shall incur in enforcing or attempting to enforce the Master Lease against Master Landlord.

(d) No Liability for Master Landlord’s Obligations. Sublandlord shall have no liability to Subtenant with respect to (i) representations and warranties made by Master Landlord under the Master Lease, (ii) any indemnification obligations of Master Landlord under the Master Lease or other obligations or liabilities of Master Landlord with respect to compliance with law, condition of the Sublease Premises or hazardous materials, or (iii) Master Landlord’s repair, maintenance, restoration, upkeep, insurance and similar obligations under the Master Lease, regardless of whether the incorporation of one or more provisions of the Master Lease into the Sublease might otherwise operate to make Sublandlord liable therefor.

(e) Approvals and Consents. With respect to any consent or approval required to be obtained from the Master Landlord under the Master Lease, such approval or consent must be obtained from Master Landlord and Sublandlord, and the approval or consent of Sublandlord may be withheld if Master Landlord’s approval or consent is not obtained.

10. Preservation of Master Lease. So long as Subtenant complies with its obligations under this Sublease: (a) Sublandlord shall preserve the Master Lease and keep the Master Lease in full force and effect throughout the Term; (b) Sublandlord shall not agree to any amendment of the Master Lease; (c) Sublandlord shall not, without Subtenant’s prior written consent, exercise any right to terminate the Master Lease, other than on account of casualty or condemnation; and (d) Sublandlord shall perform all of its obligations under the Master Lease not assumed by Subtenant hereunder, including without limitation the prompt payment to Master Landlord of all sums paid by Subtenant to Sublandlord hereunder.

11. Insurance.

(a) Generally. Subtenant shall be responsible for compliance with the insurance provisions applicable to the Tenant under the Master Lease. Such insurance shall insure the performance by Subtenant of its indemnification obligations hereunder and shall name Master Landlord and Sublandlord as additional insureds. Subtenant shall use reasonable commercial efforts to obtain endorsements for all insurance required under this Sublease which require the insurance company to endeavor to give thirty (30) days written notice to Master Landlord and Sublandlord before cancellation or change in the coverage, insureds or amount of any policy. Subtenant shall provide both Master Landlord and Sublandlord with certificates of insurance evidencing such coverage prior to the commencement of this Sublease.

(b) Waiver of Subrogation. The waiver of subrogation provision contained in Section 17 of the Master Lease shall be deemed to be a three party agreement binding among and inuring to the benefit of Sublandlord, Subtenant and Master Landlord (by reason of its consent hereto).

12. Assignment and Subletting. Subtenant shall not assign, sublet, transfer, pledge, hypothecate or otherwise encumber the Sublease Premises, this Sublease or any interest therein, or permit the use or occupancy of the Sublease Premises by any other person other than Subtenant, without the prior written consent of Sublandlord and Master Landlord, under the terms and conditions of the Master Lease. Any transfer, circumstance or event which constitutes an assignment of subletting under the Master Lease shall constitute an assignment or subletting under this Sublease.

13. Parking. Until the Expansion Date, Sublandlord shall retain the use of all of the parking rights that Sublandlord may have in connection with the Premises pursuant to the Master Lease. On and after the Expansion Date, Subtenant shall have all such parking rights.

14. Early Termination of Master Lease. If, without the fault of Sublandlord or Subtenant, the Master Lease should terminate prior to the expiration of this Sublease, neither party shall have any liability to the other party.

15. Consent of Master Landlord. If Subtenant desires to take any action that requires the consent of Master Landlord pursuant to the terms of the Master Lease, including, without limitation, making any modification, alteration or improvement of the Sublease Premises or entering into a further sublease or assignment of this Sublease, then, notwithstanding anything to the contrary herein, (a) Subtenant shall not take any such action until it obtains the consent of both Sublandlord and Master Landlord and (b) Subtenant shall request that Sublandlord obtain Master Landlord’s consent on Subtenant’s behalf, unless Sublandlord agrees that Subtenant may contact Master Landlord directly with respect to the specific action for which Master Landlord’s consent is required.

16. Surrender of Sublease Premises. Subtenant shall surrender the Sublease Premises to Sublandlord broom-clean and in as good a condition as on the Commencement Date, ordinary wear and tear excepted, and use of Hazardous Materials excepted. Prior to expiration of earlier termination of this Sublease, Subtenant shall remove any alterations, additions and improvements made by or at the request of Subtenant (to the extent required to do so under the terms of the Master Lease) and all of Subtenant’s trade fixtures, equipment and personal property, and shall restore the Sublease Premises to its prior condition, ordinary wear and tear excepted, repairing all damage caused by or related to any such removal, all at Subtenant’s expense. If the Sublease Premises are not so surrendered, then Subtenant shall be liable to Sublandlord for all cost incurred by Sublandlord (including any charges by Master Landlord under the Master Lease) in returning the Premises to such required condition.

17. Holdover. Any holdover by Subtenant shall be governed by Section 8 of the Master Lease, as incorporated herein by reference. Without limiting the provisions of such Section 8, Subtenant shall indemnify, protect, defend and hold harmless both Sublandlord and Master Landlord from and against any and all loss and liability resulting from Subtenant’s delay in surrendering the Premises, as set forth in said Section 8.

18. No Third Party Rights. The benefit of the provisions of this Sublease is expressly limited to Sublandlord and Subtenant and their respective permitted successors and assigns. Under no circumstances will any third party be construed to have any rights as a third party beneficiary with respect to any of said provisions.

19. Time of Essence. It is expressly understood and agreed that time is of the essence with respect to each and every provision of this Sublease.

20. Condition Precedent: Approval of Master Landlord. This Sublease shall be conditioned upon, and shall not take effect until, receipt of the written consent of Master Landlord thereto. Upon receipt of such consent, this Sublease shall be effective as of the Commencement Date. If Master Landlord does not consent in writing to this Sublease within thirty (30) days after Subtenant’s execution of this Sublease, then Subtenant may, at any time thereafter until such approval is obtained, terminate this Sublease upon written notice to Sublandlord, whereupon any monies previously paid by Subtenant to Sublandlord shall be reimbursed to Subtenant.

21. Notices. The addresses specified in the Master Lease for receipt of notices to each of the parties are deleted and replaced with the following:



To Sublandlord at:						NexSteppe Inc.
						Attn: Vice President, Finance

To Subtenant at:						Before Commencement Date:

						Global Blood Therapeutics, Inc. 400 East Jamie Court, Suite 101 South San Francisco, CA 94080 Attn: Chief Financial Officer

						After Commencement Date:

						Global Blood Therapeutics, Inc. 400 East Jamie Court, Suite 101 South San Francisco, CA 94080 Attn: Chief Financial Officer

22. Brokers. Each party hereto represents and warrants that it has dealt with no broker in connection with this Sublease and the transactions contemplated herein. Each party shall indemnify, protect, defend and hold the other party harmless from all costs and expenses (including reasonable attorneys’ fees) arising from or relating to a breach of the foregoing representation and warranty.

23. Notices To or From Master Landlord. Each party shall promptly deliver a copy of any notice received from or delivered to Master Landlord respecting the Sublease Premises or the right or obligations of Sublandlord or Subtenant hereunder.

24. Quiet Enjoyment. So long as Subtenant pays the rent and performs its obligations under this Sublease, Sublandlord shall take no action, or fail to take any action, which would interfere with the right of Subtenant to peaceably have, hold and enjoy the Sublease Premises during the Term, subject to the terms of the Master Lease.

25. Indemnity. Each of Sublandord and Subtenant (in such capacity, the “Indemnifying Party”) shall indemnify, defend, protect, and hold harmless the other party (in such capacity, the “Indemnified Party”), its respective officers, agents, and employees (its “Agents”), from and against all claims, demands, actions, causes of action, losses, liabilities and expenses, including without limitation reasonable attorneys’ fees (collectively “Claims”) which may be brought against the Indemnified Party or its Agents or which the Indemnified Party or its Agents may pay or incur by reason of any breach or default of this Sublease by the Indemnifying Party, or the acts, omissions, negligence or willful misconduct of the Indemnifying Party or its Agents in or about the Sublease Premises, the Building or the Project during the Term, except to the extent that the Claims are caused by the gross negligence or willful misconduct of the Indemnified Party or its Agents. Without limiting the foregoing, Sublandlord specifically acknowledges that, while Sublandlord has used and currently uses Hazardous Materials in the Lab Space and the Shared Lab Area, Subtenant does not intend to do so, and that Sublandlord’s obligation under this Section 25 shall extend to Sublandlord’s use of Hazardous Materials in each such location. The provisions of this Section 25 shall survive the termination or earlier expiration of this Sublease.

26. Successors. This Sublease shall be binding on and inure to the benefit of the parties hereto and their respective successors and permitted assigns, subject to the limitations on Subtenant’s right to transfer incorporated herein by reference from the Master Lease.

27. Counterparts. This Sublease may be executed in one or more counterparts each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Signature copies may be detached from the counterparts and attached to a single copy of this Sublease physically to form one document. A facsimile counterpart signature delivered to each party shall be deemed an original for the purpose of the execution of this Sublease.

28. No Conflict. In the event of any conflict between the terms of this Sublease and the terms of the Master Lease, as between Sublandlord and Subtenant, the terms of this Sublease shall prevail.

29. Entire Agreement. This Sublease and the provisions of the Master Lease incorporated herein by the express terms of this Sublease constitute the complete and exclusive agreement among the parties with respect to the matters contained herein and supersede all prior written or oral agreements or statements by and among the parties hereto, provided that this Sublease shall be at all times subject to all of the terms and conditions of the Master Lease.

[THIS SPACE INTENTIONALLY LEFT BLANK]

EXECUTED as of the date first written above.


SUBLANDLORD:

NEXSTEPPE INC, a Delaware corporation

By:		/s/ C. Hans Miller
Name:		C. Hans Miller
Title:		Vice President, Finance


SUBTENANT:

GLOBAL BLOOD THERAPEUTICS, INC. a Delaware corporation

By:		/s/ Jeffrey Farrow
Name:		Jeffrey Farrow
Title:		Chief Financial Officer

[SIGNATURE PAGE TO SUBLEASE]

EXHIBIT A

MASTER LEASE

EXHIBIT B

OUTLINE OF SUBLEASE PREMISES AND LAB SPACE

LOGO

EX-31.1 3 d446427dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ted W. Love, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Global Blood Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2016

/s/ Ted W. Love, M.D.

Ted W. Love, M.D.

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 4 d446427dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeffrey Farrow, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Global Blood Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

b)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2016

/s/ Jeffrey Farrow

Jeffrey Farrow

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 5 d446427dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

GLOBAL BLOOD THERAPEUTICS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Global Blood Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ted W. Love, President and Chief Executive Officer of the Company, and Jeffrey Farrow, Chief Financial Officer, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Ted W. Love, M.D.

Ted W. Love, M.D.

President and Chief Executive Officer

(Principal Executive Officer)

November 9, 2016

/s/ Jeffrey Farrow

Jeffrey Farrow

Chief Financial Officer

(Principal Financial Officer)

November 9, 2016

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Global Blood Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.INS 6 gbt-20160930.xml XBRL INSTANCE DOCUMENT

1430000

50000

18.75

37316451 2000000000

18.75

158497000

3351000

53000

0.001

2943000

36516130

224032000

221266000

150000000

13664000

47000

217837000

37000

1578000

5016291

3038000

921000

363789000

5863000

0.001

5000000

1723000

905000

13932000

224032000

775000

13157000

1706000

119000

35600000

2626000

5569000

6.59

210100000

10.99

823118

2000

-153726000

33533000

14082000

2508295

140000

10.78

2703252

4823000 777041 0.01 728000 850000

140000

208616000

728000

850000

208616000

2703252

12864000

1484701

607000

752220

777041

193000

76118

24821

47495

3715000

206000

970000

678000

1 2

52069000

2242000

38000

0.001

2102000

29359800

153074000

150820000

150000000

86000

148502000

29000

2147000

3361000

287000

239231000

4400000

0.001

5000000

1096000

720000

12279000

153074000

1556000

10723000

1222000

88000

2114000

4216000

140795000

8.71

5000

-98465000

140000

2058787

4025000 1097288 1470000 677000

140000

148642000

1470000

677000

148642000

1091038

6250

3151000

129000

596000

340000

326424

0.70

99285

P2Y4M24D

99285

3.40

227139

6400000

130000

3161979

106342000

106428000

-4.83

1731000

5473000

606000

-30775000

1928000

4492000

489000

851000

210000

30795000

-30775000

-775000

-34955000

-30795000

-7000

2108000

128446000

-29000

601000

-21243000

775000

126360000

65000

25257000

44000

4180000

1731000

7242559

20000 66000 4180000

1171506

1990473

0.018

0.770

0.00

0.015

0.738

P5Y3M18D

P6Y3M18D

1366000

365000

499000

1232000

65000

<div> Stock-based Compensation We measure and recognize stock-based compensation expense, including employee and non-employee equity awards, based on fair value at the grant date. We use the Black-Scholes option-pricing model to calculate fair value. Stock-based compensation expense recognized in the statements of operations is based on options ultimately expected to vest, taking into consideration estimated forfeitures. Stock-based compensation expense is revised in subsequent periods, if necessary, if actual forfeitures differ from these estimates. When estimating forfeitures, we consider historic voluntary termination behaviors as well as trends of actual option forfeitures. For options granted to non-employees, we revalue the unearned portion of the stock-based compensation and the resulting change in fair value is recognized in the statements of operations over the period the related services are rendered. </div>

Global Blood Therapeutics, Inc.

3455472

10-Q 0001629137 2016-09-30

69335000

-1.72

<div> Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation. </div>

5884000

247000

2016 false --12-31

14821000

<div> Fair Value Measurement The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. </div>

<div> Cash and Cash Equivalents We consider all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. Cash equivalents, which consist primarily of amounts invested in money market accounts, are stated at fair value. </div>

841000

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> 6. Stock-based Awards <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Equity Incentive Plans <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In July 2015, we adopted the 2015 Stock Option and Incentive Plan (the “2015 Plan”). Under the 2015 Plan, 1,430,000 shares of our common stock were initially reserved for the issuance of stock options, restricted stock, and other equity-based awards to employees, non-employee directors, and consultants under terms and provisions established by the Board of Directors and approved by our stockholders. The 2015 Plan also provides for automatic annual increases in the number of shares reserved for future issuance. As of September 30, 2016, there were 1,484,701 shares available for future grants under the 2015 Plan. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In 2012, we adopted the 2012 Plan under which the Board of Directors was authorized to grant incentive stock options to employees, including officers and members of the Board of Directors who are also employees of ours, and non-statutory stock options (options that do not qualify as incentive options) and/or our restricted stock and other equity-based awards to employees, officers, directors, or consultants of ours. Upon adoption of the 2015 Plan, no new awards or grants are permitted under the 2012 Plan. <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Employee Stock Purchase Plan <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In July 2015, we adopted the 2015 Employee Stock Purchase Plan (the “2015 ESPP”). Under the 2015 ESPP, 50,000 shares of our common stock were initially reserved for employee purchases of our common stock under terms and provisions established by the Board of Directors and approved by our stockholders. The 2015 ESPP also provides for automatic annual increases in the number of shares reserved for future issuance. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Stock Option Awards <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following summarizes option activity under the 2015 Plan and the 2012 Plan: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number of Options</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average remaining contractual term (years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="10"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> (in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Balance Outstanding, December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,058,787</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8.71</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Options granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,034,575</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16.74</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Options exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(103,602</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.95</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Options canceled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(286,508</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18.96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Balance Outstanding, September 30, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,703,252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10.99</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,600</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Exercisable, September 30, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">823,118</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.59</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,082</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Vested and expected to vest, September 30, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,508,295</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10.78</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33,533</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Stock Options Granted to Employees with Service-Based Vesting Conditions Valuation Assumptions <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The fair values of stock options granted to employees were calculated using the following assumptions: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="48%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Expected term (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0-6.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3-6.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3-6.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3-6.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70.6%-70.9%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73.8%-75.3%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70.6%-82.3%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73.8%-77.0%</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.3%-1.5%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.6%-1.8%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.1%-1.9%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.5%-1.8%</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Dividend yield </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Performance-Contingent Awards <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> On April 9, 2015, our Board of Directors granted a total of 326,424 performance-contingent awards to members of our senior management team. Of the total performance-contingent awards granted, 227,139 were performance-contingent options and 99,285 were performance-contingent shares of restricted common stock. The exercise price of each performance-contingent option and the purchase price for the performance-contingent restricted shares is $3.40 per share, which the Board of Directors determined was the fair market value on the grant date. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> These awards have dual triggers of vesting based upon the successful achievement of four corporate operating milestones within specified timelines, as well as a requirement for continued employment. When a performance goal is deemed to be probable of achievement, time-based vesting and recognition of stock-based compensation expense commences. In the event any of the corporate operating milestones are not achieved by the specified timelines, such vesting tranche will terminate and no longer be exercisable with respect to that portion of the shares. During the nine months ended September 30, 2016, the Compensation Committee of our Board of Directors modified one of the corporate operating milestones, which resulted in two of the corporate operating milestones being achieved; accordingly, an aggregate of 94,502 shares underlying options and 49,643 shares of restricted stock associated with these two milestones vested and, as a result, $1.5 million of compensation cost was recognized for the performance-contingent awards, including $1.4 million of compensation cost related to the modified corporate operating milestone. One of the remaining two corporate operating milestones was not met within the timeframe required for achievement during the nine months ended September 30, 2016; accordingly, 47,500 shares underlying options and 24,821 shares of restricted stock associated with the milestone were forfeited. As of September 30, 2016, unvested performance-contingent awards included 47,495 shares underlying options and 24,821 shares of restricted stock associated with the remaining operating milestone. <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Market-Condition Award <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> On April 9, 2015, our Board of Directors granted a market-condition award to our Chief Executive Officer of 99,285 shares of restricted common stock. The market-condition award does not vest until our market capitalization (determined based on the number of shares of common stock outstanding multiplied by the closing market price for our common stock as reported on NASDAQ) exceeds at least $2.0 billion for 20 consecutive trading days on or before the date twenty-four (24) months after the closing of our initial public offering, or IPO. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The fair value of the market-condition award of $0.70 was determined on the grant date utilizing a lattice model that was prepared by a third party valuation firm with an expected term of 2.4 years. In August 2015, we began to recognize compensation costs for this award concurrent with the closing of our IPO. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Stock-Based Compensation Expense <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Total stock-based compensation recognized by function was as follows (in thousands): <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,019</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">527</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,065</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,232</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,133</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">347</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,819</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">499</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,152</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">874</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,884</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,731</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Total stock-based compensation recognized for employees and non-employees was as follows (in thousands): <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Employee options and restricted stock awards </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,044</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">534</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,651</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,366</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Non-employee options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">108</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">340</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">233</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">365</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,152</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">874</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,884</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,731</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Unrecognized Stock-Based Compensation Expense and Weighted-Average Remaining Amortization Period <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> As of September 30, 2016 the unrecognized stock-based compensation cost, net of expected forfeitures, and the estimated weighted-average amortization period, using the straight-line attribution method, was as follows (in thousands, except amortization period): <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Unrecognized Compensation Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted-average remaining amortization period (years)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Options </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,864</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Restricted stock awards </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">607</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> 2015 ESPP </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">193</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total unrecognized stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,664</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-55261000

Non-accelerated Filer

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements are as follows (in thousands): <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center">September 30, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Financial Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom" colspan="5"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">208,616</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">208,616</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total financial assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">208,616</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">208,616</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center">December 31, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Financial Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom" colspan="5"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">148,642</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">148,642</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total financial assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">148,642</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">148,642</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

1746000

484000

-1478000

3000

55668000

-55261000

-1106000

<div> Property and equipment consists of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Laboratory equipment </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,715</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,151</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Computer equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">970</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">596</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Leasehold improvements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">678</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">340</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Construction-in-progress </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">206</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">129</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total property and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,569</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,216</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less: accumulated depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,943</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,102</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Property and equipment, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,626</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,114</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-55261000

-55668000

-25000

118112000

1109000

-47671000

1106000

116995000

103602

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The fair values of stock options granted to employees were calculated using the following assumptions: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="48%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Expected term (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0-6.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3-6.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3-6.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3-6.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70.6%-70.9%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73.8%-75.3%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70.6%-82.3%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73.8%-77.0%</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.3%-1.5%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.6%-1.8%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.1%-1.9%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.5%-1.8%</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Dividend yield </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> </tr> </table> </div>

<div> Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Share issuances under equity incentive plan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,703,252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,990,473</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,703,252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,990,473</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Restricted stock subject to future vesting </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">752,220</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,171,506</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">752,220</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,171,506</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,455,472</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,161,979</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,455,472</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,161,979</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> </tr> </table> </div>

P8Y8M12D

<div> The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders during the three and nine months ended September 30, 2016 and 2015, respectively (in thousands, except share and per share data):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Numerator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Net loss </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(20,985</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(14,764</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(55,261</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(30,775</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Accretion and dividends on redeemable convertible preferred stock </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(787</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4,180</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Net loss attributable to common stockholders </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(20,985</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(15,551</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(55,261</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(34,955</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Denominator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Weighted average common shares outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36,353,958</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,288,610</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32,074,779</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,242,559</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Net loss per share attributable to common stockholders, basic and diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.58</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.90</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.72</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4.83</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> </tr> </table> </div>

<div> Total stock-based compensation recognized by function was as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,019</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">527</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,065</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,232</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,133</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">347</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,819</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">499</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,152</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">874</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,884</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,731</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Total stock-based compensation recognized for employees and non-employees was as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Employee options and restricted stock awards </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,044</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">534</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,651</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,366</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Non-employee options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">108</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">340</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">233</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">365</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="top"> Total stock-based compensation expense </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">$</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom" align="right">3,152</td> <td style="WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom" nowrap="nowrap">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">$</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom" align="right">874</td> <td style="WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom" nowrap="nowrap">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">$</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom" align="right">5,884</td> <td style="WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom" nowrap="nowrap">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">$</td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom" align="right">1,731</td> </tr> </table> </div>

16.74

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> We have reserved the following shares of common stock for issuance: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Restricted shares subject to future vesting </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">752,220</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Options issued and outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,703,252</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Options available for future grants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,484,701</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Employee stock purchase plan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">76,118</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total common stock reserved for issuance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,016,291</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

P7Y10M24D

286508

0.95

GBT

40847000

1117000

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Accrued liabilities consist of the following (in thousands): <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Accrued clinical and manufacturing expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,823</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,025</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Accrued professional and consulting services </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">921</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">287</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">119</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">88</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total accrued liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,863</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,400</td> </tr> </table> </div>

<div> The following summarizes option activity under the 2015 Plan and the 2012 Plan:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number of Options</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average remaining contractual term (years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="10"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> (in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Balance Outstanding, December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,058,787</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8.71</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Options granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,034,575</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16.74</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Options exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(103,602</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.95</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Options canceled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(286,508</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18.96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Balance Outstanding, September 30, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,703,252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10.99</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,600</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Exercisable, September 30, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">823,118</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.59</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,082</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Vested and expected to vest, September 30, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,508,295</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10.78</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33,533</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> </tr> </table> </div>

1034575

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> 9. License Agreement <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In September 2015, we executed an agreement with the Regents of the University of California, or the Regents, for an exclusive license to those rights the Regents may own in certain patents and patent applications relating to GBT440 and GBT440 analogs, and in exchange have committed to pay a royalty of less than 1% on future net sales. In connection with this agreement we issued 85,714 shares of our common stock with an estimated fair value of $4.5 million, which was recorded in research and development expense in our statement of operations. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">   </div>

<div> As of September 30, 2016 the unrecognized stock-based compensation cost, net of expected forfeitures, and the estimated weighted-average amortization period, using the straight-line attribution method, was as follows (in thousands, except amortization period):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Unrecognized Compensation Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted-average remaining amortization period (years)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Options </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,864</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Restricted stock awards </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">607</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> 2015 ESPP </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">193</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total unrecognized stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,664</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">  </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> <td style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">   </td> </tr> </table> </div>

5884000

32074779

18.96

P8Y7M6D

407000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Restricted shares subject to repurchase and related liability were as follows (in thousands, except share data): <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Restricted shares subject to repurchase: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Shares issued to founders </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,250</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Shares issued pursuant to the 2012 Stock Option and Grant Plan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">777,041</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,091,038</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total restricted shares subject to repurchase </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">777,041</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,097,288</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Liability pertaining to restricted shares subject to repurchase </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Other liabilities, current </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">850</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">677</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Other liabilities, noncurrent </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">728</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,470</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total liabilities pertaining to shares subject to repurchase </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,578</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,147</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

752220

2703252

P2Y6M

0.019

0.823

0.00

0.011

0.706

P5Y3M18D

P6Y1M6D

1500000

1400000

P1Y9M18D

P24M

P20D

P2M12D

49643

24821

94502

47500

5651000

233000

3819000

2065000

4500000

85714

P9Y

117000000

267228

3161979

-0.90

874000

2669000

-14764000

14775000

-14764000

-15551000

-14775000

12106000

17288610

11000 787000

1171506

1990473

0.018

0.753

0.00

0.016

0.738

P5Y3M18D

P6Y3M18D

534000

340000

347000

527000

3455472

-0.58

3152000

5999000

-20985000

21144000

-20985000

-21144000

15145000

36353958

159000

752220

2703252

0.015

0.709

0.00

0.013

0.706

P6Y

P6Y1M6D

3044000

108000

2133000

1019000

0001629137 gbt:ManagementAndAdvisoryServicesMemberus-gaap:MajorityShareholderMember 2016-06-25 2016-09-30 0001629137 us-gaap:ResearchAndDevelopmentExpenseMember 2016-06-25 2016-09-30 0001629137 us-gaap:GeneralAndAdministrativeExpenseMember 2016-06-25 2016-09-30 0001629137 gbt:NonEmployeeStockPlanMember 2016-06-25 2016-09-30 0001629137 gbt:EmployeeAndDirectorStockPlanMember 2016-06-25 2016-09-30 0001629137 us-gaap:EmployeeStockOptionMemberus-gaap:MaximumMember 2016-06-25 2016-09-30 0001629137 us-gaap:EmployeeStockOptionMemberus-gaap:MinimumMember 2016-06-25 2016-09-30 0001629137 us-gaap:EmployeeStockOptionMember 2016-06-25 2016-09-30 0001629137 gbt:ShareIssuancesUnderEquityIncentivePlanMember 2016-06-25 2016-09-30 0001629137 us-gaap:RestrictedStockMember 2016-06-25 2016-09-30 0001629137 2016-06-25 2016-09-30 0001629137 gbt:ManagementAndAdvisoryServicesMemberus-gaap:MajorityShareholderMember 2015-07-01 2015-09-30 0001629137 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001629137 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001629137 gbt:NonEmployeeStockPlanMember 2015-07-01 2015-09-30 0001629137 gbt:EmployeeAndDirectorStockPlanMember 2015-07-01 2015-09-30 0001629137 us-gaap:EmployeeStockOptionMemberus-gaap:MaximumMember 2015-07-01 2015-09-30 0001629137 us-gaap:EmployeeStockOptionMemberus-gaap:MinimumMember 2015-07-01 2015-09-30 0001629137 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001629137 gbt:ShareIssuancesUnderEquityIncentivePlanMember 2015-07-01 2015-09-30 0001629137 us-gaap:RestrictedStockMember 2015-07-01 2015-09-30 0001629137 2015-07-01 2015-09-30 0001629137 us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember 2016-06-25 2016-07-31 0001629137 us-gaap:OverAllotmentOptionMember 2016-06-25 2016-07-31 0001629137 2015-01-01 2015-12-31 0001629137 us-gaap:CommonStockMember 2016-09-01 2016-09-30 0001629137 gbt:ManagementAndAdvisoryServicesMemberus-gaap:MajorityShareholderMember 2016-01-01 2016-09-30 0001629137 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001629137 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-09-30 0001629137 gbt:NonEmployeeStockPlanMember 2016-01-01 2016-09-30 0001629137 gbt:EmployeeAndDirectorStockPlanMember 2016-01-01 2016-09-30 0001629137 gbt:PerformanceContingentAwardsStockOptionsMember 2016-01-01 2016-09-30 0001629137 gbt:PerformanceContingentAwardsRestrictedStockMember 2016-01-01 2016-09-30 0001629137 gbt:EmployeeStockPurchasePlanMember 2016-01-01 2016-09-30 0001629137 us-gaap:RestrictedStockMemberus-gaap:ChiefExecutiveOfficerMember 2016-01-01 2016-09-30 0001629137 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0001629137 us-gaap:PerformanceSharesMemberus-gaap:ManagementMember 2016-01-01 2016-09-30 0001629137 us-gaap:PerformanceSharesMember 2016-01-01 2016-09-30 0001629137 us-gaap:EmployeeStockOptionMemberus-gaap:MaximumMember 2016-01-01 2016-09-30 0001629137 us-gaap:EmployeeStockOptionMemberus-gaap:MinimumMember 2016-01-01 2016-09-30 0001629137 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001629137 gbt:ShareIssuancesUnderEquityIncentivePlanMember 2016-01-01 2016-09-30 0001629137 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0001629137 2016-01-01 2016-09-30 0001629137 gbt:ManagementAndAdvisoryServicesMemberus-gaap:MajorityShareholderMember 2015-01-01 2015-09-30 0001629137 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001629137 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0001629137 gbt:NonEmployeeStockPlanMember 2015-01-01 2015-09-30 0001629137 gbt:EmployeeAndDirectorStockPlanMember 2015-01-01 2015-09-30 0001629137 us-gaap:EmployeeStockOptionMemberus-gaap:MaximumMember 2015-01-01 2015-09-30 0001629137 us-gaap:EmployeeStockOptionMemberus-gaap:MinimumMember 2015-01-01 2015-09-30 0001629137 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001629137 gbt:ShareIssuancesUnderEquityIncentivePlanMember 2015-01-01 2015-09-30 0001629137 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001629137 2015-01-01 2015-09-30 0001629137 us-gaap:CommonStockMember 2016-06-24 2016-06-24 0001629137 us-gaap:ManagementMember 2015-04-09 2015-04-09 0001629137 gbt:PerformanceContingentAwardsStockOptionsMemberus-gaap:ManagementMember 2015-04-09 2015-04-09 0001629137 gbt:PerformanceContingentAwardsRestrictedStockMemberus-gaap:ManagementMember 2015-04-09 2015-04-09 0001629137 us-gaap:RestrictedStockMemberus-gaap:ChiefExecutiveOfficerMember 2015-04-09 2015-04-09 0001629137 us-gaap:PerformanceSharesMemberus-gaap:ManagementMember 2015-04-09 2015-04-09 0001629137 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001629137 us-gaap:ComputerEquipmentMember 2015-12-31 0001629137 us-gaap:ConstructionInProgressMember 2015-12-31 0001629137 us-gaap:EquipmentMember 2015-12-31 0001629137 us-gaap:RestrictedStockMembergbt:FoundersMember 2015-12-31 0001629137 us-gaap:RestrictedStockMembergbt:TwoThousandTwelveStockOptionAndGrantPlanMember 2015-12-31 0001629137 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001629137 us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001629137 us-gaap:OtherCurrentLiabilitiesMember 2015-12-31 0001629137 us-gaap:OtherNoncurrentLiabilitiesMember 2015-12-31 0001629137 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001629137 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001629137 gbt:RestrictedCashMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001629137 2015-12-31 0001629137 2014-12-31 0001629137 us-gaap:MajorityShareholderMember 2016-09-30 0001629137 us-gaap:ManagementMember 2016-09-30 0001629137 us-gaap:LeaseholdImprovementsMember 2016-09-30 0001629137 us-gaap:ComputerEquipmentMember 2016-09-30 0001629137 us-gaap:ConstructionInProgressMember 2016-09-30 0001629137 us-gaap:EquipmentMember 2016-09-30 0001629137 gbt:PerformanceContingentAwardsStockOptionsMember 2016-09-30 0001629137 gbt:PerformanceContingentAwardsRestrictedStockMember 2016-09-30 0001629137 gbt:EmployeeStockPurchasePlanMember 2016-09-30 0001629137 us-gaap:RestrictedStockMembergbt:TwoThousandTwelveStockOptionAndGrantPlanMember 2016-09-30 0001629137 us-gaap:RestrictedStockMember 2016-09-30 0001629137 us-gaap:EmployeeStockOptionMembergbt:TwoThousandFifteenStockOptionAndIncentivePlanMember 2016-09-30 0001629137 us-gaap:EmployeeStockOptionMember 2016-09-30 0001629137 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0001629137 us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0001629137 us-gaap:OtherCurrentLiabilitiesMember 2016-09-30 0001629137 us-gaap:OtherNoncurrentLiabilitiesMember 2016-09-30 0001629137 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0001629137 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0001629137 gbt:RestrictedCashMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0001629137 2016-09-30 0001629137 2015-09-30 0001629137 us-gaap:CommonStockMember 2016-06-24 0001629137 us-gaap:RestrictedStockMemberus-gaap:ChiefExecutiveOfficerMember 2015-04-09 0001629137 2016-11-01 0001629137 us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember 2016-07-31 0001629137 gbt:EmployeeStockPurchasePlanMembergbt:TwoThousandFifteenEmployeeStockPurchasePlanMember 2015-07-31 0001629137 us-gaap:EmployeeStockOptionMembergbt:TwoThousandFifteenStockOptionAndIncentivePlanMember 2015-07-31 shares iso4217:USD shares iso4217:USD pure gbt:Milestone gbt:Board_member gbt:Segment

EX-101.SCH 7 gbt-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Organization and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Balance Sheet Components link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Stock-based Awards link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Net Loss per Share Attributable to Common Stockholders link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - License Agreement link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Balance Sheet Components (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Stock-based Awards (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Organization and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Fair Value Measurements - Fair Value Assets Measured on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Balance Sheet Components - Property and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Balance Sheet Components - Accrued Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Balance Sheet Components - Other Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Issuance (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Stockholders' Equity - Schedule of Restricted Shares Subject to Repurchase (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Stock-based Awards - Plan Summary - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Stock-based Awards - Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Stock-based Awards - Valuation Assumptions for Stock Awards (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Stock-based Awards - Performance-Contingent and Market-Condition Awards - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Stock-based Awards - Stock-based Compensation Expense Recognized (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Stock-based Awards - Unrecognized Stock-based Compensation Cost (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Potentially Dilutive Securities that were Not Included in Diluted per Share Calculations (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - License Agreement - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 gbt-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 gbt-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 gbt-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable, Current Accounts payable Accrued clinical and manufacturing expenses, current. Accrued Clinical And Manufacturing Expenses Current Accrued clinical and manufacturing expenses Accrued Liabilities, Current Accrued liabilities Total accrued liabilities Accrued Professional Fees, Current Accrued professional and consulting services Accrued Rent, Current Deferred rent, current Accrued Rent, Noncurrent Deferred rent, noncurrent Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Additional Paid in Capital Additional paid-in capital Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Allocated Share-based Compensation Expense Compensation expense recognized Total stock-based compensation expense Amendment Flag Amendment Flag Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from earnings per share Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Assets Total assets Assets [Abstract] Assets Assets, Current Total current assets Assets, Current [Abstract] Current assets: Award Type [Axis] Award Type [Axis] Balance Sheet Components [Abstract] Balance Sheet Components [Abstract] Balance Sheet Components [Abstract] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Basis of Accounting, Policy [Policy Text Block] Basis of Preparation Capital Expenditures Incurred but Not yet Paid Accrued purchase of property and equipment Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Financial assets, fair value Cash and Cash Equivalents, Period Increase (Decrease) Net increase in cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Chief Executive Officer [Member] Chief Executive Officer [Member] Class of Stock [Domain] Class of Stock [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Commitments and Contingencies Commitments and contingencies Common Stock, Capital Shares Reserved for Future Issuance Shares reserved for future issuance Common Stock [Member] Common Stock [Member] Common Stock, Par or Stated Value Per Share Common stock, par value Common stock restricted shares subject to repurchase. Common Stock Restricted Shares Subject To Repurchase Total restricted shares subject to repurchase Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, $0.001 par value, 150,000,000 shares authorized as of September 30, 2016 (unaudited) and December 31, 2015, respectively; 36,516,130 and 29,359,800 shares issued and outstanding as of September 30, 2016 (unaudited) and December 31, 2015, respectively Compensation Related Costs, Policy [Policy Text Block] Stock-based Compensation Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Computer Equipment [Member] Computer Equipment [Member] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Consolidation, Policy [Policy Text Block] Principles of Consolidation Construction in Progress [Member] Construction-in-Progress [Member] Conversion of Stock, Amount Issued Conversion of redeemable convertible preferred stock to common stock at closing of initial public offering Current Fiscal Year End Date Current Fiscal Year End Date Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Accrued offering costs Deferred compensation arrangement with individual nonvested shares. Deferred Compensation Arrangement With Individual Nonvested Shares Shares issued to founders Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent Total liabilities pertaining to shares subject to repurchase Depreciation, Depletion and Amortization Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-based Awards Document and Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic and Diluted Net loss per share attributable to common stockholders, basic and diluted Earnings Per Share, Basic and Diluted [Abstract] Numerator: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Denominator: Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Attributable to Common Stockholders Earnings Per Share [Text Block] Net Loss per Share Attributable to Common Stockholders Employee And Director Stock Plan [Member] Employee And Director Stock Plan [Member] Employee And Director Stock Plan [Member] Employee-related Liabilities, Current Accrued compensation Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Total unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Weighted-average remaining amortization period Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Unrecognized compensation cost, restricted stock awards Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation cost, options Employee Stock Option [Member] Stock Options [Member] Employee stock purchase plan. Employee Stock Purchase Plan [Member] ESPP [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equipment [Member] Laboratory Equipment [Member] Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Asset Class [Domain] Asset Class [Domain] Asset Class [Axis] Asset Class [Axis] Fair Value, by Balance Sheet Grouping [Table Text Block] Fair Value, Assets Measured on Recurring Basis Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurement Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Measurements, Recurring [Member] Fair Value Measurements, Recurring [Member] Founders. Founders [Member] Founders [Member] Gain (Loss) on Disposition of Property Plant Equipment Loss on disposal of fixed assets General and Administrative Expense General and administrative General and Administrative Expense [Member] General and Administrative Expense [Member] Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Increase (Decrease) in Accounts Payable, Trade Accounts payable Increase (Decrease) in Employee Related Liabilities Accrued compensation Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Other Accrued Liabilities Accrued liabilities Increase (Decrease) in Other Current Assets Other assets, current Increase (Decrease) in Other Noncurrent Liabilities Other liabilities Increase (Decrease) in Prepaid Expense Prepaid expenses In Process Research and Development, Policy [Policy Text Block] Accruals of Research and Development Costs Interest and other nonoperating income expense net. Interest And Other Nonoperating Income Expense Net Interest and other (expense) income, net Issuance of Stock and Warrants for Services or Claims Fair value of stock issued for license Leasehold Improvements [Member] Leasehold Improvements [Member] Liabilities Total liabilities Liabilities and Equity Total liabilities and stockholders' equity Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: License Agreement [Abstract] License Agreement [Abstract] License Agreement [Abstract] Majority Shareholder [Member] Third Rock Ventures [Member] Management and advisory services. Management And Advisory Services [Member] Management and Advisory Services [Member] Management [Member] Senior Management [Member] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Money Market Funds [Member] Money Market Funds [Member] Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss) Attributable to Parent Net loss Net loss Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common stockholders Net loss attributable to common stockholders New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Noncash Investing and Financing Items [Abstract] SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION: Non Employee Stock Plan [Member] Non Employee Stock Plan [Member] Non Employee Stock Plan [Member] Number of board of directors affiliated with related party. Number Of Board Of Directors Affiliated With Related Party Number of board members Number of Operating Segments Number of operating segments Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income (Loss) Loss from operations Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization and Basis of Presentation Other Accrued Liabilities, Current Other Other Assets, Current Other assets, current Other Current Liabilities [Member] Other Liabilities, Current [Member] Other Liabilities, Current Other liabilities, current Total other liabilities, current Other Liabilities, Noncurrent Other liabilities, noncurrent Total other liabilities, noncurrent Other Liabilities [Table Text Block] Other Liabilities Other Noncurrent Liabilities [Member] Other Liabilities, Noncurrent [Member] Over-Allotment Option [Member] Over-Allotment Option [Member] Payments for repurchase of shares under incentive and share based compensation plans excluding stock options. Payments For Repurchase Of Shares Under Incentive And Share Based Compensation Plans Excluding Stock Options Repurchase of unvested restricted stock awards Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Performance contingent awards, restricted stock. Performance Contingent Awards Restricted Stock [Member] Performance Contingent Awards Restricted Stock [Member] Performance-contingent awards, stock options. Performance Contingent Awards Stock Options [Member] Performance Contingent Awards Stock Options [Member] Performance Shares [Member] Performance Shares [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Value, Issued Preferred stock, $0.001 par value, 5,000,000 shares authorized as of September 30, 2016 (unaudited) and December 31, 2015 Prepaid Expense, Current Prepaid expenses Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options Proceeds from issuance of restricted stock awards Proceeds from Stock Options Exercised Proceeds from issuance of common stock in settlement of employee stock purchase plan and exercise of stock options Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Gross Total property and equipment Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Property, Plant and Equipment [Table Text Block] Property and Equipment Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Related Party [Domain] Related Party [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Related Party [Axis] Related Party [Axis] Related Party Transactions Disclosure [Text Block] Related Party Transactions Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party Related party expenses Research and Development [Abstract] Research and Development [Abstract] Research And Development Arrangement Contract To Be Performed By Others Royalty Percentage Research And Development Arrangement Contract To Be Performed By Others Royalty Percentage Royalty fee as a percentage of future sales, less than Research and Development Expense Research and development Research and Development Expense [Member] Research and Development Expense [Member] Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Research, Development, and Computer Software Disclosure [Text Block] License Agreement Restricted Cash and Cash Equivalents, Noncurrent Restricted cash Restricted cash. Restricted Cash [Member] Restricted Cash [Member] Restricted Stock [Member] Restricted Stock [Member] Retained Earnings (Accumulated Deficit) Accumulated deficit Sale of Stock [Domain] Sale of Stock [Domain] EX-101.PRE 11 gbt-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 g446427g54c50.jpg GRAPHIC begin 644 g446427g54c50.jpg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htm IDEA: XBRL DOCUMENT v3.5.0.2

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2016

Nov. 01, 2016

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2016

Document Fiscal Year Focus 2016

Document Fiscal Period Focus Q3

Trading Symbol GBT

Entity Registrant Name Global Blood Therapeutics, Inc.

Entity Central Index Key 0001629137

Current Fiscal Year End Date --12-31

Entity Filer Category Non-accelerated Filer

Entity Common Stock, Shares Outstanding 37,316,451

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Document and Entity Information [Abstract]
+ References
No definition available.
+ Details

Name: gbt_DocumentAndEntityInformationAbstract

Namespace Prefix: gbt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

Current assets:

Cash and cash equivalents $ 217,837 $ 148,502

Prepaid expenses 1,706 1,222

Other assets, current 1,723 1,096

Total current assets 221,266 150,820

Property and equipment, net 2,626 2,114

Restricted cash 140 140

Total assets 224,032 153,074

Current liabilities:

Accounts payable 3,038 3,361

Accrued liabilities 5,863 4,400

Accrued compensation 3,351 2,242

Other liabilities, current 905 720

Total current liabilities 13,157 10,723

Other liabilities, noncurrent 775 1,556

Total liabilities 13,932 12,279

Commitments and contingencies

Stockholders' equity:

Preferred stock, $0.001 par value, 5,000,000 shares authorized as of September 30, 2016 (unaudited) and December 31, 2015

Common stock, $0.001 par value, 150,000,000 shares authorized as of September 30, 2016 (unaudited) and December 31, 2015, respectively; 36,516,130 and 29,359,800 shares issued and outstanding as of September 30, 2016 (unaudited) and December 31, 2015, respectively 37 29

Additional paid-in capital 363,789 239,231

Accumulated deficit (153,726) (98,465)

Total stockholders' equity 210,100 140,795

Total liabilities and stockholders' equity $ 224,032 $ 153,074

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Assets
-URI http://asc.fasb.org/extlink&oid=6509628

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 15 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares

Sep. 30, 2016

Dec. 31, 2015

Statement of Financial Position [Abstract]

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 5,000,000 5,000,000

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 150,000,000 150,000,000

Common stock, shares issued 36,516,130 29,359,800

Common stock, shares outstanding 36,516,130 29,359,800

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Operating expenses:

Research and development $ 15,145 $ 12,106 $ 40,847 $ 25,257

General and administrative 5,999 2,669 14,821 5,473

Related party expenses 65

Total operating expenses 21,144 14,775 55,668 30,795

Loss from operations (21,144) (14,775) (55,668) (30,795)

Interest and other (expense) income, net 159 11 407 20

Net loss (20,985) (14,764) (55,261) (30,775)

Comprehensive loss (20,985) (14,764) (55,261) (30,775)

Net loss attributable to common stockholders $ (20,985) $ (15,551) $ (55,261) $ (34,955)

Net loss per share attributable to common stockholders, basic and diluted $ (0.58) $ (0.90) $ (1.72) $ (4.83)

Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted 36,353,958 17,288,610 32,074,779 7,242,559

X

- Definition
Interest and other nonoperating income expense net.
+ References
No definition available.
+ Details

Name: gbt_InterestAndOtherNonoperatingIncomeExpenseNet

Namespace Prefix: gbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 17 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ (55,261) $ (30,775)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 841 606

Loss on disposal of fixed assets 29

Stock-based compensation 5,884 1,731

Fair value of stock issued for license 4,492

Changes in operating assets and liabilities:

Prepaid expenses (484) (489)

Other assets, current (3) (210)

Accounts payable (1,478) 851

Accrued liabilities 1,746 1,928

Accrued compensation 1,109 601

Other liabilities (25) (7)

Net cash used in operating activities (47,671) (21,243)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of property and equipment (1,106) (775)

Net cash used in investing activities (1,106) (775)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of common stock, net of issuance costs 116,995 126,360

Proceeds from issuance of restricted stock awards 2,108

Repurchase of unvested restricted stock awards (66)

Proceeds from issuance of common stock in settlement of employee stock purchase plan and exercise of stock options 1,117 44

Net cash provided by financing activities 118,112 128,446

Net increase in cash and cash equivalents 69,335 106,428

Cash and cash equivalents at beginning of period 148,502 52,069

Cash and cash equivalents at end of period 217,837 158,497

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:

Accretion of Series A and Series B redeemable convertible preferred stock 4,180

Conversion of redeemable convertible preferred stock to common stock at closing of initial public offering 106,342

Accrued purchase of property and equipment $ 247

Accrued offering costs $ 130

X

- Definition
Payments for repurchase of shares under incentive and share based compensation plans excluding stock options.
+ References
No definition available.
+ Details

Name: gbt_PaymentsForRepurchaseOfSharesUnderIncentiveAndShareBasedCompensationPlansExcludingStockOptions

Namespace Prefix: gbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
+ Details

Name: us-gaap_ConversionOfStockAmountIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586
+ Details

Name: us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in current assets classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in noncurrent operating liabilities classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards other than stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of accretion of temporary equity to its redemption value during the period.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityAccretionToRedemptionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 18 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2

Organization and Basis of Presentation
9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Basis of Presentation

1. Organization and Basis of Presentation

Global Blood Therapeutics Inc. (the “Company”, “we”, “us”, and “our”) was incorporated in Delaware in February 2011 and commenced operations in May 2012. We are a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. Our primary activities have been establishing our facilities, recruiting personnel, conducting development of our product candidates, including clinical trials, and raising capital. Our principal operations are based in South San Francisco, California, and we operate in one segment.

Follow-on Offering

On June 24, 2016, we completed a follow-on offering and issued 6,400,000 shares of common stock at a price of $18.75 per share. In July 2016, we sold an additional 267,228 shares of our common stock directly to the underwriters when they exercised their over-allotment option at the price of $18.75 per share. We received total proceeds of $117.0 million from the offering, net of underwriting costs and commissions, and offering expenses.

Need for Additional Capital

In the course of our development activities, we have sustained operating losses and we expect such losses to continue over the next several years. Our ultimate success depends on the outcome of our research and development activities. Since inception through September 30, 2016, we have incurred cumulative net losses of $153.7 million. We expect to incur additional losses in the future to conduct product research and development and we recognize the need to raise additional capital to fully implement our business plan. We intend to raise such capital through the issuance of additional equity, and potentially through borrowings, and strategic alliances with partner companies. However, if such financing is not available at adequate levels, we will need to reevaluate our operating plans. We believe that our existing cash and cash equivalents will be sufficient to fund our cash requirements for at least the next twelve months.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64809438&loc=d3e5614-111684

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2

Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Preparation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2015 has been derived from audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as our annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair presentation of our financial information. The results of operations for the three and nine months ended September 30, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016 or for any other interim period or for any other future year.

The accompanying interim unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2015 included in our Annual Report on Form 10-K, filed with the SEC on March 29, 2016.

Use of Estimates

The preparation of the accompanying unaudited interim condensed consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of costs and expenses during the reporting period. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results could differ from these estimates under different assumptions or conditions.

Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation.

Cash and Cash Equivalents

We consider all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. Cash equivalents, which consist primarily of amounts invested in money market accounts, are stated at fair value.

Accruals of Research and Development Costs

We record accruals for estimated costs of research, preclinical, nonclinical and clinical studies and manufacturing development. These costs are a significant component of our research and development expenses. A substantial portion of our ongoing research and development activities are conducted by third-party service providers, including contract research organizations. We accrue the costs incurred under our agreements with these third parties based on actual work completed in accordance with agreements established with these third parties. We determine the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrual balance in each reporting period. As actual costs become known, we adjust our accruals. We have not experienced any material deviations between accrued clinical trial expenses and actual clinical trial expenses. However, actual services performed, number of subjects enrolled, and the rate of subject enrollment may vary from our estimates, resulting in adjustments to clinical trial expense in future periods. Changes in these estimates that result in material changes to our accruals could materially affect our results of operations.

Concentration of Credit Risk

Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Our cash and cash equivalents are held primarily in one large financial institution in the United States as of September 30, 2016. We believe that this financial institution is financially sound, and accordingly, minimal credit risk exists with respect to this financial institution.

Fair Value Measurement

The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.

Research and Development Costs

Research and development costs are expensed as incurred and consist of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to other nonemployees and entities that conduct certain research and development activities and manufacturing of clinical materials on our behalf. Amounts incurred in connection with license agreements are also included in research and development expense. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and then expensed as the related goods are delivered or the services are performed.

Stock-based Compensation

We measure and recognize stock-based compensation expense, including employee and non-employee equity awards, based on fair value at the grant date. We use the Black-Scholes option-pricing model to calculate fair value. Stock-based compensation expense recognized in the statements of operations is based on options ultimately expected to vest, taking into consideration estimated forfeitures. Stock-based compensation expense is revised in subsequent periods, if necessary, if actual forfeitures differ from these estimates. When estimating forfeitures, we consider historic voluntary termination behaviors as well as trends of actual option forfeitures. For options granted to non-employees, we revalue the unearned portion of the stock-based compensation and the resulting change in fair value is recognized in the statements of operations over the period the related services are rendered.

Net Loss per Share Attributable to Common Stockholders

Net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. The net loss attributable to common stockholders is calculated by adjusting our net loss for the accretion and dividends on redeemable convertible preferred stock prior to the conversion of the redeemable convertible preferred stock upon our initial public offering, or IPO, in August 2015. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since the effects of potentially dilutive securities are antidilutive given our net loss.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial statements upon adoption.

In February 2016, the FASB issued Accounting Standards Update, or ASU No. 2016-02, Leases. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. We are currently in the process of evaluating the impact the adoption of this new standard will have on our financial position or results of operations.

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting. The new standard simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are currently in the process of evaluating the impact the adoption of this new standard will have on our financial position or results of operations and have not elected to early adopt the amendment.

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. The new standard provides guidance on eight specific cash flow classification issues. The standard is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. We believe that the adoption of this new standard will have no impact on our financial position or results of operations and have not elected to early adopt the amendment.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18854-107790
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2

Fair Value Measurements
9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

3. Fair Value Measurements

Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, restricted cash, accounts payable and accrued liabilities that approximate fair value due to their relatively short maturities.

Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;

Level 2 – Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

Level 3 – Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.

Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements are as follows (in thousands):

 September 30, 2016

 Level 1 Level 2 Level 3 Total

Financial Assets:


Money market funds
 $ 208,616 $ — $ — $ 208,616









Total financial assets
 $ 208,616 $ — $ — $ 208,616









 December 31, 2015

 Level 1 Level 2 Level 3 Total

Financial Assets:


Money market funds
 $ 148,642 $ — $ — $ 148,642









Total financial assets
 $ 148,642 $ — $ — $ 148,642









Our financial instruments consist of Level 1 assets. Where quoted prices for identical assets are available in an active market, securities are classified as Level 1. Level 1 assets consist of highly liquid money market funds, which as of September 30, 2016 and December 31, 2015 includes $140,000 of funds that are collateral for our facility lease that are included within restricted cash. There were no unrealized gains and losses in our investments in these money market funds.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2

Balance Sheet Components
9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Balance Sheet Components

4. Balance Sheet Components

Property and Equipment

Property and equipment consists of the following (in thousands):

 September 30, 2016 December 31, 2015

Laboratory equipment
 $ 3,715 $ 3,151

Computer equipment
 970 596

Leasehold improvements
 678 340

Construction-in-progress
 206 129





Total property and equipment
 5,569 4,216

Less: accumulated depreciation and amortization
 (2,943 ) (2,102 )





Property and equipment, net
 $ 2,626 $ 2,114





Accrued liabilities

Accrued liabilities consist of the following (in thousands):

 September 30, 2016 December 31, 2015

Accrued clinical and manufacturing expenses
 $ 4,823 $ 4,025

Accrued professional and consulting services
 921 287

Other
 119 88





Total accrued liabilities
 $ 5,863 $ 4,400





Other liabilities, current and noncurrent

Other liabilities consist of the following (in thousands):

 September 30, 2016 December 31, 2015

Restricted shares subject to repurchase, current
 $ 850 $ 677

Deferred rent, current
 53 38

Other taxes payable
 2 5





Total other liabilities, current
 $ 905 $ 720





Restricted shares subject to repurchase, noncurrent
 $ 728 $ 1,470

Deferred rent, noncurrent
 47 86





Total other liabilities, noncurrent
 $ 775 $ 1,556





X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.
+ References
No definition available.
+ Details

Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stockholders' Equity
9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Stockholders' Equity

5. Stockholders’ Equity

Common Stock

We have reserved the following shares of common stock for issuance:

 September 30, 2016

Restricted shares subject to future vesting
 752,220

Options issued and outstanding
 2,703,252

Options available for future grants
 1,484,701

Employee stock purchase plan
 76,118



Total common stock reserved for issuance
 5,016,291



Restricted Stock

We have issued restricted stock awards to employees under our 2012 Stock Option and Grant Plan (the “2012 Plan”). Under the related stock purchase agreements, we have the right to repurchase the common stock at the lower of fair market value and the stockholders’ original purchase price which right lapses according to individual vesting schedules. In order to vest, the holders are required to provide continued service to us. Upon vesting, the appropriate amounts are transferred from liabilities to additional paid-in capital. If the employment or other service relationship of the holder of any unvested restricted common stock is terminated for any reason, we have the right to repurchase the unvested shares at the lower of fair market value or the stockholder’s original purchase price. As such, the shares subject to future vesting are not deemed outstanding for accounting purposes until the shares vest.

Restricted shares subject to repurchase and related liability were as follows (in thousands, except share data):

 September 30, 2016 December 31, 2015

Restricted shares subject to repurchase:


Shares issued to founders
 — 6,250

Shares issued pursuant to the 2012 Stock Option and Grant Plan
 777,041 1,091,038





Total restricted shares subject to repurchase
 777,041 1,097,288





Liability pertaining to restricted shares subject to repurchase


Other liabilities, current
 $ 850 $ 677

Other liabilities, noncurrent
 728 1,470





Total liabilities pertaining to shares subject to repurchase
 $ 1,578 $ 2,147

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stock-based Awards
9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-based Awards

6. Stock-based Awards

Equity Incentive Plans

In July 2015, we adopted the 2015 Stock Option and Incentive Plan (the “2015 Plan”). Under the 2015 Plan, 1,430,000 shares of our common stock were initially reserved for the issuance of stock options, restricted stock, and other equity-based awards to employees, non-employee directors, and consultants under terms and provisions established by the Board of Directors and approved by our stockholders. The 2015 Plan also provides for automatic annual increases in the number of shares reserved for future issuance. As of September 30, 2016, there were 1,484,701 shares available for future grants under the 2015 Plan.

In 2012, we adopted the 2012 Plan under which the Board of Directors was authorized to grant incentive stock options to employees, including officers and members of the Board of Directors who are also employees of ours, and non-statutory stock options (options that do not qualify as incentive options) and/or our restricted stock and other equity-based awards to employees, officers, directors, or consultants of ours. Upon adoption of the 2015 Plan, no new awards or grants are permitted under the 2012 Plan.

Employee Stock Purchase Plan

In July 2015, we adopted the 2015 Employee Stock Purchase Plan (the “2015 ESPP”). Under the 2015 ESPP, 50,000 shares of our common stock were initially reserved for employee purchases of our common stock under terms and provisions established by the Board of Directors and approved by our stockholders. The 2015 ESPP also provides for automatic annual increases in the number of shares reserved for future issuance.

Stock Option Awards

The following summarizes option activity under the 2015 Plan and the 2012 Plan:

 Number
of Options Weighted-
Average
Exercise
Price Weighted-
Average
remaining
contractual
term (years) Aggregate
Intrinsic
Value

 (in thousands)

Balance Outstanding, December 31, 2015
 2,058,787 $ 8.71 9.0

Options granted
 1,034,575 $ 16.74

Options exercised
 (103,602 ) $ 0.95

Options canceled
 (286,508 ) $ 18.96





Balance Outstanding, September 30, 2016
 2,703,252 $ 10.99 8.7 $ 35,600





Exercisable, September 30, 2016
 823,118 $ 6.59 7.9 $ 14,082





Vested and expected to vest, September 30, 2016
 2,508,295 $ 10.78 8.6 $ 33,533





Stock Options Granted to Employees with Service-Based Vesting Conditions Valuation Assumptions

The fair values of stock options granted to employees were calculated using the following assumptions:

 Three Months Ended
September 30, Nine Months Ended
September 30,

 2016 2015 2016 2015

Expected term (in years)
 6.0-6.1 5.3-6.3 5.3-6.1 5.3-6.3

Volatility
 70.6%-70.9% 73.8%-75.3% 70.6%-82.3% 73.8%-77.0%

Risk-free interest rate
 1.3%-1.5% 1.6%-1.8% 1.1%-1.9% 1.5%-1.8%

Dividend yield
 — — — —

Performance-Contingent Awards

On April 9, 2015, our Board of Directors granted a total of 326,424 performance-contingent awards to members of our senior management team. Of the total performance-contingent awards granted, 227,139 were performance-contingent options and 99,285 were performance-contingent shares of restricted common stock. The exercise price of each performance-contingent option and the purchase price for the performance-contingent restricted shares is $3.40 per share, which the Board of Directors determined was the fair market value on the grant date.

These awards have dual triggers of vesting based upon the successful achievement of four corporate operating milestones within specified timelines, as well as a requirement for continued employment. When a performance goal is deemed to be probable of achievement, time-based vesting and recognition of stock-based compensation expense commences. In the event any of the corporate operating milestones are not achieved by the specified timelines, such vesting tranche will terminate and no longer be exercisable with respect to that portion of the shares. During the nine months ended September 30, 2016, the Compensation Committee of our Board of Directors modified one of the corporate operating milestones, which resulted in two of the corporate operating milestones being achieved; accordingly, an aggregate of 94,502 shares underlying options and 49,643 shares of restricted stock associated with these two milestones vested and, as a result, $1.5 million of compensation cost was recognized for the performance-contingent awards, including $1.4 million of compensation cost related to the modified corporate operating milestone. One of the remaining two corporate operating milestones was not met within the timeframe required for achievement during the nine months ended September 30, 2016; accordingly, 47,500 shares underlying options and 24,821 shares of restricted stock associated with the milestone were forfeited. As of September 30, 2016, unvested performance-contingent awards included 47,495 shares underlying options and 24,821 shares of restricted stock associated with the remaining operating milestone.

Market-Condition Award

On April 9, 2015, our Board of Directors granted a market-condition award to our Chief Executive Officer of 99,285 shares of restricted common stock. The market-condition award does not vest until our market capitalization (determined based on the number of shares of common stock outstanding multiplied by the closing market price for our common stock as reported on NASDAQ) exceeds at least $2.0 billion for 20 consecutive trading days on or before the date twenty-four (24) months after the closing of our initial public offering, or IPO.

The fair value of the market-condition award of $0.70 was determined on the grant date utilizing a lattice model that was prepared by a third party valuation firm with an expected term of 2.4 years. In August 2015, we began to recognize compensation costs for this award concurrent with the closing of our IPO.

Stock-Based Compensation Expense

Total stock-based compensation recognized by function was as follows (in thousands):

 Three Months Ended
September 30, Nine Months Ended
September 30,

 2016 2015 2016 2015

Research and development
 $ 1,019 $ 527 $ 2,065 $ 1,232

General and administrative
 2,133 347 3,819 499









Total stock-based compensation expense
 $ 3,152 $ 874 $ 5,884 $ 1,731









Total stock-based compensation recognized for employees and non-employees was as follows (in thousands):

 Three Months Ended
September 30, Nine Months Ended
September 30,

 2016 2015 2016 2015

Employee options and restricted stock awards
 $ 3,044 $ 534 $ 5,651 $ 1,366

Non-employee options
 108 340 233 365









Total stock-based compensation expense
 $ 3,152 $ 874 $ 5,884 $ 1,731









Unrecognized Stock-Based Compensation Expense and Weighted-Average Remaining Amortization Period

As of September 30, 2016 the unrecognized stock-based compensation cost, net of expected forfeitures, and the estimated weighted-average amortization period, using the straight-line attribution method, was as follows (in thousands, except amortization period):

 Unrecognized
Compensation Cost Weighted-average
remaining amortization
period (years)

Options
 $ 12,864 2.5

Restricted stock awards
 607 1.8

2015 ESPP
 193 0.2





Total unrecognized stock-based compensation expense
 $ 13,664



X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65895303&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2

Net Loss per Share Attributable to Common Stockholders
9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Net Loss per Share Attributable to Common Stockholders

7. Net Loss per Share Attributable to Common Stockholders

The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders during the three and nine months ended September 30, 2016 and 2015, respectively (in thousands, except share and per share data):

 Three Months Ended
September 30, Nine Months Ended
September 30,

 2016 2015 2016 2015

Numerator:


Net loss
 $ (20,985 ) $ (14,764 ) $ (55,261 ) $ (30,775 )

Accretion and dividends on redeemable convertible preferred stock
 — (787 ) — (4,180 )









Net loss attributable to common stockholders
 $ (20,985 ) $ (15,551 ) $ (55,261 ) $ (34,955 )









Denominator:


Weighted average common shares outstanding
 36,353,958 17,288,610 32,074,779 7,242,559









Net loss per share attributable to common stockholders, basic and diluted
 $ (0.58 ) $ (0.90 ) $ (1.72 ) $ (4.83 )









Since we were in a loss position for all periods presented, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:

 Three Months Ended
September 30, Nine Months Ended
September 30,

 2016 2015 2016 2015

Share issuances under equity incentive plan
 2,703,252 1,990,473 2,703,252 1,990,473

Restricted stock subject to future vesting
 752,220 1,171,506 752,220 1,171,506









Total
 3,455,472 3,161,979 3,455,472 3,161,979









X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2

Related Party Transactions
9 Months Ended

Sep. 30, 2016

Related Party Transactions [Abstract]

Related Party Transactions

8. Related Party Transactions

Our largest investors include investment funds controlled by Third Rock Ventures, LLC (“TRV”) and two members of our Board of Directors are affiliated with TRV. Management and advisory fee expenses incurred with TRV were zero for both the three and nine months ended September 30, 2016 and zero and $65,000 for the three and nine months ended September 30, 2015, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2

License Agreement
9 Months Ended

Sep. 30, 2016

Research and Development [Abstract]

License Agreement

9. License Agreement

In September 2015, we executed an agreement with the Regents of the University of California, or the Regents, for an exclusive license to those rights the Regents may own in certain patents and patent applications relating to GBT440 and GBT440 analogs, and in exchange have committed to pay a royalty of less than 1% on future net sales. In connection with this agreement we issued 85,714 shares of our common stock with an estimated fair value of $4.5 million, which was recorded in research and development expense in our statement of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23218-108380

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Basis of Preparation

Basis of Preparation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2015 has been derived from audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as our annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair presentation of our financial information. The results of operations for the three and nine months ended September 30, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016 or for any other interim period or for any other future year.

The accompanying interim unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2015 included in our Annual Report on Form 10-K, filed with the SEC on March 29, 2016.

Use of Estimates

Use of Estimates

The preparation of the accompanying unaudited interim condensed consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of costs and expenses during the reporting period. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results could differ from these estimates under different assumptions or conditions.

Principles of Consolidation

Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation.

Cash and Cash Equivalents

Cash and Cash Equivalents

We consider all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. Cash equivalents, which consist primarily of amounts invested in money market accounts, are stated at fair value.

Accruals of Research and Development Costs

Accruals of Research and Development Costs

We record accruals for estimated costs of research, preclinical, nonclinical and clinical studies and manufacturing development. These costs are a significant component of our research and development expenses. A substantial portion of our ongoing research and development activities are conducted by third-party service providers, including contract research organizations. We accrue the costs incurred under our agreements with these third parties based on actual work completed in accordance with agreements established with these third parties. We determine the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrual balance in each reporting period. As actual costs become known, we adjust our accruals. We have not experienced any material deviations between accrued clinical trial expenses and actual clinical trial expenses. However, actual services performed, number of subjects enrolled, and the rate of subject enrollment may vary from our estimates, resulting in adjustments to clinical trial expense in future periods. Changes in these estimates that result in material changes to our accruals could materially affect our results of operations.

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Our cash and cash equivalents are held primarily in one large financial institution in the United States as of September 30, 2016. We believe that this financial institution is financially sound, and accordingly, minimal credit risk exists with respect to this financial institution.

Fair Value Measurement

Fair Value Measurement

The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.

Research and Development Costs

Research and Development Costs

Research and development costs are expensed as incurred and consist of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to other nonemployees and entities that conduct certain research and development activities and manufacturing of clinical materials on our behalf. Amounts incurred in connection with license agreements are also included in research and development expense. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and then expensed as the related goods are delivered or the services are performed.

Stock-based Compensation

Stock-based Compensation

We measure and recognize stock-based compensation expense, including employee and non-employee equity awards, based on fair value at the grant date. We use the Black-Scholes option-pricing model to calculate fair value. Stock-based compensation expense recognized in the statements of operations is based on options ultimately expected to vest, taking into consideration estimated forfeitures. Stock-based compensation expense is revised in subsequent periods, if necessary, if actual forfeitures differ from these estimates. When estimating forfeitures, we consider historic voluntary termination behaviors as well as trends of actual option forfeitures. For options granted to non-employees, we revalue the unearned portion of the stock-based compensation and the resulting change in fair value is recognized in the statements of operations over the period the related services are rendered.

Net Loss per Share Attributable to Common Stockholders

Net Loss per Share Attributable to Common Stockholders

Net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. The net loss attributable to common stockholders is calculated by adjusting our net loss for the accretion and dividends on redeemable convertible preferred stock prior to the conversion of the redeemable convertible preferred stock upon our initial public offering, or IPO, in August 2015. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since the effects of potentially dilutive securities are antidilutive given our net loss.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial statements upon adoption.

In February 2016, the FASB issued Accounting Standards Update, or ASU No. 2016-02, Leases. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. We are currently in the process of evaluating the impact the adoption of this new standard will have on our financial position or results of operations.

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting. The new standard simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are currently in the process of evaluating the impact the adoption of this new standard will have on our financial position or results of operations and have not elected to early adopt the amendment.

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. The new standard provides guidance on eight specific cash flow classification issues. The standard is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. We believe that the adoption of this new standard will have no impact on our financial position or results of operations and have not elected to early adopt the amendment.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f(1))
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_CompensationRelatedCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 55
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68064133&loc=d3e61082-112788

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13531-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68064133&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64809438&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.15)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InProcessResearchAndDevelopmentPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Research and Development
-URI http://asc.fasb.org/extlink&oid=6523717
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6132-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2

Fair Value Measurements (Tables)
9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring Basis

Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements are as follows (in thousands):

 September 30, 2016

 Level 1 Level 2 Level 3 Total

Financial Assets:


Money market funds
 $ 208,616 $ — $ — $ 208,616









Total financial assets
 $ 208,616 $ — $ — $ 208,616









 December 31, 2015

 Level 1 Level 2 Level 3 Total

Financial Assets:


Money market funds
 $ 148,642 $ — $ — $ 148,642









Total financial assets
 $ 148,642 $ — $ — $ 148,642









X

- Definition
Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13476-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13467-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611
+ Details

Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2

Balance Sheet Components (Tables)
9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Property and Equipment

Property and equipment consists of the following (in thousands):

 September 30, 2016 December 31, 2015

Laboratory equipment
 $ 3,715 $ 3,151

Computer equipment
 970 596

Leasehold improvements
 678 340

Construction-in-progress
 206 129





Total property and equipment
 5,569 4,216

Less: accumulated depreciation and amortization
 (2,943 ) (2,102 )





Property and equipment, net
 $ 2,626 $ 2,114





Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

 September 30, 2016 December 31, 2015

Accrued clinical and manufacturing expenses
 $ 4,823 $ 4,025

Accrued professional and consulting services
 921 287

Other
 119 88





Total accrued liabilities
 $ 5,863 $ 4,400

Other Liabilities

Other liabilities consist of the following (in thousands):

 September 30, 2016 December 31, 2015

Restricted shares subject to repurchase, current
 $ 850 $ 677

Deferred rent, current
 53 38

Other taxes payable
 2 5





Total other liabilities, current
 $ 905 $ 720





Restricted shares subject to repurchase, noncurrent
 $ 728 $ 1,470

Deferred rent, noncurrent
 47 86





Total other liabilities, noncurrent
 $ 775 $ 1,556





X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of other liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stockholders' Equity (Tables)
9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Schedule of Common Stock Reserved for Issuance

We have reserved the following shares of common stock for issuance:

 September 30, 2016

Restricted shares subject to future vesting
 752,220

Options issued and outstanding
 2,703,252

Options available for future grants
 1,484,701

Employee stock purchase plan
 76,118



Total common stock reserved for issuance
 5,016,291



Schedule of Restricted Shares Subject to Repurchase

Restricted shares subject to repurchase and related liability were as follows (in thousands, except share data):

 September 30, 2016 December 31, 2015

Restricted shares subject to repurchase:


Shares issued to founders
 — 6,250

Shares issued pursuant to the 2012 Stock Option and Grant Plan
 777,041 1,091,038





Total restricted shares subject to repurchase
 777,041 1,097,288





Liability pertaining to restricted shares subject to repurchase


Other liabilities, current
 $ 850 $ 677

Other liabilities, noncurrent
 728 1,470





Total liabilities pertaining to shares subject to repurchase
 $ 1,578 $ 2,147

X

- Definition
Schedule of restricted shares subject to repurchase.
+ References
No definition available.
+ Details

Name: gbt_ScheduleOfRestrictedSharesSubjectToRepurchaseTableTextBlock

Namespace Prefix: gbt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644
+ Details

Name: us-gaap_ScheduleOfStockByClassTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stock-based Awards (Tables)
9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Option Activity

The following summarizes option activity under the 2015 Plan and the 2012 Plan:

 Number
of Options Weighted-
Average
Exercise
Price Weighted-
Average
remaining
contractual
term (years) Aggregate
Intrinsic
Value

 (in thousands)

Balance Outstanding, December 31, 2015
 2,058,787 $ 8.71 9.0

Options granted
 1,034,575 $ 16.74

Options exercised
 (103,602 ) $ 0.95

Options canceled
 (286,508 ) $ 18.96





Balance Outstanding, September 30, 2016
 2,703,252 $ 10.99 8.7 $ 35,600





Exercisable, September 30, 2016
 823,118 $ 6.59 7.9 $ 14,082





Vested and expected to vest, September 30, 2016
 2,508,295 $ 10.78 8.6 $ 33,533





Valuation Assumptions for Stock Awards

The fair values of stock options granted to employees were calculated using the following assumptions:

 Three Months Ended
September 30, Nine Months Ended
September 30,

 2016 2015 2016 2015

Expected term (in years)
 6.0-6.1 5.3-6.3 5.3-6.1 5.3-6.3

Volatility
 70.6%-70.9% 73.8%-75.3% 70.6%-82.3% 73.8%-77.0%

Risk-free interest rate
 1.3%-1.5% 1.6%-1.8% 1.1%-1.9% 1.5%-1.8%

Dividend yield
 — — — —

Stock-based Compensation Expense Recognized

Total stock-based compensation recognized by function was as follows (in thousands):

 Three Months Ended
September 30, Nine Months Ended
September 30,

 2016 2015 2016 2015

Research and development
 $ 1,019 $ 527 $ 2,065 $ 1,232

General and administrative
 2,133 347 3,819 499









Total stock-based compensation expense
 $ 3,152 $ 874 $ 5,884 $ 1,731









Total stock-based compensation recognized for employees and non-employees was as follows (in thousands):

 Three Months Ended
September 30, Nine Months Ended
September 30,

 2016 2015 2016 2015

Employee options and restricted stock awards
 $ 3,044 $ 534 $ 5,651 $ 1,366

Non-employee options
 108 340 233 365









Total stock-based compensation expense
 $ 3,152 $ 874 $ 5,884 $ 1,731

Unrecognized Stock-based Compensation Cost

As of September 30, 2016 the unrecognized stock-based compensation cost, net of expected forfeitures, and the estimated weighted-average amortization period, using the straight-line attribution method, was as follows (in thousands, except amortization period):

 Unrecognized
Compensation Cost Weighted-average
remaining amortization
period (years)

Options
 $ 12,864 2.5

Restricted stock awards
 607 1.8

2015 ESPP
 193 0.2





Total unrecognized stock-based compensation expense
 $ 13,664



X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the total compensation cost related to nonvested awards not yet recognized and the weighted-average period over which it is expected to be recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2

Net Loss per Share Attributable to Common Stockholders (Tables)
9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss per Share

The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders during the three and nine months ended September 30, 2016 and 2015, respectively (in thousands, except share and per share data):

 Three Months Ended
September 30, Nine Months Ended
September 30,

 2016 2015 2016 2015

Numerator:


Net loss
 $ (20,985 ) $ (14,764 ) $ (55,261 ) $ (30,775 )

Accretion and dividends on redeemable convertible preferred stock
 — (787 ) — (4,180 )









Net loss attributable to common stockholders
 $ (20,985 ) $ (15,551 ) $ (55,261 ) $ (34,955 )









Denominator:


Weighted average common shares outstanding
 36,353,958 17,288,610 32,074,779 7,242,559









Net loss per share attributable to common stockholders, basic and diluted
 $ (0.58 ) $ (0.90 ) $ (1.72 ) $ (4.83 )









Potentially Dilutive Securities that were Not Included in Diluted per Share Calculations

Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:

 Three Months Ended
September 30, Nine Months Ended
September 30,

 2016 2015 2016 2015

Share issuances under equity incentive plan
 2,703,252 1,990,473 2,703,252 1,990,473

Restricted stock subject to future vesting
 752,220 1,171,506 752,220 1,171,506









Total
 3,455,472 3,161,979 3,455,472 3,161,979









X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2

Organization and Basis of Presentation - Additional Information (Detail)
$ / shares in Units, $ in Thousands
1 Months Ended 9 Months Ended

Jun. 24, 2016

$ / shares

shares

Jul. 31, 2016

USD ($)

$ / shares

shares

Sep. 30, 2016

USD ($)

Segment

Sep. 30, 2015

USD ($)

Dec. 31, 2015

USD ($)

Class of Stock [Line Items]

Number of operating segments | Segment 1

Proceeds from issuance of common stock, net of issuance costs $ 116,995 $ 126,360

Accumulated deficit $ (153,726) $ (98,465)

Over-Allotment Option [Member]

Class of Stock [Line Items]

Proceeds from issuance of common stock, net of issuance costs $ 117,000

Common Stock [Member]

Class of Stock [Line Items]

Stock issued in secondary public offering | shares 6,400,000

Share price per share | $ / shares $ 18.75

Common Stock [Member] | Over-Allotment Option [Member]

Class of Stock [Line Items]

Stock issued in secondary public offering | shares 267,228

Share price per share | $ / shares $ 18.75

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2

Fair Value Measurements - Fair Value Assets Measured on Recurring Basis (Detail) - Fair Value Measurements, Recurring [Member] - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Financial assets, fair value $ 208,616 $ 148,642

Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Financial assets, fair value 208,616 148,642

Money Market Funds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Financial assets, fair value 208,616 148,642

Money Market Funds [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Financial assets, fair value $ 208,616 $ 148,642

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016
+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2

Fair Value Measurements - Additional Information (Detail) - Fair Value Measurements, Recurring [Member] - USD ($)

Sep. 30, 2016

Dec. 31, 2015

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Financial assets, fair value $ 208,616,000 $ 148,642,000

Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Financial assets, fair value 208,616,000 148,642,000

Money Market Funds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Financial assets, fair value 208,616,000 148,642,000

Money Market Funds [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Financial assets, fair value 208,616,000 148,642,000

Money Market Funds [Member] | Level 1 [Member] | Restricted Cash [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Financial assets, fair value $ 140,000 $ 140,000

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016
+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=gbt_RestrictedCashMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2

Balance Sheet Components - Property and Equipment (Detail) - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

Property, Plant and Equipment [Line Items]

Total property and equipment $ 5,569 $ 4,216

Less: accumulated depreciation and amortization (2,943) (2,102)

Property and equipment, net 2,626 2,114

Laboratory Equipment [Member]

Property, Plant and Equipment [Line Items]

Total property and equipment 3,715 3,151

Computer Equipment [Member]

Property, Plant and Equipment [Line Items]

Total property and equipment 970 596

Leasehold Improvements [Member]

Property, Plant and Equipment [Line Items]

Total property and equipment 678 340

Construction-in-Progress [Member]

Property, Plant and Equipment [Line Items]

Total property and equipment $ 206 $ 129

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2

Balance Sheet Components - Accrued Liabilities (Detail) - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

Balance Sheet Components [Abstract]

Accrued clinical and manufacturing expenses $ 4,823 $ 4,025

Accrued professional and consulting services 921 287

Other 119 88

Total accrued liabilities $ 5,863 $ 4,400

X

- Definition
Accrued clinical and manufacturing expenses, current.
+ References
No definition available.
+ Details

Name: gbt_AccruedClinicalAndManufacturingExpensesCurrent

Namespace Prefix: gbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Balance Sheet Components [Abstract]
+ References
No definition available.
+ Details

Name: gbt_BalanceSheetComponentsAbstract

Namespace Prefix: gbt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2

Balance Sheet Components - Other Liabilities (Detail) - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

Balance Sheet Components [Abstract]

Restricted shares subject to repurchase, current $ 850 $ 677

Deferred rent, current 53 38

Other taxes payable 2 5

Total other liabilities, current 905 720

Restricted shares subject to repurchase, noncurrent 728 1,470

Deferred rent, noncurrent 47 86

Total other liabilities, noncurrent $ 775 $ 1,556

X

- Definition
Balance Sheet Components [Abstract]
+ References
No definition available.
+ Details

Name: gbt_BalanceSheetComponentsAbstract

Namespace Prefix: gbt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award obligation to repurchase shares current liability.
+ References
No definition available.
+ Details

Name: gbt_ShareBasedCompensationArrangementByShareBasedPaymentAwardObligationToRepurchaseSharesCurrentLiability

Namespace Prefix: gbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment award obligation to repurchase shares noncurrent liability.
+ References
No definition available.
+ Details

Name: gbt_ShareBasedCompensationArrangementByShareBasedPaymentAwardObligationToRepurchaseSharesNoncurrentLiability

Namespace Prefix: gbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
+ Details

Name: us-gaap_AccruedRentCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for contractual rent under lease arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedRentNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TaxesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stockholders' Equity - Schedule of Common Stock Reserved for Issuance (Detail)

Sep. 30, 2016

shares

Class of Stock [Line Items]

Shares reserved for future issuance 5,016,291

Restricted Stock [Member]

Class of Stock [Line Items]

Shares reserved for future issuance 752,220

Stock Options [Member]

Class of Stock [Line Items]

Shares reserved for future issuance 2,703,252

Shares reserved for future issuance 1,484,701

ESPP [Member]

Class of Stock [Line Items]

Shares reserved for future issuance 76,118

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=gbt_EmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stockholders' Equity - Schedule of Restricted Shares Subject to Repurchase (Detail) - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

Class of Stock [Line Items]

Total restricted shares subject to repurchase 777,041 1,097,288

Total liabilities pertaining to shares subject to repurchase $ 1,578 $ 2,147

Other Liabilities, Current [Member]

Class of Stock [Line Items]

Total liabilities pertaining to shares subject to repurchase 850 677

Other Liabilities, Noncurrent [Member]

Class of Stock [Line Items]

Total liabilities pertaining to shares subject to repurchase $ 728 $ 1,470

2012 Stock Option and Grant Plan [Member] | Restricted Stock [Member]

Class of Stock [Line Items]

Shares issued pursuant to the 2012 Stock Option and Grant Plan 777,041 1,091,038

Founders [Member] | Restricted Stock [Member]

Class of Stock [Line Items]

Shares issued to founders 6,250

X

- Definition
Common stock restricted shares subject to repurchase.
+ References
No definition available.
+ Details

Name: gbt_CommonStockRestrictedSharesSubjectToRepurchase

Namespace Prefix: gbt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Deferred compensation arrangement with individual nonvested shares.
+ References
No definition available.
+ Details

Name: gbt_DeferredCompensationArrangementWithIndividualNonvestedShares

Namespace Prefix: gbt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=gbt_TwoThousandTwelveStockOptionAndGrantPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=gbt_FoundersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stock-based Awards - Plan Summary - Additional Information (Detail) - shares

Sep. 30, 2016

Jul. 31, 2015

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options available for future grants 1,484,701

2015 Plan [Member] | Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares authorized for issuance 1,430,000

Options available for future grants 1,484,701

2015 ESPP [Member] | ESPP [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares authorized for issuance 50,000

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=gbt_TwoThousandFifteenStockOptionAndIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=gbt_TwoThousandFifteenEmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=gbt_EmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stock-based Awards - Stock Option Activity (Detail) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended

Sep. 30, 2016

Dec. 31, 2015

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]

Beginning balance, outstanding, Number of Options 2,058,787

Options granted, Number of Options 1,034,575

Options exercised, Number of Options (103,602)

Options canceled, Number of Options (286,508)

Ending balance, outstanding, Number of Options 2,703,252 2,058,787

Exercisable, Number of Options 823,118

Vested and expected to vest, Number of Options 2,508,295

Weighted- Average Exercise Price

Beginning balance, Outstanding, Weighted-Average Exercise Price $ 8.71

Options granted, Weighted-Average Exercise Price 16.74

Options exercised, Weighted-Average Exercise Price 0.95

Options canceled,Weighted-Average Exercise Price 18.96

Ending balance, Outstanding, Weighted-Average Exercise Price 10.99 $ 8.71

Exercisable, Weighted-Average Exercise Price 6.59

Vested and expected to vest, Weighted-Average Exercise Price $ 10.78

Beginning, Outstanding, Weighted-Average remaining contractual term 8 years 8 months 12 days 9 years

Exercisable, Weighted-Average remaining contractual term 7 years 10 months 24 days

Vested and expected to vest, Weighted-Average remaining contractual term 8 years 7 months 6 days

Balance Outstanding, Aggregate Intrinsic Value $ 35,600

Exercisable, Aggregate Intrinsic Value 14,082

Vested and expected to vest, Aggregate Intrinsic Value $ 33,533

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 43 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stock-based Awards - Valuation Assumptions for Stock Awards (Detail) - Stock Options [Member]
3 Months Ended 9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Volatility, minimum 70.60% 73.80% 70.60% 73.80%

Volatility, maximum 70.90% 75.30% 82.30% 77.00%

Risk-free interest rate, minimum 1.30% 1.60% 1.10% 1.50%

Risk-free interest rate, maximum 1.50% 1.80% 1.90% 1.80%

Dividend yield 0.00% 0.00% 0.00% 0.00%

Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected term (in years) 6 years 5 years 3 months 18 days 5 years 3 months 18 days 5 years 3 months 18 days

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected term (in years) 6 years 1 month 6 days 6 years 3 months 18 days 6 years 1 month 6 days 6 years 3 months 18 days

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stock-based Awards - Performance-Contingent and Market-Condition Awards - Additional Information (Detail)
3 Months Ended 9 Months Ended

Apr. 09, 2015

USD ($)

Milestone

$ / shares

shares

Sep. 30, 2016

USD ($)

Milestone

shares

Sep. 30, 2015

USD ($)

Sep. 30, 2016

USD ($)

Milestone

$ / shares

shares

Sep. 30, 2015

USD ($)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Grants in period 1,034,575

Exercise price of options granted | $ / shares $ 16.74

Compensation expense recognized | $ $ 3,152,000 $ 874,000 $ 5,884,000 $ 1,731,000

Senior Management [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of operating milestones for performance vesting | Milestone 4

Number of operating milestones achieved | Milestone 1 1

Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Compensation expense recognized | $ $ 1,500,000

Performance Shares [Member] | Senior Management [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Grants in period 326,424

Compensation expense recognized | $ $ 1,400,000

Performance Contingent Awards Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares vested 94,502

Number of shares forfeited 47,500

Number of shares unvested 47,495 47,495

Performance Contingent Awards Stock Options [Member] | Senior Management [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Grants in period 227,139

Exercise price of options granted | $ / shares $ 3.40

Performance Contingent Awards Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares vested 49,643

Number of shares forfeited 24,821

Number of shares unvested 24,821 24,821

Performance Contingent Awards Restricted Stock [Member] | Senior Management [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted shares granted in period 99,285

Exercise price of restricted shares granted | $ / shares $ 3.40

Restricted Stock [Member] | Chief Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted shares granted in period 99,285

Minimum market capitalization | $ $ 2,000,000,000

Minimum consecutive trading days for market capitalization 20 days

Expiration period from IPO 24 months

Weighted-average grant date fair value of restricted shares | $ / shares $ 0.70

Expected term 2 years 4 months 24 days

X

- Definition
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average exercise price.
+ References
No definition available.
+ Details

Name: gbt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: gbt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based compensation arrangement by share-based payment award, number of performance milestones.
+ References
No definition available.
+ Details

Name: gbt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceMilestones

Namespace Prefix: gbt_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based compensation arrangement by share-based payment award, number of performance milestones achieved.
+ References
No definition available.
+ Details

Name: gbt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceMilestonesAchieved

Namespace Prefix: gbt_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Share-based compensation arrangement by share-based payment award, vesting condition, aggregate market value, common stock.
+ References
No definition available.
+ Details

Name: gbt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingConditionAggregateMarketValueCommonStock

Namespace Prefix: gbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment award vesting condition consecutive trading period.
+ References
No definition available.
+ Details

Name: gbt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingConditionConsecutiveTradingPeriod

Namespace Prefix: gbt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_ManagementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=gbt_PerformanceContingentAwardsStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=gbt_PerformanceContingentAwardsRestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stock-based Awards - Stock-based Compensation Expense Recognized (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock-based compensation expense $ 3,152 $ 874 $ 5,884 $ 1,731

Employee And Director Stock Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock-based compensation expense 3,044 534 5,651 1,366

Non Employee Stock Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock-based compensation expense 108 340 233 365

Research and Development Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock-based compensation expense 1,019 527 2,065 1,232

General and Administrative Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock-based compensation expense $ 2,133 $ 347 $ 3,819 $ 499

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=gbt_EmployeeAndDirectorStockPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=gbt_NonEmployeeStockPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2

Stock-based Awards - Unrecognized Stock-based Compensation Cost (Detail)
$ in Thousands
9 Months Ended

Sep. 30, 2016

USD ($)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total unrecognized compensation cost $ 13,664

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognized compensation cost, options $ 12,864

Weighted-average remaining amortization period 2 years 6 months

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognized compensation cost, restricted stock awards $ 607

Weighted-average remaining amortization period 1 year 9 months 18 days

ESPP [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognized compensation cost, restricted stock awards $ 193

Weighted-average remaining amortization period 2 months 12 days

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Unrecognized cost of unvested options awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=gbt_EmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2

Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Numerator:

Net loss $ (20,985) $ (14,764) $ (55,261) $ (30,775)

Accretion and dividends on redeemable convertible preferred stock (787) (4,180)

Net loss attributable to common stockholders $ (20,985) $ (15,551) $ (55,261) $ (34,955)

Denominator:

Weighted average common shares outstanding 36,353,958 17,288,610 32,074,779 7,242,559

Net loss per share attributable to common stockholders, basic and diluted $ (0.58) $ (0.90) $ (1.72) $ (4.83)

X

- Definition
Temporary equity accretion to redemption value and dividends adjustment.
+ References
No definition available.
+ Details

Name: gbt_TemporaryEquityAccretionToRedemptionValueAndDividendsAdjustment

Namespace Prefix: gbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 48 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2

Net Loss per Share Attributable to Common Stockholders - Potentially Dilutive Securities that were Not Included in Diluted per Share Calculations (Detail) - shares
3 Months Ended 9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from earnings per share 3,455,472 3,161,979 3,455,472 3,161,979

Share Issuances under Equity Incentive Plan [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from earnings per share 2,703,252 1,990,473 2,703,252 1,990,473

Restricted Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from earnings per share 752,220 1,171,506 752,220 1,171,506

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gbt_ShareIssuancesUnderEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2

Related Party Transactions - Additional Information (Detail)
3 Months Ended 9 Months Ended

Sep. 30, 2016

USD ($)

Board_member

Sep. 30, 2015

USD ($)

Sep. 30, 2016

USD ($)

Board_member

Sep. 30, 2015

USD ($)

Related Party Transaction [Line Items]

Related party expenses $ 65,000

Third Rock Ventures [Member]

Related Party Transaction [Line Items]

Number of board members | Board_member 2 2

Third Rock Ventures [Member] | Management and Advisory Services [Member]

Related Party Transaction [Line Items]

Related party expenses $ 0 $ 0 $ 0 $ 65,000

X

- Definition
Number of board of directors affiliated with related party.
+ References
No definition available.
+ Details

Name: gbt_NumberOfBoardOfDirectorsAffiliatedWithRelatedParty

Namespace Prefix: gbt_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=gbt_ManagementAndAdvisoryServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2

License Agreement - Additional Information (Detail)
$ in Millions
1 Months Ended

Sep. 30, 2016

USD ($)

shares

Class of Stock [Line Items]

Royalty fee as a percentage of future sales, less than 1.00%

Common Stock [Member]

Class of Stock [Line Items]

Number of shares issued in research agreement | shares 85,714

Value of shares issued in research agreement | $ $ 4.5

X

- Definition
Research And Development Arrangement Contract To Be Performed By Others Royalty Percentage
+ References
No definition available.
+ Details

Name: gbt_ResearchAndDevelopmentArrangementContractToBePerformedByOthersRoyaltyPercentage

Namespace Prefix: gbt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 104 170 1 false 35 0 false 7 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.globalbloodtx.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.globalbloodtx.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.globalbloodtx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.globalbloodtx.com/taxonomy/role/StatementOfIncome Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.globalbloodtx.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 107 - Disclosure - Organization and Basis of Presentation Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Organization and Basis of Presentation Notes 6 false false R7.htm 108 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies Notes 7 false false R8.htm 109 - Disclosure - Fair Value Measurements Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements Notes 8 false false R9.htm 110 - Disclosure - Balance Sheet Components Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock Balance Sheet Components Notes 9 false false R10.htm 111 - Disclosure - Stockholders' Equity Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity Notes 10 false false R11.htm 112 - Disclosure - Stock-based Awards Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-based Awards Notes 11 false false R12.htm 113 - Disclosure - Net Loss per Share Attributable to Common Stockholders Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Loss per Share Attributable to Common Stockholders Notes 12 false false R13.htm 114 - Disclosure - Related Party Transactions Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions Notes 13 false false R14.htm 115 - Disclosure - License Agreement Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlock License Agreement Notes 14 false false R15.htm 116 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 15 false false R16.htm 117 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) Tables http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock 16 false false R17.htm 118 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables Balance Sheet Components (Tables) Tables http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock 17 false false R18.htm 119 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Stockholders' Equity (Tables) Tables http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock 18 false false R19.htm 120 - Disclosure - Stock-based Awards (Tables) Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-based Awards (Tables) Tables http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 19 false false R20.htm 121 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) Sheet http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Loss per Share Attributable to Common Stockholders (Tables) Tables http://www.globalbloodtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 20 false false R21.htm 122 - Disclosure - Organization and Basis of Presentation - Additional Information (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformation Organization and Basis of Presentation - Additional Information (Detail) Details 21 false false R22.htm 123 - Disclosure - Fair Value Measurements - Fair Value Assets Measured on Recurring Basis (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureFairValueMeasurementsFairValueAssetsMeasuredOnRecurringBasis Fair Value Measurements - Fair Value Assets Measured on Recurring Basis (Detail) Details 22 false false R23.htm 124 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation Fair Value Measurements - Additional Information (Detail) Details 23 false false R24.htm 125 - Disclosure - Balance Sheet Components - Property and Equipment (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipment Balance Sheet Components - Property and Equipment (Detail) Details 24 false false R25.htm 126 - Disclosure - Balance Sheet Components - Accrued Liabilities (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureBalanceSheetComponentsAccruedLiabilities Balance Sheet Components - Accrued Liabilities (Detail) Details 25 false false R26.htm 127 - Disclosure - Balance Sheet Components - Other Liabilities (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureBalanceSheetComponentsOtherLiabilities Balance Sheet Components - Other Liabilities (Detail) Details 26 false false R27.htm 128 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Issuance (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuance Stockholders' Equity - Schedule of Common Stock Reserved for Issuance (Detail) Details 27 false false R28.htm 129 - Disclosure - Stockholders' Equity - Schedule of Restricted Shares Subject to Repurchase (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureStockholdersEquityScheduleOfRestrictedSharesSubjectToRepurchase Stockholders' Equity - Schedule of Restricted Shares Subject to Repurchase (Detail) Details 28 false false R29.htm 130 - Disclosure - Stock-based Awards - Plan Summary - Additional Information (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureStockbasedAwardsPlanSummaryAdditionalInformation Stock-based Awards - Plan Summary - Additional Information (Detail) Details 29 false false R30.htm 131 - Disclosure - Stock-based Awards - Stock Option Activity (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivity Stock-based Awards - Stock Option Activity (Detail) Details 30 false false R31.htm 132 - Disclosure - Stock-based Awards - Valuation Assumptions for Stock Awards (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureStockbasedAwardsValuationAssumptionsForStockAwards Stock-based Awards - Valuation Assumptions for Stock Awards (Detail) Details 31 false false R32.htm 133 - Disclosure - Stock-based Awards - Performance-Contingent and Market-Condition Awards - Additional Information (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureStockbasedAwardsPerformanceContingentAndMarketConditionAwardsAdditionalInformation Stock-based Awards - Performance-Contingent and Market-Condition Awards - Additional Information (Detail) Details 32 false false R33.htm 134 - Disclosure - Stock-based Awards - Stock-based Compensation Expense Recognized (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationExpenseRecognized Stock-based Awards - Stock-based Compensation Expense Recognized (Detail) Details 33 false false R34.htm 135 - Disclosure - Stock-based Awards - Unrecognized Stock-based Compensation Cost (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureStockbasedAwardsUnrecognizedStockbasedCompensationCost Stock-based Awards - Unrecognized Stock-based Compensation Cost (Detail) Details 34 false false R35.htm 136 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShare Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Detail) Details 35 false false R36.htm 137 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Potentially Dilutive Securities that were Not Included in Diluted per Share Calculations (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersPotentiallyDilutiveSecuritiesThatWereNotIncludedInDilutedPerShareCalculations Net Loss per Share Attributable to Common Stockholders - Potentially Dilutive Securities that were Not Included in Diluted per Share Calculations (Detail) Details 36 false false R37.htm 138 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) Details 37 false false R38.htm 139 - Disclosure - License Agreement - Additional Information (Detail) Sheet http://www.globalbloodtx.com/taxonomy/role/DisclosureLicenseAgreementAdditionalInformation License Agreement - Additional Information (Detail) Details 38 false false All Reports Book All Reports gbt-20160930.xml gbt-20160930.xsd gbt-20160930_cal.xml gbt-20160930_def.xml gbt-20160930_lab.xml gbt-20160930_pre.xml true true ZIP 57 0001193125-16-764353-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-16-764353-xbrl.zip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

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Nov. 01, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	GBT
Entity Registrant Name	Global Blood Therapeutics, Inc.
Entity Central Index Key	0001629137
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		37,316,451

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 217,837	$ 148,502
Prepaid expenses	1,706	1,222
Other assets, current	1,723	1,096
Total current assets	221,266	150,820
Property and equipment, net	2,626	2,114
Restricted cash	140	140
Total assets	224,032	153,074
Current liabilities:
Accounts payable	3,038	3,361
Accrued liabilities	5,863	4,400
Accrued compensation	3,351	2,242
Other liabilities, current	905	720
Total current liabilities	13,157	10,723
Other liabilities, noncurrent	775	1,556
Total liabilities	13,932	12,279
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized as of September 30, 2016 (unaudited) and December 31, 2015
Common stock, $0.001 par value, 150,000,000 shares authorized as of September 30, 2016 (unaudited) and December 31, 2015, respectively; 36,516,130 and 29,359,800 shares issued and outstanding as of September 30, 2016 (unaudited) and December 31, 2015, respectively	37	29
Additional paid-in capital	363,789	239,231
Accumulated deficit	(153,726)	(98,465)
Total stockholders' equity	210,100	140,795
Total liabilities and stockholders' equity	$ 224,032	$ 153,074

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	36,516,130	29,359,800
Common stock, shares outstanding	36,516,130	29,359,800

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating expenses:
Research and development	$ 15,145	$ 12,106	$ 40,847	$ 25,257
General and administrative	5,999	2,669	14,821	5,473
Related party expenses				65
Total operating expenses	21,144	14,775	55,668	30,795
Loss from operations	(21,144)	(14,775)	(55,668)	(30,795)
Interest and other (expense) income, net	159	11	407	20
Net loss	(20,985)	(14,764)	(55,261)	(30,775)
Comprehensive loss	(20,985)	(14,764)	(55,261)	(30,775)
Net loss attributable to common stockholders	$ (20,985)	$ (15,551)	$ (55,261)	$ (34,955)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.58)	$ (0.90)	$ (1.72)	$ (4.83)
Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted	36,353,958	17,288,610	32,074,779	7,242,559

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (55,261)	$ (30,775)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	841	606
Loss on disposal of fixed assets		29
Stock-based compensation	5,884	1,731
Fair value of stock issued for license		4,492
Changes in operating assets and liabilities:
Prepaid expenses	(484)	(489)
Other assets, current	(3)	(210)
Accounts payable	(1,478)	851
Accrued liabilities	1,746	1,928
Accrued compensation	1,109	601
Other liabilities	(25)	(7)
Net cash used in operating activities	(47,671)	(21,243)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(1,106)	(775)
Net cash used in investing activities	(1,106)	(775)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of issuance costs	116,995	126,360
Proceeds from issuance of restricted stock awards		2,108
Repurchase of unvested restricted stock awards		(66)
Proceeds from issuance of common stock in settlement of employee stock purchase plan and exercise of stock options	1,117	44
Net cash provided by financing activities	118,112	128,446
Net increase in cash and cash equivalents	69,335	106,428
Cash and cash equivalents at beginning of period	148,502	52,069
Cash and cash equivalents at end of period	217,837	158,497
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Accretion of Series A and Series B redeemable convertible preferred stock		4,180
Conversion of redeemable convertible preferred stock to common stock at closing of initial public offering		106,342
Accrued purchase of property and equipment	$ 247
Accrued offering costs		$ 130

Organization and Basis of Presentation	9 Months Ended
Organization and Basis of Presentation	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Global Blood Therapeutics Inc. (the “Company”, “we”, “us”, and “our”) was incorporated in Delaware in February 2011 and commenced operations in May 2012. We are a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. Our primary activities have been establishing our facilities, recruiting personnel, conducting development of our product candidates, including clinical trials, and raising capital. Our principal operations are based in South San Francisco, California, and we operate in one segment. *Follow-on Offering* On June 24, 2016, we completed a follow-on offering and issued 6,400,000 shares of common stock at a price of $18.75 per share. In July 2016, we sold an additional 267,228 shares of our common stock directly to the underwriters when they exercised their over-allotment option at the price of $18.75 per share. We received total proceeds of $117.0 million from the offering, net of underwriting costs and commissions, and offering expenses. *Need for Additional Capital* In the course of our development activities, we have sustained operating losses and we expect such losses to continue over the next several years. Our ultimate success depends on the outcome of our research and development activities. Since inception through September 30, 2016, we have incurred cumulative net losses of $153.7 million. We expect to incur additional losses in the future to conduct product research and development and we recognize the need to raise additional capital to fully implement our business plan. We intend to raise such capital through the issuance of additional equity, and potentially through borrowings, and strategic alliances with partner companies. However, if such financing is not available at adequate levels, we will need to reevaluate our operating plans. We believe that our existing cash and cash equivalents will be sufficient to fund our cash requirements for at least the next twelve months.

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies *Basis of Preparation* The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2015 has been derived from audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as our annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair presentation of our financial information. The results of operations for the three and nine months ended September 30, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016 or for any other interim period or for any other future year. The accompanying interim unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2015 included in our Annual Report on Form 10-K, filed with the SEC on March 29, 2016. *Use of Estimates* The preparation of the accompanying unaudited interim condensed consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of costs and expenses during the reporting period. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results could differ from these estimates under different assumptions or conditions. *Principles of Consolidation* The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation. *Cash and Cash Equivalents* We consider all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. Cash equivalents, which consist primarily of amounts invested in money market accounts, are stated at fair value. *Accruals of Research and Development Costs* We record accruals for estimated costs of research, preclinical, nonclinical and clinical studies and manufacturing development. These costs are a significant component of our research and development expenses. A substantial portion of our ongoing research and development activities are conducted by third-party service providers, including contract research organizations. We accrue the costs incurred under our agreements with these third parties based on actual work completed in accordance with agreements established with these third parties. We determine the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrual balance in each reporting period. As actual costs become known, we adjust our accruals. We have not experienced any material deviations between accrued clinical trial expenses and actual clinical trial expenses. However, actual services performed, number of subjects enrolled, and the rate of subject enrollment may vary from our estimates, resulting in adjustments to clinical trial expense in future periods. Changes in these estimates that result in material changes to our accruals could materially affect our results of operations. *Concentration of Credit Risk* Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Our cash and cash equivalents are held primarily in one large financial institution in the United States as of September 30, 2016. We believe that this financial institution is financially sound, and accordingly, minimal credit risk exists with respect to this financial institution. *Fair Value Measurement* The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. *Research and Development Costs* Research and development costs are expensed as incurred and consist of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to other nonemployees and entities that conduct certain research and development activities and manufacturing of clinical materials on our behalf. Amounts incurred in connection with license agreements are also included in research and development expense. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and then expensed as the related goods are delivered or the services are performed. *Stock-based Compensation* We measure and recognize stock-based compensation expense, including employee and non-employee equity awards, based on fair value at the grant date. We use the Black-Scholes option-pricing model to calculate fair value. Stock-based compensation expense recognized in the statements of operations is based on options ultimately expected to vest, taking into consideration estimated forfeitures. Stock-based compensation expense is revised in subsequent periods, if necessary, if actual forfeitures differ from these estimates. When estimating forfeitures, we consider historic voluntary termination behaviors as well as trends of actual option forfeitures. For options granted to non-employees, we revalue the unearned portion of the stock-based compensation and the resulting change in fair value is recognized in the statements of operations over the period the related services are rendered. *Net Loss per Share Attributable to Common Stockholders* Net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. The net loss attributable to common stockholders is calculated by adjusting our net loss for the accretion and dividends on redeemable convertible preferred stock prior to the conversion of the redeemable convertible preferred stock upon our initial public offering, or IPO, in August 2015. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since the effects of potentially dilutive securities are antidilutive given our net loss. *Recent Accounting Pronouncements* From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial statements upon adoption. In February 2016, the FASB issued Accounting Standards Update, or ASU No. 2016-02, Leases. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. We are currently in the process of evaluating the impact the adoption of this new standard will have on our financial position or results of operations. In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting. The new standard simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are currently in the process of evaluating the impact the adoption of this new standard will have on our financial position or results of operations and have not elected to early adopt the amendment. In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. The new standard provides guidance on eight specific cash flow classification issues. The standard is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. We believe that the adoption of this new standard will have no impact on our financial position or results of operations and have not elected to early adopt the amendment.

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	8. Related Party Transactions Our largest investors include investment funds controlled by Third Rock Ventures, LLC (“TRV”) and two members of our Board of Directors are affiliated with TRV. Management and advisory fee expenses incurred with TRV were zero for both the three and nine months ended September 30, 2016 and zero and $65,000 for the three and nine months ended September 30, 2015, respectively.

License Agreement	9 Months Ended
License Agreement	Sep. 30, 2016
Research and Development [Abstract]
License Agreement	9. License Agreement In September 2015, we executed an agreement with the Regents of the University of California, or the Regents, for an exclusive license to those rights the Regents may own in certain patents and patent applications relating to GBT440 and GBT440 analogs, and in exchange have committed to pay a royalty of less than 1% on future net sales. In connection with this agreement we issued 85,714 shares of our common stock with an estimated fair value of $4.5 million, which was recorded in research and development expense in our statement of operations.

Organization and Basis of Presentation - Additional Information (Detail) $ / shares in Units, $ in Thousands		1 Months Ended	9 Months Ended
	Jun. 24, 2016 $ / shares shares	Jul. 31, 2016 USD ($) $ / shares shares	Sep. 30, 2016 USD ($) Segment	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)
Class of Stock [Line Items]
Number of operating segments \| Segment			1
Proceeds from issuance of common stock, net of issuance costs			$ 116,995	$ 126,360
Accumulated deficit			$ (153,726)		$ (98,465)
Over-Allotment Option [Member]
Class of Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs		$ 117,000
Common Stock [Member]
Class of Stock [Line Items]
Stock issued in secondary public offering \| shares	6,400,000
Share price per share \| $ / shares	$ 18.75
Common Stock [Member] \| Over-Allotment Option [Member]
Class of Stock [Line Items]
Stock issued in secondary public offering \| shares		267,228
Share price per share \| $ / shares		$ 18.75

Fair Value Measurements - Fair Value Assets Measured on Recurring Basis (Detail) - Fair Value Measurements, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets, fair value	$ 208,616	$ 148,642
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets, fair value	208,616	148,642
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets, fair value	208,616	148,642
Money Market Funds [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets, fair value	$ 208,616	$ 148,642

Fair Value Measurements - Additional Information (Detail) - Fair Value Measurements, Recurring [Member] - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets, fair value	$ 208,616,000	$ 148,642,000
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets, fair value	208,616,000	148,642,000
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets, fair value	208,616,000	148,642,000
Money Market Funds [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets, fair value	208,616,000	148,642,000
Money Market Funds [Member] \| Level 1 [Member] \| Restricted Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets, fair value	$ 140,000	$ 140,000

Balance Sheet Components - Property and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 5,569	$ 4,216
Less: accumulated depreciation and amortization	(2,943)	(2,102)
Property and equipment, net	2,626	2,114
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	3,715	3,151
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	970	596
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	678	340
Construction-in-Progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 206	$ 129

Balance Sheet Components - Accrued Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Balance Sheet Components [Abstract]
Accrued clinical and manufacturing expenses	$ 4,823	$ 4,025
Accrued professional and consulting services	921	287
Other	119	88
Total accrued liabilities	$ 5,863	$ 4,400

Balance Sheet Components - Other Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Balance Sheet Components [Abstract]
Restricted shares subject to repurchase, current	$ 850	$ 677
Deferred rent, current	53	38
Other taxes payable	2	5
Total other liabilities, current	905	720
Restricted shares subject to repurchase, noncurrent	728	1,470
Deferred rent, noncurrent	47	86
Total other liabilities, noncurrent	$ 775	$ 1,556

Stockholders' Equity - Schedule of Common Stock Reserved for Issuance (Detail)	Sep. 30, 2016 shares
Class of Stock [Line Items]
Shares reserved for future issuance	5,016,291
Restricted Stock [Member]
Class of Stock [Line Items]
Shares reserved for future issuance	752,220
Stock Options [Member]
Class of Stock [Line Items]
Shares reserved for future issuance	2,703,252
Shares reserved for future issuance	1,484,701
ESPP [Member]
Class of Stock [Line Items]
Shares reserved for future issuance	76,118

Stock-based Awards - Plan Summary - Additional Information (Detail) - shares	Sep. 30, 2016	Jul. 31, 2015
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options available for future grants	1,484,701
2015 Plan [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance		1,430,000
Options available for future grants	1,484,701
2015 ESPP [Member] \| ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance		50,000

Stock-based Awards - Performance-Contingent and Market-Condition Awards - Additional Information (Detail)		3 Months Ended		9 Months Ended
	Apr. 09, 2015 USD ($) Milestone $ / shares shares	Sep. 30, 2016 USD ($) Milestone shares	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) Milestone $ / shares shares	Sep. 30, 2015 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period				1,034,575
Exercise price of options granted \| $ / shares				$ 16.74
Compensation expense recognized \| $		$ 3,152,000	$ 874,000	$ 5,884,000	$ 1,731,000
Senior Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of operating milestones for performance vesting \| Milestone	4
Number of operating milestones achieved \| Milestone		1		1
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense recognized \| $				$ 1,500,000
Performance Shares [Member] \| Senior Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period	326,424
Compensation expense recognized \| $				$ 1,400,000
Performance Contingent Awards Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested				94,502
Number of shares forfeited				47,500
Number of shares unvested		47,495		47,495
Performance Contingent Awards Stock Options [Member] \| Senior Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period	227,139
Exercise price of options granted \| $ / shares	$ 3.40
Performance Contingent Awards Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested				49,643
Number of shares forfeited				24,821
Number of shares unvested		24,821		24,821
Performance Contingent Awards Restricted Stock [Member] \| Senior Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares granted in period	99,285
Exercise price of restricted shares granted \| $ / shares	$ 3.40
Restricted Stock [Member] \| Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares granted in period	99,285
Minimum market capitalization \| $	$ 2,000,000,000
Minimum consecutive trading days for market capitalization				20 days
Expiration period from IPO				24 months
Weighted-average grant date fair value of restricted shares \| $ / shares	$ 0.70
Expected term	2 years 4 months 24 days

Stock-based Awards - Unrecognized Stock-based Compensation Cost (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	$ 13,664
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, options	$ 12,864
Weighted-average remaining amortization period	2 years 6 months
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, restricted stock awards	$ 607
Weighted-average remaining amortization period	1 year 9 months 18 days
ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, restricted stock awards	$ 193
Weighted-average remaining amortization period	2 months 12 days

Related Party Transactions - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2016 USD ($) Board_member	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) Board_member	Sep. 30, 2015 USD ($)
Related Party Transaction [Line Items]
Related party expenses				$ 65,000
Third Rock Ventures [Member]
Related Party Transaction [Line Items]
Number of board members \| Board_member	2		2
Third Rock Ventures [Member] \| Management and Advisory Services [Member]
Related Party Transaction [Line Items]
Related party expenses	$ 0	$ 0	$ 0	$ 65,000

License Agreement - Additional Information (Detail) $ in Millions	1 Months Ended
	Sep. 30, 2016 USD ($) shares
Class of Stock [Line Items]
Royalty fee as a percentage of future sales, less than	1.00%
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued in research agreement \| shares	85,714
Value of shares issued in research agreement \| $	$ 4.5